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Abstract 
 
Colorectal cancer (CRC) is one of the leading causes of cancer mortality 
worldwide. It is the most common of all gastrointestinal malignancies. 
Unfortunately, most CRC tumors are benign, grow slowly and do not show 
symptoms until they grow larger. Wide geographical, racial and ethnic differences 
in incidence are observed for this type of cancer. In rapidly developing nations as 
India, the incidence of CRC is 4.2 and 3.2 per 100,000 in males and females, 
respectively, which is comparatively much lower compared with rates in developed 
nations. Despite many advances in early diagnosis, surgical techniques, molecular 
and therapeutic characterization made over the past decade, CRC still remains a 
major health burden with high unmet medical, diagnostic and clinical needs. 
The past decade has uncovered various new pathways in the development of 
CRC. Several studies have been performed to identify the prognostic impact of 
various clinico-pathological factors. The survival rates of CRC in Asian countries 
are lower as compared to European and other Western developed countries. This 
can be attributed mainly to late diagnosis and less awareness about the disease in 
low socioeconomic populations.  
Early detection and proper treatment are some of the key strategies for improving 
overall survival. In this direction some improvement in the CRC patient survival rate 
has been observed due to the combinatorial use of chemotherapeutics alone/and 
or with targeted therapy. 5-Fluoro Uracil (5-FU) was the only drug used for 
 xxvi 
decades for CRC treatment. With the use of combination drugs in chemotherapy 
for example, 5-FU plus Leucovorin (LV), either with irinotican (FOLFIRI) and 
oxaliplatin (FOLFOX), has led to an improvement in survival. Two FDA approved 
monoclonal antibodies (MAb) targeted at epidermal growth factor receptor (EGFR), 
the chimeric IgG1 MAb cetuximab and the fully humanized IgG2 panitumumab, 
and a VEGF inhibitor bevacizumab have proven to be effective in combination with 
chemotherapy or as single agent for the treatment of metastatic colorectal cancer 
(mCRC). However, clinicians require accurate outcome prediction to adopt 
appropriate therapeutic regime.  
The efficacy of MAb is not consistent for every patient; some patients experience a 
dramatic response to MAb, whereas others show no response. Accurate 
biomarkers are not yet available for differentiating between responders and non-
responders, i.e. resistant population. V-Ki-ras2 Kirsten rat sarcoma viral oncogene 
homolog (KRAS) has been a well-established predictive biomarker and it is 
mandatory to test for KRAS gene mutations before giving cetuximab or 
panitumumab to CRC patient. However, recent studies have demonstrated that not 
all KRAS wild type tumors are responders of targeted therapy. Therefore, further 
molecular characterization of the EGFR signaling pathway is required. Various 
signaling molecules downstream of KRAS, such as v-Raf murine sarcoma viral 
oncogene homolog B (BRAF) and Neuroblastoma RAS viral oncogene homolog 
(NRAS), have been extensively studied to evaluate the effect of molecular 
alterations in these genes on the response of therapy. The majority of these 
studies have been carried in Western developed nations like USA, UK. Only three 
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studies have been published on the Indian population, which have tried to evaluate 
the rate of mutations in RAS-RAF or PIK3 signaling pathway in CRC. 
Therefore, the current study is taken up to better understand the molecular 
mechanism that may predict the efficacy of EGFR  targeted mAb therapy in Indian 
population. In this study the frequency of KRAS, BRAF, NRAS and PIK3CA was 
studied  by analysis of a larger cohort of CRC patients (n=203). To study the 
mutation profiling in Indian CRC patients, these four molecular markers were 
assessed in 203 histologically confirmed CRC patients and the correlation of 
different clinicopathological factors was evaluated.  
Formalin-fixed paraffin-embedded colorectal cancer tissues (n = 203) were 
prospectively collected from Indian CRC patients from all over India between the 
period from January 2013 to July 2016. Genomic DNA was isolated from tissue 
sections using Invitrogen DNA extraction kit and screened for mutations in KRAS 
(exon 2, exon 3), BRAF (exon 15), NRAS (exon 2, exon 3) and PIK3CA (exon 9, 
exon 20) genes using automated DNA sequencing. Treatment data were also 
studied on the basis of different clinico-pathological features of the tumor. 
Correlation between these molecular signatures and clinico-pathological 
characteristics was further studied so as to meet the unmet medical need for 
personalized medicine and to help in improvisation of survival rates in the Indian 
population.  
In 36% of CRC cases, at least one mutation in the analyzed hot spot region was 
observed. The prevalence of KRAS, BRAF, NRAS and PIK3CA mutations in the 
Indian population was found to be 24%, 6%, 2% and 4%, respectively. In KRAS 
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wild type (WT) population, approximately 12% of CRC patients have mutations in 
NRAS, BRAF or PIK3CA. BRAF mutations were found to be mutually exclusive 
with KRAS mutations (n=12/203). Coexistence of PIK3CA and KRAS mutations 
was observed. The statistical analysis of clinico-pathological characteristics and 
mutation showed significant association between KRAS mutations with age and 
tumor differentiation (p<0.05).  
In the case of BRAF, a more statistically significant correlation was observed in 
moderately differentiating and poorly differentiating adenocarcinomas than in well-
differentiated adenocarcinomas. No significant association was observed between 
any of the clinico-pathological features with NRAS or PIK3CA mutations. To study 
the effect of clinicopathological features on survival 30 patients were 
retrospectively analyzed. Overall survival of 37% with median survival of 25 
months was observed for the Indian population, which is much lower than that 
observed in developed nations, where the overall survival rates are 64%. 
Significant association was observed in the survival rate of patients and grade of 
tumor i.e. poorly differentiated adenocarcinoma (PDA). Significantly lower survival 
rates were observed in PDA in comparison to moderately differentiated 
adenocarcinoma (MDA). 
The current experimental evidence of survival rates of CRC patients in relation to 
different clinico-pathological features in the Indian population indicates that there 
are factors which influence prognosis of colorectal cancer patients. However, life 
expectancy has not increased drastically in recent years.  This study further 
indicates that KRAS, BRAF, NRAS and PIK3CA mutations in Indian CRC patients 
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occur at lower levels compared to those of Western developed nations. Our 
findings are consistent with the published literature that differences in patients' 
origins and related genetic backgrounds contribute to and even determine the 
incidence rate of somatic mutations in candidate cancer genes. This study 
supports the existing data that clinical and pathological characteristics of a tumour 
are important determinants of prognosis in CRC patients worldwide. 
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Chapter 1       Introduction 
Colorectal cancer (CRC) is a major health burden worldwide. It is one of the 
leading causes of mortality from cancer, affecting both males and females. The 
optimal approach to the diagnosis, management and treatment of CRC involves 
multidisciplinary and integrated management practices. The field is rapidly 
changing because of recent advancements in molecular characterization of CRC 
and introduction of targeted therapy and diverse patient response, better biological 
drugs and the effective combination regimes being employed for treatment (Patil et 
al., 2016).  
Two monoclonal antibodies (MAb) targeted at epidermal growth factor receptor 
(EGFR), the chimeric IgG1 MAb cetuximab and the fully humanized IgG2 
panitumumab, have proven to be effective in combination with chemotherapy or as 
single agent for treatment of metastatic colorectal cancer (mCRC) (Cunningham et 
al., 2004). However, the efficacy of MAb is not consistent for every patient; some 
patients experience dramatic response to MAb, whereas others show no response. 
In order to facilitate selection of mCRC patients who may benefit from anti-EGFR 
MAbs treatments, a clear need for identifying predictive biomarkers that indicate 
likelihood of response amongst potential recipients is currently widely appreciated 
(Patil et al., 2016). 
 
It has been reported that oncogenic activations of intracellular signaling pathways 
downstream of EGFR, including the RAS-RAF- MAPK plays an important role in 
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generating resistance to anti-EGFR MAbs. To date, KRAS mutations have been 
identified as a predictive marker of resistance to anti-EGFR MAbs in patients with 
mCRC, and the use of anti-EGFR MAbs is now restricted to CRC patients with 
wild-type KRAS (Karapetis et al., 2008). 
In patients with KRAS wild type tumors, it remains unclear why a large number of 
patients are still not responsive to the treatment. Other oncogenic mutations, such 
as BRAF, NRAS and PIK3CA are found likely to be promising predictors for the 
resistance in mCRC patients with wild-type KRAS (Moroni et al., 2005, Karapetis et 
al., 2008). 
Most of the studies that investigated the predictive value of KRAS, BRAF, NRAS, 
and PIK3CA mutations were performed in western developed countries (De Roock 
et al., 2011, Bozzao et al., 2011, Kawazoe et al., 2015). Little is known about the 
relation of these biomarkers with the clinical outcomes of MAb treatment in Indian 
patients with CRC. 
 
Hence, this study was undertaken to investigate the status of KRAS, BRAF, 
NRAS and PIK3CA mutations in Indian CRC patients, in order to clarify the 
rate of mutations and to detect the correlation between mutations and 
clinico-pathological factors. 
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1.1 Research Question 
In the case of the Indian patient cohort, how different will the mutation profiling of 
KRAS, BRAF, NRAS and PIK3CA genes involved in CRC, and how the correlation 
with clinico-pathological data, impact the clinical outcome and survival? 
 
1.2 Hypotheses 
This project investigated the hypothesis that rate of mutations in critical CRC genes 
involved in the tumor growth and survival i.e. KRAS, BRAF, NRAS and PIK3CA 
differ according to racial differences. 
 It also investigated the hypothesis that different clinicopathological factors would 
have impact on clinical outcome of the patient in the context of Indian patient 
cohort.  This hypothesis was addressed by pursuing the following aims and 
objectives.  
I. IA. Performing immunohistochemistry on CRC patient tumor samples 
(n=203) to investigate the tumor percentage and also to grade and 
categorize the tumors according to World Health Organization (WHO) 
criteria. 
IB. Screening all these colorectal cancer patient samples for 
i) KRAS mutations in exon 1 (codons 12 and 13) and exon 2 (codon 61) 
of KRAS gene.  
ii) BRAF mutations in exon 15 (codon 600)  
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iii) NRAS gene mutations exon 1 (codons 12 and 13) and exon 2 (codon 
61) and  
iv) PIK3CA gene mutations exon 9 (codons 542 and 545) and exon 20 
(codon 1047)  
IC. Analysing the frequency of mutations in these four gene in Indian 
CRC patients.  
II. Investigate the possible correlation between the mutations observed and clinico-
pathological factors. 
III. Examine the correlation between clinicopathological characteristics and survival 
outcome in the Indian CRC patient cohort (n=30). 
Figure 1.1: Schematic outline of Aims and Objectives of the study. 
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1.3 Thesis Outline 
Chapter two discusses the literature review related to the thesis topic with main 
focus on the diagnosis, biomarker analysis and treatment of metastatic CRC 
(mCRC). Also, reviewed here is the biomarker validation for personalized medicine 
and new candidate predictive and prognostic biomarkers requiring further 
investigations in prospective trials. 
 
Chapter three lists the materials and methodologies used in the experiments. 
 
Chapter four describes the standardization and validation of the assays for KRAS, 
BRAF, NRAS and PIK3CA mutation detection in CRC patient samples. 
 
Chapter five investigates the correlation between the mutations observed in 
KRAS, BRAF, NRAS and PIK3CA genes with the clinico-pathological data of the 
patients. 
 
Chapter six examines the correlation between clinicopathological characteristics 
and survival outcome in the Indian CRC patient cohort. 
Chapter seven provides the conclusion of the thesis and discusses future 
perspectives. 
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Chapter 2     Literature Review 
 
2.1 Introduction 
Cancer is one of the major cause of death worldwide. According to the World 
Cancer report, cancer rates will increase by 50% from 2015 to 2020. There will 
be 24 million people with cancer by 2035 (Stewart and Wild, 2016). According 
to the World Health Organization (WHO), one in five men and one in six women 
develop cancer before the age of 75 and one in eight men and one in twelve 
women die of this disease. Hence, WHO has labelled it as global ‘tidal wave’ of 
cancer (Siegel et al., 2015). Cancer is also a leading cause of economic loss. 
The annual economic cost of cancer is around 1.16 trillion USD (Siegel et al., 
2015). 
 
Cancer is mostly associated to Western developed countries. However, it has 
been observed recently that less developed or developing countries have 
shown a dramatically rise in new cancer cases. According to Globocan 2012, 
the highest incidence of new cancer cases and highest mortality is observed in 
Asian countries with 48% and 54.9% respectively (Ferlay, 2012) (Ferlay et al., 
2015). Figure 2.1 describes the global cancer incidence and mortality rate and 
Figure 2.2 describes the prevalence of different types of cancer in males and 
females. 
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Figure 2.1: Global cancer incidence and mortality according to Globocan 
2012(Ferlay, 2012). 
 
Figure Legend: According to the estimates of International agency for Research on 
Cancer (IARC) 2012, global cancer incidence was estimated as 14.1 million cases with 
highest percentage observed in Asian countries (48%) followed by European (24.4%), 
American (20.5%), African (6%) and Oceania  (1.1%) countries. Similarly, overall 
mortality was estimated to be 8.2 million cases with highest percentage observed in 
again Asian countries (54.9%) and lowest in Oceania (0.7%). 
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Figure 2.2: Gender wise global cancer incidence and mortality according to 
Globocan 2012(Ferlay, 2012).  
 
Figure Legend: According to the estimates of International agency for Research on 
Cancer (IARC) 2012, in females, highest incidence of breast cancer (25.2%) is 
observed followedy colorectum (9.2%) and lung (8.8%) whereas in males, lung cancer 
(16.7%) cases are the highest followed by prostate (15%) and colorectum (10%). 
Similarly, in case of mortality, breast cancer (14.7%) is leading cause of mortality in 
females followed by lung (13.8%) and colorectum (9%) whereas in males lung cancer 
(23.6%) is leading cause of mortality.  
 
 
The prevalence of cancer in India is estimated to be around 2.5 million 
with 800,000 new cases and 500,000 deaths due to cancer per year (Rath 
and Gandhi, 2014). The cancer numbers in the Indian subcontinent are 
increasing due to inadequate medical facilities, less patient awareness or 
education and late detection. An increasing trend has been observed in cancer 
incidence in the past few years as seen in the data compiled by the Indian 
Council of Medical Research (ICMR) (Rath and Gandhi, 2014) (Figure 2.3) 
 
 
Incidence and mortality 
number in thousands 
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Figure 2.3: Increasing trend of cancers in India (Image source ICMR(Rath and 
Gandhi, 2014)). 
 
 
Figure Legend: According to Indian Council of Medical Research (ICMR), increasing 
trend is observed in cancer incidence in India. By 2020, it has been estimated that the 
cancer incidence would reach to around 1100 thousand cases with increasing 
incidence observed in females in comparison to males. 
 
 
According to the study published by Marimutthu et al in 2008, the highest Indian 
incidence of cancer is seen in Delhi (Figure 2.4) with the most frequently 
observed cancers being lung, breast, stomach, oral, colon and rectum 
(Marimuthu, 2008).  
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Figure 2.4: Cancer prevalence in metropolitan cities of India (Image source: 
Marimutthu et al, 2008 (Marimuthu, 2008)). 
 
 
Figure Legend: Amongst the five metropolitan cities highest incidence of cancer is 
recorded in Delhi with around 14000 cases followed by Mumbai, Chennai, Bangalore 
and Bhopal. Higher cancer incidence is observed in females in comparison to males 
except in case of Bhopal.  
 
Colorectal cancer is one of the leading causes of cancer mortality worldwide. It 
is the most common of all gastrointestinal malignancies. It is the third most 
common cancer in men and the second in women with 60% of cases occurring 
in developed regions (Ferlay et al., 2010). Colorectal cancer develops as a 
result of stepwise progression through several genetic alterations (Migliore et 
al., 2011).  The past decade has uncovered various new pathways in the 
development of colorectal cancer. Despite this, an integrated view of the 
genetic and genomic changes and their implication on colorectal tumorigenesis 
remains to be obtained.  
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2.2 Epidemiology 
 
Colorectal cancer is an important public health problem. In 2012, there were an 
estimated total of 1,234,000 incident cases of colorectal cancer diagnosed 
worldwide (Ferlay, 2012). It is the third most common cancer in men with 
746,000 cases diagnosed and second in women with 614,000 cases diagnosed 
worldwide (Ferlay, 2012). This cancer affects men and women almost equally 
and accounts for 10% of total cancer burden in men and 9.2% in women (M.P 
Curado, 2008). Age standardized rates of colorectal cancer incidence are 
higher in men than in women (overall sex ratio of the ASR’s 1.4:1) (Ferlay, 
2012). About 41% of new cases of colorectal cancer occur outside 
industrialized countries, indicating that colorectal cancer is not just a disease of 
the developed world. Rapidly increasing populations, changes in lifestyle 
associated with economic development, together with the epidemiologic 
transition of less developed countries is leading to increasing numbers of 
colorectal cancer cases. 
 
2.2.1  Colorectal cancer incidence varies globally 
There is a large geographic variation in the global distribution of colorectal 
cancer (World Cancer Research Fund et al., 2007). Countries with highest 
incidence rates include Australia, New Zealand, Canada, the United States and 
parts of Europe. The countries with the lowest risk include China, India and 
parts of Africa and South America (Boyle and Ferlay, 2005). The incidence 
rates vary up to 10-fold between countries with the highest rates and those with 
the lowest rates (Center et al., 2009b). The incidence of colorectal cancer 
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ranges from more than 40 per 100,000 people in US, Australia, New Zealand, 
and Western Europe to less than 5 per 100,000 in Africa and some parts of 
Asia (World Cancer Research Fund et al., 2007). Slovakia had the highest 
incidence rate in 2012 of colorectal cancer in men followed by Hungary and the 
Czech Republic, with age standardized rates per 100,000 as 61, 56 and 54, 
respectively. New Zealand, Israel, Denmark and Norway had the highest 
incidence rates with 38, 36 and 34, respectively (Figure. 2.5 and 2.6A). The 
incidence shows considerable variation among racially or ethnically defined 
populations in multiracial or ethnic countries. For example, in 2009, 136,717 
people in the US were diagnosed with colorectal cancer, including 70,223 men 
and 66,494 women. African Americans have the highest incidence of colorectal 
cancer, followed by White, Hispanic, Asian Pacific Islander and American 
Indian/Inuits. Incidence rates reported (per 100,000) for all the races, Whites, 
African American, Asia/Pacific Islander, American Indian/Inuit, Hispanic are 
42.5, 41.3, 50.8, 33.7, 30.6, 36.4, (per 100,000), respectively (Figure. 2.6B) 
(Jemal et al., 2010a). Although the majority of colorectal cancer incidence rates 
in men are observed in Europe and North America, select registries in Asia also 
have recorded two to four fold increases in the incidence of colorectal cancer in 
men (Sung et al., 2005, Shin et al., 2012). However, among women colorectal 
cancer incidence rates have declined in New Zealand and Australia but have 
continued to increase in Israel (Center et al., 2009a). Lower rates of colorectal 
cancer are observed in women when compared to men. This may be due to 
behavioral differences, such as smoking rates and differing effects of obesity in 
men and women (McCormack and Boffetta, 2011, Frezza et al., 2006). 
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Asia has greatest diversity with regards to incidence of colorectal cancer High 
incidence rates are observed in China, Japan, South Korea, Singapore and 
Israel (Shin et al., 2012, Yiu et al., 2004) comparatively much lower are 
observed in Nepal, Bhutan and India (3.2, 3.5 and 6.1 per 100,000 
respectively).  These variations are due to different socioeconomic levels. 
However, increased incidence rates are observed in the developing countries 
which can be attributed to westernization, including consumption of high calorie 
food and physical inactivity. Among ethnic groups in Asia, the incidence of 
colorectal cancer is higher in Chinese (Lu et al., 2003, Yang et al., 2004). A 
rapid increase in incidence has also been observed in Taiwan and Iran in recent 
years (Moghimi-Dehkordi et al., 2008, Safaee et al., 2012, Su et al., 2012). 
Iranian data suggests a younger age distribution compared to Western 
countries, probably related to lifestyle changes (Mahmodlou et al., 2012, 
Khayamzadeh et al., 2011, Malekzadeh et al., 2009) 
In India, the annual incidence rate of colon cancer is 4.9 and that of rectal 
cancer is 4.1 in men per 100,000 and in women it is 3.9 per 100,000. The 
annual incidence rate in men, as recorded in 2013, is highest in 
Thiruvananthapuram (state of Kerala) (4.9) followed by Bengaluru (state of 
Karnataka) (3.9) and Mumbai (state of Maharashtra) (3.7) whereas in women, it 
is highest in the state of Nagaland (5.1) (Rath and Gandhi, 2014). 
 
2.2.2  Mortality of colorectal cancer 
In 2013, around 771,000 people died globally of CRC. The age standardized 
mortality rate is higher in men (10 per 100,000) as compared to women (6.9 per 
100,000). The mortality rate is higher in developed countries (11.6 per 100,000) 
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than in less developed countries (6.6 per 100,000) which could be due to the 
stage distribution at diagnosis (early diagnosis facility), awareness and 
availability of population screening programs and level of health care in each 
country. Western Africa has the lowest mortality rate (3.0 per 100,000) in the 
world and highest is seen in Central and Eastern Europe (11.7 per 100,000) 
(Figure 2.5) (Kuipers et al., 2015).  
 
However, recently, mortality trend analysis has shown that the colorectal cancer 
mortality has reduced in both men and women over the last several years. 
Along with the US, Australia, New Zealand and Western Europe, colorectal 
cancer mortality rates have also decreased in a few Asian (Japan and 
Singapore) and Eastern European countries. The decreasing mortality rates 
may be due to improvements in colorectal cancer treatments or to early 
detection i.e by introduction of colonoscopy. Increased mortality rates of 
colorectal cancer have been observed in South American countries, Russia, 
Romania, China, Croatia, Latvia and Spain (Figure 2.7A). The increasing 
mortality trends in these countries may be a reflection of increasing colorectal 
cancer trends observed in economically transitioning countries. This increase 
may also reflect lack of screening programs and changes in lifestyle, dietary 
factors and urbanization (Kuipers et al., 2015).  
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Mortality rates for colorectal cancer also vary with race and ethnicity. There is a 
six-fold variation in male mortality rates among different regions of the world 
and a five-fold variation in female versus male rates. In the US in 2009 the 
mortality rates reported (per 100,000, age adjusted to 2000 US standard 
population) for all races, whites, African Americans, Asia/Pacific Islanders, 
American Indian/Inuit and Hispanic are 15.7, 15.3, 22.1, 10.4, 12.6 and 12.1, 
respectively (Figure 2.7B) (Jemal et al., 2010a). Among men, African Americans 
are more likely to die of colorectal cancer followed by white, Hispanic, 
American, Indian/Inuit and Asia/Pacific Islander. In women, African Americans 
are more likely to die of colorectal cancer, followed by white, American 
Indian/Inuit, Hispanic and Asia/Pacific Islander. In Singapore, where different 
ethnic groups live in a similar environment, the incidence of colorectal cancer is 
lower in Indian and Malay population, in comparison to Chinese (Yang et al., 
2003). 
 
In 2012, mortality rates were the highest in Central and Eastern Europe (20 and 
12 per 100,000 in males and females, respectively) and the lowest in middle 
Africa and South central Asia (3-4 per 100,000) in both the sexes (Ferlay, 
2012). 
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Figure 2.5: Age standardized Incidence and Mortality of colorectal cancer in 
men and women per 100,000 across geographical zones (Kupiers et al, Primer, 
2015). 
 
Figure Legend: Highest incidence and mortality rates of colorectal cancer are 
observed in Australia and New Zealand, Europe and Northern America with males 
showing the higher rates in comparison to females. 
 
Figure 2.6A: Incidence rates of colorectal cancer. Data according to (Ferlay, 
2012). 
 
Figure Legend: In males the highest incidence of CRC is observed in Slovakia where 
as in females its observed in New Zealand  
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Figure 2.6B: Incidence rates of colorectal cancer in US. Data according to 
(Jemal et al., 2010b). 
Figure Legend: In U.S highest incidence of CRC is observed in African Americans and 
lowest is observed in American Indians/ Alaska Native. 
Figure 2.7A: Mortality Rates of colorectal cancer. Data according to (Ferlay et 
al., 2010). 
 
Figure Legend: The highest mortality rate is observed in males compared to females. 
In Hungary and Slovakia the mortality rate is highest amongst males whereas in case 
of females the mortality rate is highest in Hungary, New Zealand and Uruguay.  
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Figure 2.7B: Mortality rates of colorectal cancer in US. Data according to 
(Jemal et al., 2010b). 
 
Figure Legend: In U.S highest mortality rate of CRC is observed in African Americans 
and lowest is observed in Asia/Pacific Islanders. 
 
2.3 Pathophysiology 
Colorectal cancer usually develops over a period of 10-15 years where most of  
colorectal cancers are silent tumors, which grow slowly and do not produce 
symptoms until they grow to a large size. Colorectal cancer genesis is a 
multistep process involving accumulation of genetic and epigenetic changes 
that transform normal glandular epithelial cells into invasive adenocarcinoma. 
Colorectal cancer arises from mucosal colonic polyp. Some individuals are 
more prone to develop polyp, especially those with personal or family history of 
polyp and or colorectal cancer and those who carry specific genes for hereditary 
forms of colorectal cancer (Lanza et al., 2011). The two most common 
histologic types of polyps found in colon and rectum are described below. 
 
2.3.1 Hyperplastic polyps 
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These polyps are non-dysplastic and have little potential for malignant 
transformation (Figure 2.8). Histologically, these polyps contain an increased 
number of glandular cells with decreased cytoplasmic mucous, but lack nuclear 
hyperchromatism, stratification or atypia (Lanza et al., 2011). Recent evidence 
shows that serrated variants similar in morphology to hyperplastic polyps, but 
with malignant potential. These exhibit hyper methylation and arise primarily in 
proximal colon and may account for one third of all colorectal cancers 
(Torlakovic et al., 2003) . 
2.3.2 Adenomatous polyps 
These polyps most likely turn into colon cancer. These are considered pre-
cancerous. Adenomatous nuclei are mostly hyper chromatic, enlarged and 
crowded together in a palisade manner as seen in Figure 2.8 (Lanza et al., 
2011). Adenomas are common; an estimated one-third to one-half of all 
individuals will eventually develop one or more adenomas (Bond and Practice 
Parameters Comm Amer, 2000). Adenomas are further classified as tubular, 
villous or tubulovillious (Flejou, 2011). Adenomas usually grow on stalk and 
resemble mushrooms (Figure 2.8). They tend to grow slowly over a decade or 
more. The risk of adenoma developing into cancer increases with the size of 
adenoma and the time for which it is actually growing. In the early stages the 
abnormal cells are contained in the polyp, which can be removed. However, as 
cancer cells grow and divide inside the polyp, they can eventually invade 
nearby colon tissue and can grow into and beyond the walls of colon and 
rectum (Arnold et al., 2005)  
 
Chapter 2. Literature Review 
 20 
Figure 2.8: Diagrammatic representation of hyperplastic and adenomatous 
polyps. 
Figure Legend: Polyps are finger like projections growing from the lining of colon. 
There are two types of polyps-Hyperplastic and adenomatous. Hyperplastic polyps are 
pale, curved elevations and may rarely develop into cancer. However, adenomatous 
polyps are hyper chromatic, large, cigar shaped, crowded and resemble mushroom. 
These polyps turn into colon cancer. 
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2.3.3 Molecular abnormalities in pathogenesis of CRC 
Dr. Bert Vogelstein first described that colorectal cancer and associated polyps 
develop as a result of genetic mutations or other chemical modifications causing 
inactivation or promotion of specific genes known as tumor suppressing genes 
and tumor promoter genes (Fearon and Vogelstein, 1990) (Bosman, 2013). The 
most common molecular abnormalities that have been identified in the 
pathogenesis of colorectal cancer (Figure 2.9) (Patil et al., 2016).  
Figure 2.9: Schematic overview of molecular abnormalities in pathogenesis of 
colorectal cancer (Image source: (Patil et al., 2016).  
Figure Legend: This figure depicts the stepwise genetic events that lead to 
transformation of normal colonic epithelium to CRC. This progression requires 
accumulation of stepwise genetic changes that drive metastasis. Abbreviations: APC 
Adenomatous polyposis coli; COX, Cyclooxegenase; KRAS, v-ki-ras2 Kristen rat 
sarcoma viral oncogene homologue; MLH1, MutL homolog 1; MSH2, MutS protein 
homolog 2; DCC, Deleted in Colorectal Carcinoma; MGMT, O6-methylguanine DNA 
methyltransferase; p16 INK4A, Inhibitors of Cyclin Dependent Kinase 4; SMAD, 
Mothers against decapentaplegic homologue.  
 
According to this classical model, majority of colorectal cancers arise from 
aberrant crypt polyp which then converts into early adenoma with tubular or 
tubulovillious histology. The early adenoma then progresses to advanced 
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adenoma with/without villous histology and finally becomes a colorectal cancer. 
This process takes around 10-15 years except in patients with Lynch syndrome, 
where it can progress more rapidly (Jones et al., 2008). However, the 
understanding of molecular pathology has advanced in this past decade and 
has led to several revisions of this theory. The original theory proposed that only 
tubular and tubulovillious adenomas had the potential to progress towards 
invasive adenocarcinomas, however, it has been observed that hyperplastic 
polyps and sessile serrated polyps, accounting to around 5-10%, also have a 
potential of malignant transformation. Serrated polyps arise from histological 
and molecular events different from tubular polyps. These are classified into 
three categories- hyperplastic polyps, sessile serrated polyps and traditional 
serrated adenomas (Rex et al., 2012) (Figure 2.10). Serrated polyps that arise 
in right colon (caecum, ascending colon and transverse colon) commonly show 
Microsatellite Instability (MSI) and CpG island methylator phenotype (CIMP). 
Polyps arising in left colon (descending colon, sigmoid and rectum) show MSS 
phenotype with KRAS mutations and have attenuated form of CIMP (Bettington 
et al., 2013). 
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Figure 2.10: Events in transformation of serrated polyps to adenocarcinomas. 
 
 
Figure Legend: Hyperplastic polyps and sessile serrated polyps have potential of 
malignant transformation. Serrated polyps arise from histological and molecular events 
different from tubular polyps and are classified into three categories- hyperplastic 
polyps, sessile serrated polyps and traditional serrated adenomas. Polyps in left colon 
show presence of KRAS mutations, MGMT methylation and MSS/MSI-L status 
whereas polyps in right colon show BRAF mutations along with presence of MLH-1 
methylation and MSI-H state.  
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Figure 2.11: The WNT pathway: Image source: Reya T et al, Nature 
2005(Reya and Clevers, 2005). 
 
  
Figure Legend: WNT (Wingless plus int) pathway signaling pathway plays a vital role 
in embryonic development, proliferation and differentiation. Beta-catenin is the main 
component of WNT pathway. In normal cell, the level of beta-catenin is regulated by a 
complex of proteins - actin and tumor suppressor Adenomatous polyposis coli (APC). 
Mutation in APC leads to accumulation of APC, which travels to the nucleus and binds 
to TCF wherein it activates the genes. This process is considered as trigger for 
transforming event in colon cancer. Colorectal cancer is initiated by mutations in WNT 
signaling pathway and then progress upon deregulation of other signaling pathways 
including-RAS-RAF-MAPK, TGFB and PIK3-AKT pathway (Grady and Pritchard, 
2013). 
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2.3.4 WNT pathway 
The most common initiator of colorectal cancer is aberrant activation of WNT 
(Wingless plus int) pathway. Beta-Catenin, a major mediator of WNT pathway, 
is a membrane associated protein with function of regulation of cellular 
adhesion (Figure 2.11). In the absence of Wnt ligand, cytoplasmic beta-catenin 
forms a multiprotein complex with two other cellular proteins; axin and APC 
(Adenomatous polyposis coli). Beta-catenin then is phosphorylated by GSK3β 
(glycogen synthase kinase 3β), leading to destruction of beta-catenin by 
proteolysis. Hence, leading to low and steady state concentrations of beta-
catenin in the cytoplasm. On the other hand, when the WNT signaling is 
activated by the Wnt ligand binding to Frz receptor (Frizzled family of 
transmembrane proteins), GSK3β is blocked and beta-catenin is saved from 
rapid destruction, leading to accumulation of unphosphorylated beta-catenin in 
the cytoplasm. This accumulation leads to translocation into the nucleus where 
beta-catenin binds to transcription factors, and activates transcription of target 
genes, including those involved in cell proliferation, for example cyclin D1, 
contributing to tumour progression. Constitutive WNT signaling leads to an 
expansion of the proliferative compartment of the crypt by mutation of the 
tumour suppressor gene APC, there by destroying the equilibrium between 
proliferation and differentiation, leading to the development of precancerous 
lesions (Reya and Clevers, 2005). 
In addition to genetic mutations, epigenetic alterations seem to cooperate with 
genetic mutations to drive polyp to carcinoma transformation. There are three 
major pathways for colorectal carcinogenesis- Chromosomal instability (CIN), 
Microsatellite instability (MSI) and CpG island methylator phenotype (CIMP).  
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2.3.5 Chromosomal Instability (CIN) 
CIN is the most common and well-characterized pathway of carcinogenesis. It is 
characterized by high grade of differentiation, distal location and intermediate 
prognosis. Around 70% of colorectal cancer arise from CIN pathway (Markowitz 
and Bertagnolli, 2009). CIN pathway is associated with mutations in 
Adenomatous polyposis coli (APC) and/loss of chromosome 5q which harbors 
APC gene, loss of chromosome 18q, deletion of chromosome 17p, which 
contains tumor suppressor gene TP53, and mutations in KRAS oncogene. Only 
a small minority of CRC having CIN, have a full complement of these 
abnormalities (Grady and Carethers, 2008). 
 
APC is an important tumor suppressor gene. Pathogenic mutations in APC 
truncate the APC protein and hence interrupts the binding of APC to beta 
catenin involved in Wnt –signaling pathway (Cadigan and Liu, 2006). It is also 
seen that loss of functional APC may interfere with regulation of mitosis 
contributing to CIN. Frequency of APC mutations is observed in around 80% of 
early adenomas. Mutations of APC are observed in around 60% colonic 
cancers and 82% rectal cancers (Jass et al., 2002). 
 
DCC, SMAD2 and SMAD4 are located on chromosome 18q21.1. Allelic loss of 
18q is observed in around 60% of colorectal cancers. SMAD2 and SMAD4 are 
involved in TGF-β signaling pathway, which plays an important role in regulating 
growth and apoptosis. Mutations of SMAD4 cause juvenile polyposis syndrome 
associated with CRC (Worthley and Leggett, 2010b). 
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KRAS, a proto oncogene, plays an important role in CIN pathway. It is located 
on chromosome 12p12 and encodes a GTP binding protein. When mutated 
results in constitutive signaling through RAS-RAF-MAPK signaling pathway and 
thus permits cell to evade apoptosis and acquire growth advantage. Activating 
KRAS mutations are observed in 35-42% of colorectal cancer cases (Shen et 
al., 2007). 
p53 gene, is located on chromosome 17p13. This gene is also known as 
‘guardian of genome’. Impairment of TP53 is often a late event in colorectal 
carcinogenesis and usually occurs through allelic loss of 17p. Mutations or loss 
of heterogeneity in TP53 is observed in around 4-26% of adenomas, 50% of 
adenomas with invasive foci and 50-75%of CRC (Worthley and Leggett, 
2010a). TP53 abnormalities increase relative to advancing histological state of 
lesion. In normal functioning, p53 plays an important role in cell recovery form 
genetic damage. It increases the expression of cell cycle genes, slows down the 
cell cycle and hence provides time for DNA repair. Further, whenever there is 
great extent of DNA damage, p53 induces pro apoptotic gene, thus promoting 
early programmed cell death (Mills, 2005). 
 
These alterations of CIN pathway are the followed by subsequent events that 
promote and facilitate the progression towards malignant state. 
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2.3.6  Microsatellite Instability 
Microsatellite instability (MSI) is another important genomic instability in 
colorectal cancers. Microsatellites are nucleotides repeat DNA sequences 
distributed throughout the genome and MSI refers to the instability in these 
repeat sequences in germline DNA versus tumor DNA. These replication errors 
occur due to DNA polymerase activity while copying and inserting the repeat 
sequences during DNA replication. One of the methods to repair such 
replication errors is DNA Mismatch repair (MMR) system. Hence, dysfunction of 
MMR results in MSI. MSI is involved in development of about 15% of sporadic 
CRC cases and in about 95% of HNPCC syndrome associated tumors. CRC 
which develops through MSI pathway has distinct features like location in 
proximal colon, poor differentiation and/or mucinous histology and increased 
number of tumor infiltrating lymphocytes (Jass et al., 2002). 
 
MMR system consists of seven proteins, mlh1, mlh3, msh2, msh3, msh6, pms1 
and pms2, which associate with specific partners to form heterodimers which 
are then responsible for surveillance and correction of replication errors. 
Mutations in MLH1, MSH2, MSH6 and PMS2 are associated with HNPCC 
(Boland and Goel, 2010).  
 
To detect the frameshift mutations at the microsatellite regions in CRC, a 
standardized panel of microsatellites was created to provide uniformity in 
research and practice. This panel consists of two mono- nucleotide (BAT25, 
BAT26) and three dinucleotide microsatellites (D5S346, D2S123, and 
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D17S250). MSI-High (MSI-H) is defined as instability in more than 2 (40%) sites 
out of the five sites mentioned and MIS-Low (MSI-L) is instability at one site. 
And MSS i.e. microsatellite stable CRC has no instability in the mentioned five 
markers (Boland et al., 1998). HNPCC cause pure form of MSI, however, 
majority of MSI positive tumors i.e. MSI-H tumors occur sporadically due to 
methylation of MLH-1 promoter. Such cancers exhibit both MSI and CIMP.MSI-
H tumors share similar biology irrespective of been sporadic or inherited (Zhang 
and Li, 2013). 
 
MSI-H CRC patients show good prognosis and survival and MSI is relatively 
uncommon in metastatic CRC (Kawakami et al., 2015). MSI is frequently 
observed in women especially older women in comparison to men (Kim et al., 
2015). It has also been observed that MSI-H CRC are less responsive to 5-
flurouracil based chemotherapy (Kurzawski et al., 2004). 
 
2.3.7 CpG island methylator phenotype (CIMP) pathway 
CIMP pathway is second most common pathway for sporadic CRC. It is 
observed in around 15% of sporadic cases and in 70-80% of all dysplastic 
serrated lesions of right colon (Issa, 2008). It is observed that CIMP is closely 
associated with older age, female gender, mucinous histology, smoking, MSI, 
KRAS and BRAF mutations (Issa, 2008). 
 
CpG islands in DNA, are the regions which are proximally located in the 
transcription start site of genes. These islands contain high frequency of CG 
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dinucleotide. In various tumor suppressor genes in tumor cells, these CpG 
islands are frequently methylated resulting in repression of transcription. 
Subgroups of CRC show a wide range of hypermethylation of MLH1 gene, a 
mismatch repair gene, which is known as CpG island methylator phenotype. 
Tumors are classified as CIMP-high (CIMP-1) or CIMP-low (CIMP-2) depending 
on the extent of methylation. This methylation can be detected by a panel of 
CpG markers assessed by PCR (Shen et al., 2007). 
 
CIMP positive CRC, which show presence of MSI-H exhibit MSI-H 
characteristics like good prognosis. However, CIMP positive CRC which show 
absence of MSI-H are characterized by advanced pathology, poor clinical 
outcome and absence of tumor infiltrating lymphocytes (Jass, 2007). CRCs 
which develop via CIN pathway, including HNPCC, originate from adenomatous 
polyp. However, in CIMP pathway sessile serrated adenomas are primary 
precursors of CRC (Jass, 2007). 
 
Hence, all these three pathways of carcinogenesis have distinct clinical, 
pathological and genetic features, all being potentially useful for molecular 
characterization of CRC for improved diagnostic, prognostic and treatment 
prediction. 
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2.3.8 Clinical staging 
In the advanced stage of cancer the tumor metastasizes, shedding cells in the 
circulatory system and spreading the cancer to other organs like liver and lungs. 
The extent to which the cancer has spread is described as its stage. Staging is 
essential to determine the choice of treatment and to assess prognosis. At early 
stages, that is Stage I and II, a curative treatment is achieved by surgical 
resection or by chemotherapy, which is often applied in an adjuvant manner. 
The metastatic stage IV disease indicates a more advanced cancer and is 
usually incurable. The Stage I and II have moderate risk of relapse after surgical 
resection, whereas patients with stage III and IV have higher chance of 
recurrence (Libutti et al., 2008). 
 
In past, Dukes and Astler-Coller classification systems was most commonly 
used for staging (Dukes and Bussey, 1958, Astler and Coller, 1954). However, 
this system was not considered to be elaborate enough, hence, recently TNM 
staging system is used which is maintained by American Joint Committee on 
Cancer (AJCC). This system codes the extent of the primary tumor (T), regional 
lymph nodes (N), and distant metastases (M) and provides a stage grouping 
based on T, N, and M (Edge and Compton, 2010) (Figure 2.12). 
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Figure 2.12: TNM staging as maintained by American Joint Committee on 
Cancer (AJCC) and Union for International Cancer Control (UICC) (Source-
(Edge and Compton, 2010). 
 
 
Figure Legend: TNM Staging system is the most widely used staging system. It is 
based on extent of tumor (T), the extent of spread of lymph nodes (N) and the 
presence of metastasis (M).The status of T, N and M together decide the stage of 
cancer. The stages of cancer are further subdivided as II a or b, III a,b ,c etc. 
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Colorectal cancer may also present histologically with poorer prognostic cell 
types, such as adenosquamous or signet ring cells, and may have 
undifferentiated cells (Secco et al., 2009).  Carcinoid tumors and mucosa-
associated lymphoid tumor (MALT) lymphomas may also present as tumors in 
the colon but are not usually considered types of CRC (Oberhuber and Stolte, 
2000). Colorectal cancers can be characterized according to their location. They 
have a better prognosis rate when detected before bowel obstruction or 
perforation occurs. Incidence rates of colorectal cancer differ by sub-sites 
(Figure 2.13). Previously, tumors of the rectum were common but now the 
highest frequency of tumors are present in right ascending colon (CO and IN, 
2011). This change in incidence is attributed to improved screening and 
detection techniques to discover early polyps. 
Figure 2.13: Schematic overview of incidence of colorectal cancer. 
 
Figure Legend: According to anatomy the prevalence of CRC is predominantly higher 
in the left side of the bowel as compared to the right side (Macrae et al., 2015). 
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2.4 Risk factors 
There are many known factors that increase or decrease the risk of colorectal 
cancer. Summary of risk factors associated with colorectal cancer is provided in 
Table 2.1. Incidence and death rate for colorectal cancer increase with age. 
Further as reviewed earlier in this chapter (Section 2.2), incidence and mortality 
rates of colorectal cancer are about 35-40% higher in men than in women.  As 
suggested by Taunk and Audrey, the reason for this is not understood, but is 
likely related to the “complex interactions between gender related differences in 
exposure to hormones and risk factors” (Murphy et al., 2011). Further as 
detailed in Table 2.1, factors that increase risk also include a personal or family 
history of chronic inflammatory bowel disease (Crohn’s disease or ulcerative 
colitis), genetic mutations, high consumption of red or processed meat, 
smoking, physical inactivity, obesity and moderate to heavy alcohol 
consumption. Additional risk factors include exposure to asbestos, radiation, 
synthetic fibers, halogens (anesthetics), printing supplies and fuel (Moradi et al., 
2008).  
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Table 2.1: Summary of risk factors associated with colorectal cancer. 
 
Risk Factors References 
Genetics-Hereditary Colorectal Cancers  (Ghazi, 2012, Dunlop and Farrington, 
2009) 
Familial adenomatous polyposis  
MUTYH associated polyposis   
Lynch Syndrome   
Gardner’s Syndrome   
Peutz-Jeghers Syndrome   
Hyperplastic polyposis   
  
Family history of non-syndromic colon 
cancer 
 (Lynch et al., 2008, Jass, 2000) 
Cowden syndrome  
Bannayan Zonana Syndrome   
  
Inflammatory bowel disease  (Bewtra et al., 2013) 
Ulcerative colitis  
Crohn’s Disease  
    
History of neoplasia  (Niell et al., 2004) 
Prior colon cancer  
Breast cancer  
    
Other  (Sun and Yu, 2012, Abdulamir et al., 2011, 
Sonnenberg and Genta, 2013, Dutta et al., 
2012, Zhao et al., 2012) 
Diabetes mellitus and insulin resistance  
Strepotococcus bacteremia   
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Helicobacter pylori  
Acromegaly   
Prior cholecystectomy   
Use of androgen deprivation therapy   
   
  
Additional Factors 
 (Dong et al., 2010, Hendifar et al., 2009, 
Bardou et al., 2013) 
Age  
Gender   
Race/ethnicity   
Obesity   
Physical inactivity   
Diet   
Smoking   
Alcohol   
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Recent studies found that about one quarter of colorectal cancer cases could 
be avoided by following a healthy lifestyle (Anderson et al., 2013). Also, non-
steroidal anti-inflammatory drugs (Walker et al., 2012), estrogen and calcium 
(Lappe et al., 2007) have been found to protect against colorectal cancer. 
2.4.1 Age 
Age is one of the most important factors strongly related to CRC. The peak 
incidence of colorectal cancer occurs in the sixth and seventh decade of life. 
Incidence and mortality rate of CRC specifically increases after the age of 50 
years. Around 75% of cases of CRC occur in people above 65 years of age 
(Ferlay, 2012). However, recently it has been observed that the incidence of 
CRC is increasing in younger population. This could be due to lack of 
screening, behavioural factors such as alcohol consumption, smoking and 
lifestyle factor like obesity. It has also been observed that in the young patients 
CRC is more aggressive and has poor pathological features (Chou et al., 2011).  
2.4.2 Hereditary Factors 
Majority of CRC are sporadic, however about 20-30% of cases have a negative 
family history. People with their first degree relative having colorectal cancer or 
adenomatous polyps, diagnosed at the age of <50 years are at higher risk. Risk 
increases in individuals having two or more family members affected by 
colorectal cancer. The reason for increased risk is still unclear, however it may 
be due to genetic or environmental factors or due to combination of both 
(Boardman et al., 2007). 
2.4.3 Inherited Syndrome 
Around 5% of CRC cases are due to hereditary conditions. The most common 
inherited conditions include Hereditary nonpolyposis colorectal cancer (HNPCC) 
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or Lynch syndrome and Familial adenomatous polyposis (FAP) (Lynch et al., 
2008). HNPCC is caused by mutations DNA mismatch repair genes-MLH1, 
MSH2, MSH6, PMS2 or EPCAM (Lynch et al., 2008). Inheritance is in 
autosomal dominant pattern accounting for 2-5% of CRC and carriers of the 
mutations have around 50-80% lifetime risk of developing CRC.HNPCC display 
specific characteristics like mucinous or signet ring histology, poor 
differentiation, lymphoid infiltration and predominance of right side tumors. One 
of the most common clinical feature of HNPCC is that multiple generations get 
affected by CRC at an early age around 45 years (Jass et al., 2002). To identify 
individuals at risk, personal and family cancer history analysis, CRC molecular 
testing for MSI and MMR gene mutation analysis should be performed. 
Familial adenomatous polyposis (FAP), second most common hereditary 
colorectal cancer syndrome accounting for 1% of all colorectal cancer cases, is 
caused by mutations in Adenomatous polyposis coli (APC) and is inherited in 
autosomal dominant manner (Jasperson et al., 2010). Patients with FAP 
develop large number of adenomatous colorectal polyps that develop after first 
decade of life, unlike individuals with HNPCC who develop only few adenomas 
(Half et al., 2009). Carriers of APC gene mutations or individuals with known 
family history of FAP should start colorectal cancer screening for polyps at the 
age of 10-12 years with flexible sigmoidoscopy and should undergo annual 
colonoscopy once polyps are detected (Kastrinos and Syngal, 2011). If there 
are numerous polyps which cannot be managed by endoscopy then 
prophylactic colectomy is recommended (Galiatsatos and Foulkes, 2006).  
Other hereditary colorectal cancer syndrome include polyposis associated with 
mutations in the mutY DNA glycosylase (MUTYH) gene, Gardner Syndrome, a 
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type of FAP,  Peutz–Jeghers syndrome, caused by mutations in STK1 gene, 
serrated polyposis and juvenile polyposis. 
2.4.4 Inflammatory bowel disease (IBD) 
Chronic colitis and Crohn’s disease are significant risk factors of CRC. The risk 
increases with longer duration of IBD and is highest in patients with early onset 
and widespread manifestation (Jess et al., 2012). However, recently it has been 
observed that the incidence of CRC in IBD patients is reducing which may be 
attributed to effective anti-inflammatory treatment and improved surveillance 
(Castaño‐ Milla et al., 2014). 
2.4.5 Life Style Factors 
Life style related risk factors for CRC include lack of exercise, smoking, alcohol 
consumption and obesity. Intensity of physical activity is inversely proportional 
to risk of CRC. Increased risk is seen more in case physical inactivity and colon 
cancer than in comparison to rectal cancer. The mechanisms responsible for 
the association of reduced physical activity and increased risk to CRC are still 
not fully understood. However, there are few studies, which indicate reduction in 
insulin resistance, effects on endogenous steroid hormone metabolism and 
reduced gut transit time as possible biological mechanism responsible for 
increasing the risk of CRC (Samad et al., 2005).  
 
Carcinogens from cigarette smoking cause irreversible damage in normal 
colorectal mucosa, however, many years are required for completion of all 
carcinogenic events from the time of initiation. The association between 
smoking and CRC is stronger in case of rectal cancer in comparison to colon 
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cancer. Smoking initiates formation of adenomatous polyps which are one of 
the precursor lesion of CRC (Giovannucci, 2001). 
Studies have found increased risk of CRC with regular high alcohol intake 
(>45g/day) in comparison to nondrinkers (Cho et al., 2004). Studies have 
shown that obesity is associated with increased risk of CRC. Insulin and insulin 
like growth factors, leptin, adipose tissue induced changes of estrogen and 
androgen and inflammatory molecules are proposed to be the putative link 
between obesity and CRC. High insulin and IGF levels seen in obese people 
activate certain signaling pathways favoring pro-carcinogenic processes 
(Khandekar et al., 2011). Elevated levels of leptin in obese have shown to 
suppress apoptosis and stimulate proliferation of colonic epithelial cells (Stattin 
et al., 2004). 
 
2.4.6 Dietary factors 
Dietary factors potentially increase risk of CRC. Diet high in fats is associated 
with increased risk of CRC. Diet rich in fats seem to favor development of 
bacterial flora that degrade bile salts to potentially carcinogenic nitrogen 
compounds (Larsson and Wolk, 2006). Consumption of red and processed 
meat is also associated with increased risk of CRC. In The ERBITUX Plus 
Irinotecan for Metastatic Colorectal Cancer (EPIC) study, positive association 
between consumption of red meat and CRC was observed and also an inverse 
association between consumption of fish and CRC was seen (Norat et al., 
2005). Similarly, diet rich in fibers is inversely associated with CRC. Possible 
anti-carcinogenic effects of dietary fibers include reduction of secondary bile 
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acid production, reduction in intestinal transit time, increased fecal bulk, 
formation of short chain fatty acids from formation by colonic bacteria and 
reduction in insulin resistance (Trock et al., 1990). 
2.4.7 Race/ Ethinicity 
As reviewed earlier in Epidemiology section in this chapter,  African Americans 
have the highest incidence and mortality rate of CRC in all racial groups. Also, 
the Eastern European Jewish population i.e. Ashkenazi Jews has one of the 
highest CRC risk (Besterman-Dahan, 2008). Several mutations leading to 
increased risk of CRC in this ethnic group have been observed. The most 
common mutation is observed in APC gene, I1307K, observed in around 6% of 
American Jewish population. Individual preferences, social or cultural biases 
contribute to racial and ethic disparities, cancer prevalence in few groups is also 
linked to socio-economic status (Mitchell, 2013). 
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2.5 Diagnosis 
Colorectal cancer is associated with classical symptoms like blood in stool, pain 
in abdomen and altered bowel habits. Other symptoms include fatigue, 
shortness of breath, weight loss and anemia related symptoms. Diagnosis of 
CRC results from assessment of patient showing above mentioned symptoms 
or as a result of screening.  
Colonoscopy is a preferred method of investigation in symptomatic individuals, 
however, endoscopic methods are also available like-high definition white-light 
endoscopy, chromo-endoscopy, magnification endoscopy, narrow band 
imaging, intelligent colour enhancement and iScan imaging, autofluorescence 
endoscopy and microendoscopy. Colonoscopy is a gold standard for CRC 
diagnosis. This method has high accuracy, can enable simultaneous biopsy 
sampling and can access location of tumor. Over the past decade, colonoscopy 
has efficiently helped in reduction of CRC incidence and mortality. Past 20 year 
follow up data from UN National Polyp study has showed 53% reduction in CRC 
related mortality (Zauber et al., 2012).This method provides both diagnostic and 
therapeutic effect. The quality of colonoscopy has improved drastically over the 
past decade. The current standards utilize high power endoscopes with high 
resolution video screens to yield high definition endoscopy to improve the 
diagnosis of polyps and CRC. The invasive nature of this methodology possess 
a burden to the patients and might affect the participation in screening 
programs. However, recently various diagnostic methods and screening 
biomarkers have been introduced, such as capsule endoscopy and biomarker 
tests as mentioned in Figure 2.14 (Kuipers et al., 2015).  
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Figure 2.14: Advantages and disadvantages of different screening modalities 
used for diagnosis of CRC (Image source- Kuiper’s et al., 2013). 
 
FIT, fecal immunochemical test; gFOBT, guaiac faecal occult blood test. *Less 
problematic with newer-generation tests. 
 
There are few serological markers that allow early detection and diagnosis of 
CRC. The most widely studied marker is carcinoembryonic antigen (CEA). 
Serial CEA measurements can detect recurrent CRC and liver metastasis 
(Harrison et al., 1997). High preoperative levels of CEA are associated with 
poor prognosis. 
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2.6 Treatment strategies  
Although CRC is highly treatable if diagnosed in the early stages and surgically 
removed, recurrence after surgery and adjuvant therapy and metastatic disease 
are still major problems with a median overall survival of approximately 24 
months (Howlader et al., 2011). Nevertheless, there has been improvement in 
survival due to the introduction of new cytotoxic and targeted agents (Figure 
2.15). Systematic therapeutic efficacy is central to determining the outcome for 
patients. 
Figure 2.15: Schematic overview of advances made in treatment strategies for 
colorectal cancer. 
  
Figure Legend: CRC management has evolved evidently over the last few decades. 
Incorporation of new therapeutic concepts has led to improved survival [Image Source-
(Patil et al., 2016)]. 
 
2.6.1 Surgery 
Surgery is the mainstay curative treatment for non-metastatic colorectal cancer 
patients. The extent of surgery is determined by blood supply and distribution of 
regional lymph nodes and the choice of surgical method depends on 
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preoperative TNM staging. Tumors located at caecum and right colon are 
removed by right hemicolectomy followed by ileocolic anastomosis. Similarly, 
tumors located at hepatic flexure and transverse colon are removed by 
extended right hemicolectomy. Tumors of descending or sigmoid region are 
treated with left hemicoloectomy. Recently, complete mesocolic excision (CME) 
technique, similar to TME (Total mesorectal excision), has been introduced 
which has shown to improve overall survival and has also reduced the 
recurrence rate. To minimize surgical complications, perioperative protocols like 
fast track protocols and enhanced recovery after surgery have been designed. 
These protocols describe the list of requirements for taking care of patients at 
various steps in perioperative process (Willemsen et al., 1999). 
 
In case of operable disease primary surgery is carried out with or without 
adjuvant chemotherapy. For locally advanced disease, primary curative 
resection is unlikely hence, preoperative chemotherapy is considered (Kuipers 
et al., 2015). 
 
In case of isolated metastatic disease, resection of primary disease is carried 
out followed by metastasectomy with or without neoadjuvant and/or adjuvant 
chemotherapy. For widespread metastatic disease palliative chemotherapy 
along with supportive care is considered (Kuipers et al., 2015). 
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2.6.2 Conventional Chemotherapy 
It is unfortunate that surgical resection is not suitable for majority of metastatic 
cases, and the only option to prolong survival is systemic therapy directed at 
metastatic colonies. The conventional chemotherapy drugs used to treat 
metastatic colorectal cancer include: 
 5-Fluorouracil (abbreviated FU) 
 Capecitabine (Xeloda®) 
 Oxaliplatin (Eloxatin®) 
 Irinotecan (Camptosar®) 
These drugs work by interfering with the ability of rapidly growing cells (like 
cancer cells) to divide or reproduce themselves. Because most of an adult's 
normal cells are not actively growing, they are less affected by chemotherapy, 
with the exception of bone marrow (where the blood cells are produced), the 
hair, and the lining of the gastrointestinal tract. Effects of chemotherapy on 
these and other normal tissues cause side effects during treatment. The 
introduction of combination regimes of oxaliplatin or irinotican and 5-FU/LV 
have improved response rates, progression free survival and overall survival by 
15-20%, 5-6 and 10-12 months to 30-40%, 8 and 20-24 months, respectively 
(Colucci et al., 2005).  
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2.6.1.1 5-Fluorouracil / Leucovorin 
 
5-Fluorouracil (5-FU) has been the first choice of treatment options for 
colorectal cancer patients for over 40 years.  It is used in combination with 
leucovorin, a vitamin, which makes 5-FU more effective. 5-FU is given 
intravenously, although recently a pill form of 5-FU, capecitabine (Xeloda®) has 
been developed, which is used in metastatic colorectal cancer patients. 5-
FU/LU became the standard of care for patients with stage III and selected 
stage II colon cancer in the early 1990’s. Many clinical trials have shown that 
these regimens improve overall survival, but how they affect the risk of 
recurrence over time is not clear. Results of multiple randomized trials that have 
enrolled more than 4,000 patients comparing adjuvant chemotherapy with 5-FU-
leucovorin (5FU/LV) to surgery or 5-FU-semustine-vincristine demonstrate a 
relative reduction in mortality of between 22% and 33% (3-year OS of 71%–
78% increased to 75%–84%). Later studies have refined the use of 5-FU-
leucovorin in adjuvant settings (Gill et al., 2004).  
2.6.1.2 Oxaliplatin and Irinotican 
 
In early 2000’s, the introduction of oxaliplatin and irinotican resulted in 
meaningful improvement in the management of colorectal cancer patients. 
Irinotecan, a topoisomerase I inhibitor, was initially introduced as monotherapy 
for patients with metastatic colorectal cancer refractory to 5-FU. irinotican has 
demonstrated  clinical efficacy and tolerability in multiple non randomized and 
randomized Phase II and Phase III studies both as single agents and in 
combinations with bolus or infusional 5 FU/LV or in concomitant versus 
alternative schedules of administration (de Gramont et al., 2000). 
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In two of the second line trials of irinotican, 2.3 month (p>0.03) improvement in 
survival and 2.7 month (p>0/001) median survival improvements were observed 
(Rougier et al., 1998, Cunningham et al., 1998). 
In four Phase III trials, therapy with single agent irinotican resulted in longer 
survival time than BSC or FU/LV therapy in FU refractory patients(Cunningham 
et al., 1998, Fuchs et al., 2007, Rougier et al., 1998). A large trial involving 683 
patients compared 5-FU/LV with irinotican/bolus 5-FU/LV or single-agent 
irinotican (125 mg/m2) in weekly X 4, every-6-weeks schedules. Irinotecan/5-
FU/LV resulted in a higher response rate, a longer median time to disease 
progression, and longer median survival compared with 5-FU/LV, which showed 
efficacy comparable to that of irinotican. Grade 3 or 4 diarrhea occurred in 31% 
of patients who received irinotican alone versus 23% and 13% of patients who 
received IFL and 5-FU/LV, respectively. However, significantly greater 
incidence rates for Grade 4 neutropenia, fever, and severe mucositis were 
associated with 5-FU/LV. Combining irinotecan with 5-FU/LV did not affect 
quality-of-life scores compared with 5-FU/LV alone (Fuchs et al., 2007). Based 
on data from these trials, the United States Food and Drug Administration 
(USFDA) and European regulatory authorities approved irinotecan in 
combination with both bolus and infusional FU/LV as first-line therapy for 
mCRC, replacing FU/LV as the standard of care. Interim data from a pair of 
North American randomized trials have raised concerns regarding the safety of 
irinotecan containing regimens, with gastro-intestinal and thromboembolic 
syndromes accounting for the unexpectedly high rates of treatment-induced or 
treatment-exacerbated death (2.5% and 3.5%, respectively)(Rougier et al., 
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1998, Cunningham et al., 1998). However, European oncologists continued to 
use infusional FU/LV. 
 
To define the optimal first-line irinotecan regimen, the BICC-C trial compared 
5FU infusion plus irinotecan (FOLFIRI) to IFL and capecitabine plus irinotecan 
(CapeIri) (Fuchs et al., 2007). FOLFIRI was associated with improved 
progression-free survival (PFS) as compared with IFL (7.6 versus 5.9 months; 
p=0.004) and trended toward improved overall survival (23.1 versus 17.6 
months; p=0.09). In addition, FOLFIRI was associated with the most favorable 
toxicity profile of the three regimens, thereby establishing it as a reference 
standard for treatment of naive patients with colorectal cancer (Fuchs et al., 
2007). 
 
Similarly for oxaliplatin, a second generation platinum analogue, in an initial 
Phase III study oxaliplatin plus infusional 5FU (FOLFOX) was compared to 
infusional 5FU in the first-line setting (de Gramont et al., 2000). In the 2,246 
patients with resected stage II or stage III colon cancer in the completed 
Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the 
Adjuvant Treatment of Colon Cancer (MOSAIC [NCT00275210]) study, the toxic 
effects and efficacy of FOLFOX4 were compared with the same 5-FU-
leucovorin (5FU/LV) regimen without oxaliplatin administered for 6 months 
(André et al., 2004). Based on results from the MOSAIC trial, adjuvant 
FOLFOX4 demonstrated prolonged OS for patients with stage III colon cancer 
compared with patients receiving 5-FU-leucovorin without oxaliplatin (André et 
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al., 2009). Finally, the NCCTG-intergroup established 5FU/LV and oxaliplatin 
(FOLFOX4) as the new first-line standard regimen compared with the previously 
used irinotecan and bolus 5FU/LV (IFL) regimen (Alberts et al., 2005). Hence, 
FOLFOX has become the reference standard for the next generation of clinical 
trials for patients with stage III colon cancer. 
 
2.6.1.3 Capecitabine  
 
Later in the year of 2000, capecitabine was introduced and was found that for 
stage III colon cancer it provides equivalent outcome to intravenous 5-FU- 
leucovorin (Twelves et al., 2005). Several Phase II and III randomized trials also 
investigated the substitution of 5FU/LV by capecitabine (XELOX) and showed 
similar PFS and OS, but lower ORR (odds ratio = 0.85; 95% CI: 0.74–0.97; p = 
0.02) for XELOX compared with FOLFOX (Ducreux et al., 2011) .  
 
Grade 3 hand- foot syndrome was reported more frequently with capecitabine, 
although the condition was tolerated with a reduced dose (Van Cutsem et al., 
2001). Based on these data, capecitabine was approved in the U.S. as first-line 
therapy for patients with mCRC for whom combination therapy is not warranted. 
Oxaliplatin can be combined with synergistic efficacy with fluropyrimidines, 
irinotecan, bevacizumab and EGFR antibodies to further enhance treatment 
efficacy in metastatic colorectal cancer (Assenat et al., 2011, Tveit et al., 2010). 
In recent data from the Adjuvant Colon Cancer Endpoints (ACCENT) group, 
individual patient data from 18 phase III clinical trials of adjuvant 5-FU based 
chemotherapy for colon cancer was reviewed to show that the regimes provide 
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the beneficiary effect primarily by reducing the high risk of reoccurrence within 
the first two years of surgery. By five years after treatment with 5-FU based 
adjuvant therapy, the risk of recurrence dropped to 1.5% and dropped again to 
0.5% after eight years of treatment (Sargent et al., 2009). 
As sequential therapies cannot be predefined in treatment protocols, overall 
survival may no longer be regarded as the most sensitive end point for 
assessing the efficacy of first-line therapy; other factors, such as PFS and TTP, 
should be considered. 
2.6.2 Therapy options for colon cancer 
When the patients have undergone potentially curative resection with no 
residual disease then the Five year survival rate without adjuvant chemotherapy 
for Stage I is >90%, for Stage II is 70-80% and for Stage III is 50-60% (Mitry et 
al., 2008). In most cases adjuvant chemotherapy is well tolerated however, it 
may cause potential morbidity. Before administrating adjuvant treatment few 
patient selection criteria should be considered. A minimum of 8 lymph nodes 
and ideally >12 should be examined to determine the metastatic spread 
(Eisenhauer et al., 2009). Other factors like poorly differentiated tumors, 
presence of extramural vascular invasion or perineural invasion and T4 
classification are reportedly associated with relatively high risk of recurrence 
(Tsai et al., 2008). In addition to this MMR/MSI status should be evaluated in 
patients before administration of adjuvant therapy. 5-FU is not effective in MSI-
positive and deficient MMR patients (Sinicrope, 2010) .For patients with high 
risk Stage II tumors, capecitabine monotherapy is appropriate therapy. 
Colonoscopy should be performed after 1 year of surgery and every three years 
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thereafter (Sirohi et al., 2014). Figure 2.16 describes various adjuvant therapy 
options available to colon cancer. 
Figure 2.16: Adjuvant therapy options for colon cancer patients with no 
metastasis i.e Mo as per Indian Council for Medical Research (Sirohi et al., 
2014). 
 
5-FU-5-Fluorouracil, FOLFOX-5-FU plus oxaliplatin, CAPEOX-Capecitabine plus 
oxaliplatin. 
 
2.6.3 Therapy options for rectal cancer 
In case of rectal cancers, rate of local recurrence is higher in comparison to 
colon cancer due to limited availability to obtain wide radial resection margins at 
the time of surgery due to presence of pelvic bone (Sagar and Pemberton, 
1996). Surgery is the first option for tumors with low of positive or uninvolved 
mesorectal fascia. Short course of preoperative ratio therapy may reduce the 
local recurrence rate. Surgery is performed soon after completion of 
radiotherapy. In case of tumors associated with poor prognosis as assessed by 
MRI, T3 and T4 tumors with 4 or more lymph node involvement neoadjuvant 
chemotherapy along with radiotherapy is recommended. For Stage II and III 
rectal cancers, adjuvant chemotherapy is recommended following neoadjuvant 
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therapy (Sirohi et al., 2014). Adjuvant chemotherapy should be initiated soon 
after surgery so as to improve survival rate (Sirohi et al., 2014) (Figure 2.17).  
Figure 2.17: Neo adjuvant and Adjuvant therapy options for rectal cancer with 
no metastasis i.e Mo as per Indian Council for Medical Research (Sirohi et al., 
2014). 
 
 
5-FU-5-FluoroUracil, LV- Leucovorin, FOLFOX-5-FU plus oxaliplatin, RT- Radiotherapy 
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2.6.4 Treatment options for advanced disease i.e. mCRC 
In case of patients with resectable metastatic disease, surgery is the first option 
alternative approach been neoadjuvant chemotherapy. Adjuvant chemotherapy 
is usually recommended to reduce the rate of recurrence. The therapy options 
include FOLFOX, FOLFIRI, CAPOX or FOLFIRI or FOLFIRINOX with or without 
bevacizumab and cetuximab (in case of wild type RAS). 
For patients with unresectable mCRC, single agent chemotherapy is 
recommended. In first line treatment various options are recommended like 
capecitabine alone or 5-FU/LV alone or CAPOX with or without bevacizumab, 
FOLFOX with or without bevacizumab, FOLFIRI with or without bevacizumab or 
cetuximab, CAPIRI with or without bevacizumab, FOLFOX with or without 
Panitumumab. Before administration of Cetuximab and Panitumumab RAS 
testing is recommended (Sirohi et al., 2014) (Rossi et al., 2013). 
In case of second line treatment option single agent irinotecan or FOLFIRI, 
oxaliplatin + 5-FU, cetuximab or panitumumab with irinotecan, 5-FU with or 
without bevacizumab are the options which are taken into consideration. 
Aflibercept is also used in few cases (Sirohi et al., 2014, Carethers, 2008). 
In third line treatment option for mCRC, cetuximab with or without irinotecan has 
demonstrated to improve survival. In certain cases treatment may be offered ‘off 
study’ i.e. retreatment with previously successful regime after long disease free 
interval. Other options include reference of patients to clinical trials, treatment 
with regorafenib and best supportive care alone (Sirohi et al., 2014) (Carethers, 
2008). 
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2.6.5 Novel cytotoxic and targeted biologic therapeutics 
Recently cytotoxic drugs showed promising activity in the first-line treatment of 
patients with advanced CRC. Studies have demonstrated that the efficacy and 
safety of S-1, a novel oral fluropyrimidines, are comparable with those of 5-FU 
and capecitabine for metastatic colorectal cancer patients (Kusaba et al., 2010). 
However S-1 has mainly been studied among Asian population. Thus, at least 
for now, S-1 cannot be recommended in global populations with metastatic 
colorectal cancer as observed for many chemotherapeutic agents that the dose 
recommendation and safety vary significantly with ethnicity. A novel antifolate, 
Pemetrexed, that inhibits TS as well as folate dependent enzymes involved in 
purine synthesis, showed modest efficacy in a pair of frontline Phase II studies, 
with response rates of 15–17% (Braun et al., 2004). 
Advances in the understanding of tumor cell biology have fostered the 
development of novel biologic modifiers and molecular targeted therapeutics 
that interfere with specific tumor cell propagation mechanisms. These range 
from monoclonal antibodies to fusion proteins and small molecule inhibitors. As 
depicted in Figure 2.15, the USFDA since 2004 has approved targeted agents 
for example an antivascular endothelial growth factor (anti-VEGF) monoclonal 
antibody (mAb), bevacizumab (Avastin®; Genentech, Inc., South San 
Francisco, CA, http://www.gene.com) and a human epidermal growth factor 
receptor (HER-1/EGFR)-targeted mAb, cetuximab (Erbitux®; Imclone Systems, 
Inc., New York, NY, http://www.imclone.com), as first- and second-line mCRC 
therapy, respectively (Figure 2.18). 
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Figure 2.18: EGFR and VEGF Signaling Pathways in CRC development and 
tumor survival. 
 
 
 
Figure Legend: EGFR and VEGF signaling pathway play a pivotal role in tumor 
initiation, progression and survival, including CRC. EGFR gene is located on 
chromosome 7 and encodes a 170 kDa transmembrane receptor EGFR. EGFR 
belongs to ErBb family of receptor tyrosine kinases and is activated by several ligands, 
including EGF, transforming growth factor-α, amphiregulin (AREG), heparin-binding 
EGF, epiregulin (EREG), and betacellulin. Consequently, two pathways are activated 
by EGFR namely RAS–RAF–MAP kinase pathway and the PI3K–PTEN–Akt pathway 
which in turn leads to tumor initiation and progression. Activating mutations in RAS, 
RAF and PIK3CA can affect patients response to EGFR inhibitors. VEGF belongs to 
family of angiogenic growth factors and comprises of 5 VEGF glycoproteins. VEGFA is 
well characterized VEGF family member. Its receptor is VEGFR2. Binding of ligand 
leads to further activation of MAPK through a cascade of events leading to 
angiogenesis, proliferation, migration and survival of cells. 
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2.7 Targeting Vascular Endothelial Growth Factor (VEGF)  
VEGF is a critical regulator of angiogenesis. Since the growth and spread of 
tumors require angiogenesis, inhibiting this process makes an interesting 
strategy for the treatment of cancer (Folkman, 1971). The VEGF-A –targeting 
mAb bevacizumab (Avastin®) and  VEGF targeting Ziv-aflibercept (Zaltrap®), 
and regorafenib (Stivarga®)  have all been FDA approved for use in mCRC and 
studied in combination with chemotherapy.  
To date, there are no clinically validated biomarkers   which are in routine use, 
despite the widespread use of antiangiogenic therapy for mCRC (Duda et al., 
2013) (Mousa et al., 2015). The exact mechanism of benefit of anti-VEGF drugs 
is unclear, which has resulted in lack of biomarker based selection of patients 
for antiangiogenic therapy (Lambrechts et al., 2013).  
A retrospective analysis of baseline plasma/serum sample data for 88–97% of 
patients/study (>2000 patients), from two randomized Phase III studies 
HORIZON II and III investigating cediranib (an oral VEGFR TKI) in mCRC, 
reveals that baseline VEGF levels were treatment-independent prognostic 
biomarker for PFS and OS in both the studies (Jürgensmeier et al., 2013).  
Similarly, another retrospective analysis of the AVF2107 study data from phase 
III trial of bevacizumab in mCRC, reports the prognostic value of total circulating 
VEGF-A levels (pretreatment), but not predictive for bevacizumab based 
therapeutic benefit (Jannuzzi et al., 2015).  
In one of the phase II trials it was observed that when CRC patients were 
treated with FOLFIRI in combination with bevacizumab, significant increases in 
fibroblast growth factor 2 (FGF2), phosphatidylinositol-glycan biosynthesis class 
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F protein (PIGF), stromal cell-derived factor 1 (SDF-1) and macrophage chemo 
attractant protein 3 were observed, which may represent the mechanism of 
resistance. Also, increases in the baseline interleukin -8, (a promoter of 
angiogenesis), was observed and this was associated with decreased 
progression free survival (Kopetz et al., 2010).  
Furthermore, in the direction of achieving goal of personalized medicine, for 
host-specific variability single-nucleotide polymorphisms (SNPs) are also 
studied as potential biomarkers for response to anti angiogenic agents. Single 
nucleotide polymorphisms like VEGF1154G>A and VEGF405C>1 are found to 
be associated with improved overall survival and PFS (Formica et al., 2011). 
Also, in another study it was observed that low gene expression levels of 
VEGFA,VEGFR1 and VEGFR2 in colon cancer patients is associated with 
longer mean disease free survival (Zhang et al., 2015b).   Other biomarkers 
such as angiopoietin-2 (a key regulator of vascular remodeling along with 
VEGF) and CD133, identified as a potential biomarker of bevacizumab therapy 
outcome, need future validation for their true predictive rather than prognostic 
value reviewed in Patil et al, 2016.  
Recently, mathematical models have also been developed to address this issue 
(Finley and Popel, 2013), which could give new insight into the use of VEGF 
isoforms as predictive biomarkers. These mathematical models might shed 
some light on resistance mechanisms to anti-VEGF therapy and also be useful 
in the analysis of future large prospective studies to address these predictive 
biomarkers.   
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Hence, inhibiting the VEGF pathway has become an important strategy in the 
treatment of metastatic malignancies including metastatic colorectal cancer. 
Studies reveal that VEGF expression is elevated in a wide variety of tumor 
types including colorectal cancer. Hyper expression of VEGF is also seen to be 
associated with progression, invasion and metastasis of colorectal 
cancer(Martins et al., 2011). In case of metastatic colorectal cancer, along with 
VEGF, growth factors such as prostaglandin E2, EGF as well as molecular 
mediators of the epithelial-mesenchymal transition have been identified as 
potentiators of metastatic spread.  
Shaked et al 2008, have identified several hypothesis to explain the chemo 
sensitization action of anti-VEGF drugs. Anti-VEGF drugs work via several 
mechanisms, including increasing the delivery of cytotoxic drug via vessel 
normalization. Another possible mechanism is control of the repopulation of 
tumor cells during the chemotherapy-free intervals in between treatment cycles. 
A third hypothesis is inhibiting the mobilization of marrow derived circulating 
endothelial cells or their progenitors. This slows down the tumor growth and 
makes chemotherapy more effective (Shaked et al., 2008).   
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2.7.1 Bevacizumab-Anti VEGF monoclonal antibody 
Bevacizumab (Avastin) is a humanized monoclonal antibody that inhibits VEGF-
A through inhibition of blood vessel formation, normalization of vasculature and 
by reducing the intratumoral hydrostatic pressure (Krämer and Lipp, 2007). 
Bevacizumab binds directly to VEGF to form a protein complex which is 
incapable of further binding to VEGF receptor sites (which would initiate vessel 
growth) effectively reducing available VEGF. The Bevacizumab/VEGF complex 
is both metabolized and excreted directly. 
It received its first approval in 2004 by the US FDA for combination use with 
standard chemotherapy (as a first line treatment) and with 5-fluorouracil-based 
therapy for second line treatment for metastatic colorectal cancer. This 
recommendation was based on the E3200 trial which examined the addition of 
bevacizumab to oxaliplatin/5-FU/leucovorin (FOLFOX4) in therapy. The addition 
of bevacizumab was associated with improved progression free survival and a 
4.7 month survival advantage (20.3 versus 15.6 months, Harzard 
Ratio=0.66,p<0/001)(Kabbinavar et al., 2003). Other studies have also shown 
that bevacizumab can be safely combined with capecitabine plus oxaliplatin 
(XELOX, CAPOX), or irinotecan based regimens (Saltz et al., 2008, Hurwitz et 
al., 2004). Summary of clinical trials undertaken for bevacizumab is shown in 
Table 2.2. This strategy provides an extra option for patients with metastatic 
colorectal cancer. The challenge remains to determine which patients benefit 
most from continuing bevacizumab beyond progression. Hence, further 
investigations are required to clarify how this strategy can be used in present 
clinical scenarios, such as in v-ki-ras2 Kristen rat sarcoma viral oncogene 
homologue (KRAS) wild type tumors.  
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Table 2.2: Summary of clinical trials undertaken for bevacizumab. 
 
Study No. of 
patients 
Chemotherapy Overall 
Survival (in 
months) 
E3200- FOLFOX4 
with or without 
bevacizumab as 
second-line 
therapy in patients 
who have 
progressed on 
irinotecan-based 
therapy(Giantonio 
et al., 2007) 
 
829 Bevacizumab+FOLFOX4(n=286) 
versus FOLFOX4 alone (n=291) 
and bevacizumab alone (n=252) 
12.9 vs 10.8 
and 10.2 
BRiTE- 
Bevacizumab 
Regimens: 
Investigation of 
Treatment Effects 
and 
Safety(Grothey et 
al., 2008) 
 
1953 Bevacizumab as first and 
second line(n=642) versus 
bevacizumab as first line and 
chemotherapy as second 
line(n=531) 
31.8 versus 
19.9 
Chapter 2. Literature Review 
 62 
ARIES-  
Avastin in 
Combination With 
Chemotherapy for 
Treatment of 
Colorectal Cancer 
and Non-Small Cell 
Lung Cancer(Cohn 
et al., 2010) 
1550 FOLFOX+ Bevacizumab 
(n=968)versus FOLFIRI 
+Bevacizumab (n=243) 
23.7 versus 
25.5 
TML18147(Helwick, 
2012) 
820 Second line therapy with or 
without concomitant 
bevacizumab 
11.2 versus 
9.8 
FOLFOX4-Oxaliplatin/5-Fluorouralcil/Leucovorin, FOLFOX- oxaliplatin +5Flurouracil/Leucovorin, FOLFIRI-
5Fluorouracil/Leucovorin + Irinotican 
2.7.2 Aflibercept- a novel antiangiogenic fusion protein 
Aflibercept (Zaltrap, VEGF trap) is a fully human recombinant fusion protein 
composed of both VEGFR-1 and VEGFR-2 ligand binding components fused to 
the Fc portion of human IgG1 (W Stewart, 2011). It functions as a decoy VEGF 
receptor, binds VEGF-A, VEGF-B, and placental growth factors 1 and 2 with 
high affinity, prevents their binding to native VEGF receptors, and therefore 
inhibits angiogenesis through downstream signaling. In 2012, the USFDA 
approved Zaltrap for use in combination with 5-fluorouracil, leucovorin and 
irinotecan to treat adults with metastatic colorectal cancer that are resistant to or 
has progressed following an oxaliplatin containing regimen. This approval was 
based on a recent randomized Phase III  study VELOUR,  in which a total of 
1226 patients who had previously received oxaliplatin-based chemotherapy 
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were randomized to either FOLFIRI plus aflibercept or FOLFIRI plus placebo 
(Van Cutsem et al., 2012b). The study showed a significant increase in OS 
(13.5 vs. 12.1 months; HR 0.81) and PFS (6.9 vs. 4.7 months). There was a 
significant improvement in overall response rate in the aflibercept group when 
compared to FOLFIRI group (19.8% vs. 11.1%, p=0.0001). However, the side 
effects include hemorrhage, GI perforation and compromised wound healing. 
This agent is being evaluated in the first-line setting in combination with 
modified FOLFOX6 (mFOLFOX6) in the phase 2 Aflibercept And Modified 
FOLFOX6 As First-Line Treatment In Patients With Metastatic Colorectal 
Cancer (AFFIRM) trial (Wang and Lockhart, 2012). Hence, aflibercept is an 
important new option in oxaliplatin failing metastatic colorectal cancer patients 
in combination with FOLFIRI.  
2.7.3 Regorafenib-small molecule inhibitor 
Regorafenib (Stivarga) is an oral multi-kinase inhibitor which targets 
angiogenic, stromal and oncogenic receptor tyrosine kinase. Regorafenib can 
also inhibit c-KIT, RET, and BRAF. In September 2012, the USFDA approved 
regorafenib for the treatment of chemorefactory metastatic colorectal cancer 
patients. This approval was based on the CORRECT study (an international, 
multicentre, randomised, placebo-controlled, phase III trial) which investigated 
the use of regorafenib (160 mg orally daily for 3 out of 4 weeks) or placebo in 
760 patients (Van Cutsem et al., 2012a). The study revealed a significant 
improvement in overall survival by 29% (6.4 versus 5 months, Hazard 
Ratio:0.77). Regorafenib also significantly prolonged median progression-free 
survival (PFS) from 1.7 months to 1.9 months when added to best supportive 
care (p < 0.000001, 1-sided). The 0.2-month difference in PFS belies the 51% 
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reduction in the risk of disease progression with regorafenib. The most common 
side effects grade 3 or higher reported in patients treated with Stivarga 
included weakness or fatigue (9.6%), hand-foot syndrome (also called palmar-
plantar erythrodysesthesia) (16.6%), diarrhea (7.2%), hypertension (7.2%) , 
rash or desquamation (5.8%). Other side effects included loss of appetite, 
mouth sores (mucositis), weight loss, high blood pressure, and changes in voice 
volume or quality (dysphonia).  Approximately 8% of patients assigned to 
regorafenib permanently discontinued treatment due to adverse events, 
compared with 1% in the placebo arm. CORRECT study provides evidence that 
regorafenib is the first small-molecule multikinase inhibitor with survival benefits 
in metastatic colorectal cancer which has progressed after all standard 
therapies. It also therefore, highlights for a continuing role of targeted treatment 
after disease progression, with regorafenib offering a potential new line of 
therapy in this treatment-refractory population. Unlike bevacizumab and 
alfibercept, regorafinib is given by itself and not with other chemotherapy 
agents. The precise mechanism of action of regorafenib in mCRC remains 
unclear, and the predictive biomarkers are also not yet available for optimal 
patient selection.  
2.7.4 Identification of predictive biomarkers for anti-angiogenic agents: A 
priority for mCRC management 
Introduction of anti-angiogenic drugs over the last decade has established anti-
angiogenic therapy as a novel therapeutic modality, but their implementation 
has raised several important questions on whether we can find biomarkers to 
identify the patients who would benefit from these drugs. Validated biomarkers 
are not yet available for routine clinical use (Duda et al., 2013). The exact 
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mechanism of benefit of anti-VEGF drugs is unclear, which has resulted in lack 
of biomarker based selection of patients for antiangiogenic therapy(Lambrechts 
et al., 2013). This makes the identification of mechanistic biomarkers of 
response to anti-angiogenic therapy a priority. Researchers are currently 
studying tissue markers, blood derived markers, imaging parameters, 
genotypes and systemic measurements (Jain et al., 2009). There are limited 
and inconsistent clinical data for VEGF expression levels as the natural 
candidate for biomarker for anti-VEGF drugs.  Some studies suggest that 
circulating VEGF may predict response to anti-VEGF therapy in hepatocellular 
carcinoma (Zhu et al., 2009).  
Some phase III studies have found no association between circulation VEGF 
and response to bevacizumab (Hegde et al., 2013). In one of the phase II trials 
it was observed that when colorectal cancer patients were treated with FOLFIRI 
in combination with bevacizumab, significant increases in Fibroblast Growth 
Factor 2 (FGF2) , Phosphatidylinositol-glycan biosynthesis class F protein 
(PIGF), stromal cell-derived factor 1 (SDF-1) and macrophage chemoattractant 
protein 3 were observed, which may represent the mechanism of resistance. 
Also, increases in base line interleukin 8, which is the promoter of angiogenesis, 
was observed and this was associated with decreased progression free survival 
(Kopetz et al., 2010). Furthermore, in the direction of achieving goal of 
personalized medicine, for host-specific variability single-nucleotide 
polymorphisms (SNPs) are also studied as potential biomarkers for response to 
these anti angiogenic agents, and several SNPs have been studied as 
candidates for predictive markers for bevacizumab in non-colorectal cancers 
(Lambrechts et al., 2012). However, these have not been validated as good 
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markers to response to anti angiogenic agents in metastatic colorectal cancer 
primarily due to conflicting reports, disparity in detection/measurement of genes 
and enzyme activity, and variation in data analysis and interpretation. Recent 
mathematical models have also been developed to address this issue (Finley 
and Popel, 2013), which could give new insight into the use of VEGF isoforms 
as predictive biomarkers. These mathematical models might shed some light on 
mechanisms of resistance to anti-angiogenic therapy and also be useful in the 
analysis of future large prospective studies to address these predictive 
biomarkers. 
 
2.8 Epidermal growth factor receptor targeting agents 
 
The epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein 
which belongs to the human epidermal growth factor receptor (Her)-erbB family 
of receptor tyrosine kinases. It is composed of an extracellular ligand-binding 
domain, a hydrophobic trans-membrane region and an intracellular domain with 
tyrosine kinase activity. EGFR is activated by ligands belonging to EGF family 
of peptide growth factors which include TGF-α, EGF, amphiregulin, betacellulin 
or epiregulin. Binding of these ligands to its extracellular domain leads to 
formation of both homo or heterodimers with its family members ErbB2/Neu, 
Erbb3/Her3and Erbb4/Her4, which in turn leads to auto phosphorylation of 
intracellular tyrosine kinase domains and subsequent activation of downstream 
signaling (Ciardiello and Tortora, 2008). The most commonly activated 
downstream signaling pathways are the RAS-RAF-MAPK, the PI3K/AKT and 
the Jak2/Stat3 pathways, which in turn stimulate cancer cell proliferation, 
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survival, invasion, metastasis and neoangiogenesis (Ciardiello and Tortora, 
2008). Over-activation has been shown to induce tumorigenesis. Such 
overexpression is observed in 25% to 77% of colorectal cancers and has shown 
to be associated with tumor aggressiveness, poor prognosis and 
chemoresistance (Capdevila et al., 2009). Several mechanisms have been 
reported to contribute to this phenomenon, including mutations in the kinase 
domain of EGFR, overexpression of EGFR, and its ligands, and gene copy 
number changes. Hence, these findings led to a rational to target EGFR as a 
therapeutic strategy for colorectal cancer. EGFR inhibitors act by preventing 
ligand binding and subsequent downstream signaling of the oncogenic 
pathway.  
Cetuximab and panitumumab are two anti-EGFR mAbs that by targeting the 
extracellular domain of the receptor inhibit its dimerization and subsequent 
phosphorylation and signal transduction. These mAbs have improved patient 
outcomes and hence have been incorporated into routine clinical practice with 
the finding that the KRAS oncogene is a predictive biomarker for anti-EGFR 
therapy (Chee and Sinicrope, 2010). The therapeutic benefit of anti-EGFR 
treatment is restricted to tumors with wild-type KRAS. The use of molecular 
targeted agents has fewer yet more specific toxicities compared with 
conventional cytotoxic drugs and enables a more personalized approach to 
cancer therapy. 
2.8.1 Cetuximab 
Cetuximab (Erbitux) is a chimeric human/mouse recombinant immunoglobin (Ig) 
G1 that specifically binds to extracellular domain II of EGFR and blocks the 
ligand binding induced receptor dimerization and its further tyrosine kinase 
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activation. It also elicits antibody dependent cellular cytotoxicity against cancer 
cells (Kimura et al., 2007). In 2004, the FDA granted approval for cetuximab for 
use in combination with irinotecan for first line treatment of irinotecan refractory 
advanced colorectal cancer in patients. In 2012, FDA granted approval for 
cetuximab in combination with FOLFIRI (irinotecan, 5-FU and leucovorin) for 
first line treatment of patients with KRAS mutation negative mCRC. This 
approval was based on retrospective analyses of tumor samples from patients 
enrolled in the CRYSTAL trail and in two supportive studies, CA225025 and 
EMR 62 202 -047(OPUS). These studies led to the American and European 
health authorities restricting the use of cetuximab to patients with KRAS wild-
type tumors. The most common side effects of this medication are acne like 
rash and hypomagnesaemia (Van Cutsem et al., 2012c). A summary of clinical 
trials is shown in Table 2.3.  
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Table 2.3: Summary of clinical trials undertaken for cetuximab. 
 
Study No. of patients Chemotherapy Overall Survival 
(in months) 
CRYSTAL- 
Cetuximab 
Combined with 
Irinotecan in First-
Line Therapy for 
Metastatic 
Colorectal 
Cancer(KGaA, 
2005) 
 
1198 
63%-wild type 
KRAS 
37%-mutant 
KRAS 
Cetuximab + 
FOLFIRI (n=599) 
Versus FOLFIRI 
(n=599) 
23.5 versus 19.5-
wild type KRAS 
16.0 versus 16.7 – 
mutant KRAS 
CA225025(Huang 
et al., 2013) 
572 Cetuximab 
+BSC(n=287) 
versus BSC(n=285) 
8.6 versus 5-wild 
type KRAS 
No improvement 
for mutant KRAS 
EMR62 202-047 
OPUS- 
Oxaliplatin and 
Cetuximab in 
First-Line 
Treatment of 
Metastatic 
Colorectal 
Cancer(Chang et 
al., 2013) 
337 
57%-wild type 
KRAS 
43%-mutant 
KRAS 
Cetuximab + 
FOLFOX-4 
(n=169)versus 
FOLFOX-4 (n=168) 
22.8 versus 18.5-
wild type KRAS 
No improvement 
for mutant KRAS 
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BOND- 
Bowel Oncology 
with Cetuximab 
Antibody(Moroni 
et al., 2005) 
 
329 Cetuximab + 
Irinotecan (n=218) 
versus Cetuximab 
(n=111) 
4.1 versus 1.5 
EPIC-  
ERBITUX Plus 
Irinotecan for 
Metastatic 
Colorectal 
Cancer(Martinelli 
et al., 2009) 
 
1298 Cetuximab + 
Irinotecan(n=628) 
versus 
Irinotican(n=650) 
10.7 versus 10 
COIN- 
Continuous 
Chemotherapy 
Plus Cetuximab, 
or Intermittent 
Chemotherapy 
With Standard 
Continuous 
Palliative 
Combination 
Chemotherapy 
With Oxaliplatin 
1630 
57%-wild type 
KRAS 
43%-mutant 
KRAS  
Fluorouracil 
+Oxaliplatin 
+Cetuximab (n=815) 
versus Fluorouracil 
+Oxaliplatin (n=815) 
17.9 versus 17-
KRAS wild type 
14.4 versus 20.1-
KRAS mutant 
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and a 
Fluoropyrimidine 
in First-Line 
Treatment of 
Metastatic 
Colorectal 
Cancer(Tejpar et 
al., 2012) 
NORDIC VII- 
Cetuximab with 
Continuous or 
Intermittent 
Fluorouracil, 
Leucovorin and 
Oxaloplatin 
(NORDIC FLOX) 
versus FLOX 
Alone in First-Line 
Treatment of 
metastatic 
colorectal cancer 
(Tveit et al., 2012) 
571 
39%-mutant 
KRAS 
12%-mutant 
BRAF 
Cetuximab+ 
Oxaloplatin+ 
Fluorouracil+ 
Leucouracil versus 
Oxaliplatin+ 
Fluorouracil+ 
Leucouracil 
9.5 versus 22- 
BRAF mutant – 
strong prognostic 
marker 20.5 
versus 21-KRAS 
mutant – no 
significant 
difference 
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NORDIC VII- 
Cetuximab With 
Continuous or 
Intermittent 
Fluorouracil, 
Leucovorin, and 
Oxaliplatin 
(Nordic FLOX) 
Versus FLOX 
Alone in First-Line 
Treatment 
of Metastatic 
Colorectal 
Cancer(Tveit et al., 
2012) 
571- 
39%-mutant 
KRAS 
12%-mutant 
BRAF 
Cetuximab + 
Oxaliplatin+ 
Fluorouracil+ 
Leucouracil versus 
Oxaliplatin+ 
Fluorouracil+ 
Leucouracil 
9.5 versus 22- 
BRAF mutant-
strong prognostic 
marker 
20.5 versus 21-
KRAS mutant-no 
significant 
difference 
 
FOLFIRI-5Fluorouracil/Leucovorin + Irinotican, BSC-Best Supportive Care, FOLFOX4-Oxaliplatin/5-
Fluorouralcil/Leucovorin,  
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2.8.2 Panitumumab 
Panitumumab (Vectibix) is a human IgG2 monoclonal antibody targeting the 
extracellular domain of EGFR with high affinity and preventing its activation. 
Panitumumab is responsible for inhibition the of proliferation, angiogenisis and 
downregulation of EGFR expression (Foon et al., 2004). The most common 
side effects are skin rash and hypomagnesaemia, which are similar to those for 
cetuximab. Panitumumab was approved by the USFDA in 2006 for the 
treatment of EGFR-expressing metastatic colorectal cancer for cases where 
disease progression continues despite prior treatment. It was also approved by 
the European Medicine Agency (EMA) in 2007 and by Health Canada in 2008 
for the treatment of refractory EGFR-expressing metastatic colorectal cancer in 
patients with non-mutated (wild-type) KRAS. The approval was based on the 
result of single randomized multinational study which had 463 metastatic 
colorectal cancer patients. Patients were randomly assigned to either best 
supportive care (BSC) alone or BSC plus panitumumab (Van Cutsem et al., 
2007). The mean progression free survival was 96 days for patients receiving 
panitumumab and 60 days for patients receiving BSC alone. The median times 
of progression were similar (~8 weeks). The objective response rate for 
panitumumab monotherapy was 10 %, comparable with cetuximab 
monotherapy. A longer progression free survival with panitumumab was 
observed in wild type KRAS group (12.3 weeks) as compared to KRAS mutant 
group (7.3 weeks). 
 
Furthermore, a phase III randomized trial, called the PRIME study, evaluated 
the role of panitumumab in combination with oxaliplatin in first line chemo-naïve 
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metastatic colorectal cancer patients (Douillard et al., 2010). In this study 1183 
patients were enrolled, of which 40% had mutated KRAS. The treatment 
outcome was analyzed according to KRAS mutational status. The proportion of 
wild type and mutated patients was preserved in both of the study groups. 
There was a significant increase in progression free survival in KRAS wild-type 
patients who received panitumumab plus FOLFOX-4, as compared with the 
FOLFOX alone group (9.6 vs. 8 months; Hazard Ratio: 0.80, p=0.02). Similarly 
to cetuximab, KRAS status was predictive of panitumumab resistance. 
Another phase III randomized trial  the 20050181 study, evaluated the role of 
panitumumab in combination with FOLFIRI (Peeters et al., 2008). A total of 
1186 fluropyrimidine refractory patients were randomized to receive either 
panitumumab in combination with FOLFIRI or FOLFIRI alone. The KRAS status 
was analyzed for all patients. A significant prolonged progression free survival 
was observed in KRAS wild-type patients who received panitumumab in 
combination with FOLFIRI (5.9 months), as compared to patients who received 
FOLFIRI alone (3.9 months). There was no significant improvement in overall 
survival (14.5 vs 12.5 months; Hazard ratio: 0.85; p=0.12). 
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2.8.3 Predictive biomarkers for anti-EGFR agents 
The studies described above emphasize the role of anti-EGFR inhibitors for the 
treatment of metastatic colorectal cancer. From the results of these studies it is 
clear that primary resistance probably plays a pivotal role, and that only a 
specific subset of metastatic colorectal cancer patients might benefit from these 
anti-EGFR monoclonal antibodies. The discovery of biomarkers has led to 
improvements in the therapeutic index for these anti- EGFR antibodies. There 
are both positive and negative predictors of response which have been 
identified. 
 
2.8.3.1 KRAS 
v-ki-ras2 Kristen rat sarcoma viral oncogene homologue (KRAS), a proto 
oncogene, is a signal transducer modulated by the EGFR signaling pathway. It 
is the most frequently mutated gene in colorectal cancer (20%-40%)(Karapetis 
et al., 2008). KRAS activation induces activation of downstream components of 
the RAF-MAPK signaling pathway. KRAS is a cytoplasmic GTP-binding protein 
with low inherent GTPase activity. When the KRAS protein is bound to GTP, it 
relays signals of cellular proliferation and inhibition of apoptosis, acting as a 
typical oncogene as described in Figure 2.19 and 2.20. KRAS mutations were 
observed mainly in gene exon 2, resulting in abrogated GTPase activity and 
locking the KRAS protein in the active KRAS-GTP conformation. By activating 
the RAS/RAF/MAPK axis downstream of EGFR, these mutations render 
therapeutic modulation of EGFR irrelevant. The most frequent mutations are 
observed in codons 12 and 13 (Vaughn et al., 2011). Mutations in codons 61 
and 146 are under investigation.  
Chapter 2. Literature Review 
 76 
Figure 2.19: Activation of RAS pathway. 
 
Figure Legend: The ligand EGF (Epidermal growth factor) binds to EGFR (Epidermal 
growth factor receptor) and leads to phosphorylation of tyrosine kinase domain of the 
receptor. Upon stimulation of EGF receptor, Grb2 an adaptor protein binds to the 
tyrosine kinase domain through its SH2 domain and simultaneously binds to another 
protein SOS. This process catalyzes removal of GDP from RAS .RAS then binds to 
GTP acquiring an active conformation leading to further downstream RAF and MEK 
activation through phosphorylation. 
 
Binding of growth factors to receptor tyrosine kinases stimulates the 
autophosphorylation of specific tyrosines on the receptors. The phosphorylated 
receptor then binds to an adaptor protein called GRB2 which, in turn, recruits 
SOS to the plasma membrane. SOS is a guanine nucleotide exchange factor 
which displaces GDP from Ras, subsequently allowing the binding of GTP and 
consequently activating RAS. 
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Figure 2.20: Association of anti-EGFR therapy and KRAS mutations.  
 
Figure Legend: Anti EGFR drugs block receptor signals thus preventing downstream 
events. In case of Wild type KRAS, when EGFR receptor is blocked, it stops signaling 
and tumor cells do not proliferate. Whereas in case of mutant KRAS, it is permanently 
turned on allowing the tumor to continue to proliferate. 
 
 
Many retrospective studies and trials have shown the impact of KRAS 
mutational status on treatment efficacy with anti-EGFR monoclonal antibodies 
in metastatic colorectal cancer patients (Qiu et al., 2010). The studies have 
suggested that treatment with anti –EGFR produces better outcomes only in 
patients with wild type KRAS, whereas these drugs had no effect on mutant 
KRAS patients. Analysis of data from CRYSTAL and OPUS trials showed that 
addition of cetuximab with chemotherapy provided significant improvement in 
progression free survival and overall survival, in comparison to chemotherapy 
alone. Addition of cetuximab significantly reduced the risk of disease 
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progression by 34% in KRAS wild type patients and increased the likelihood of 
achieving a response by greater than 2 fold (Odds ratio:2.16, p<0.0001). In the 
re-analysis of CRYSTAL study done in 2015 additional RAS mutations were 
examined at KRAS exon 3 (codons 59 and 61), KRAS exon 4 (codons 117 and 
146), RAS status was evaluable in 430 of 666 patients (64.6%) (Van Cutsem et 
al., 2015) (Allegra et al., 2015). Recently, reports have suggested that different 
KRAS mutations may have different biological characteristics with respect to 
treatment sensitivity. Tumors having mutations of KRAS codon 13,  glycine to 
aspartate (G13D), have been suggested to retain cetuximab sensitivity and has 
improved outcomes in some patients during cetuximab therapy (Tejpar et al., 
2012). In the reported studies from different population backgrounds the KRAS 
mutations frequency varies from 14%-40% (Ozen et al., 2013, Mao et al., 
2012a, D. Lambrechts, 2009). These variations in patterns of KRAS mutations 
may be due to the racial differences and etiological factors. In view of the 
results of several clinical trials, KRAS mutation screening in codons 12 and 13 
for metastatic colorectal cancer treatment has been recommended (Allegra et 
al., 2009). The use of cetuximab and bevacizumab has been approved only for 
patients with KRAS wild type tumors. 
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2.8.3.2 BRAF 
 
V-raf murine sarcoma viral oncogene homologue B1 (BRAF) is a member of the 
RAF family acting downstream of KRAS in the MAPK cascade. The BRAF gene 
is another potential predictive factor. BRAF and KRAS mutations are mutually 
exclusive events in tumor (Fransen et al., 2004). The most frequently reported 
BRAF tumor mutation is a valine-to-glutamic acid amino acid (V600E) 
substitution that leads to the aberrant activation of the MEK–ERK pathway 
(Ikenoue et al., 2003). This mutation leads to a 500-fold increase in BRAF 
activity compared to the wild type form. BRAF mutations are used as exclusion 
criteria in the diagnosis of hereditary nonpolyposis colorectal cancer syndrome. 
Also, BRAF mutation is closely associated with MSI-H phenotype, MLH1 
hypermethylation and CIMP high status (Zlobec et al., 2010). The predictive 
value of BRAF mutations in KRAS wild-type patients treated with anti-EGFR 
therapy has been demonstrated by several groups. In the study carried out by 
Di Nicanlotonio et al., it was seen that among 79 patients with wild type KRAS, 
86% had wild type BRAF. No patient with a mutated BRAF had objective tumor 
response compared to 32% in patients with wild type BRAF(Di Nicolantonio et 
al., 2008). In the PETACC-3 study, BRAF mutations occurred in 7.9% of tumors 
in stage II and stage III colon cancer patients. These mutations were found to 
be prognostic for overall survival (Hazard ratio=2.2, p=0.003)(Roth et al., 2010). 
An analysis of 724 patients treated with irinotecan plus cetuximab showed 
mutated BRAF was present in 5% of patients and that it was associated with 
reduced responses compared with wild-type BRAF (6% versus 24%) (Tejpar 
and De Roock, 2009). In the CAIRO-2 study, the predictive and prognostic 
Chapter 2. Literature Review 
 80 
value of BRAF was analyzed in 516 patients. 8% of patients had BRAF 
mutations and had decreased median free survival compared to those without 
mutation (5.9 versus 12.2 months, P = .003 without cetuximab; and 6.6 vs 10.4 
months, P = .010 with cetuximab, respectively) (Tol et al., 2009). This finding 
suggests that BRAF can be a prognostic factor and not a predictive factor of 
cetuximab efficacy. Pooled analysis from CRYSTAL and OPUS data confirms 
that patients with mutated BRAF have worse prognosis than those with wild 
type BRAF. Based on these findings, BRAF genetic screening has been 
recommended in patients negative for KRAS mutations before treatment with 
anti- EGFR drugs. 
2.8.3.3 NRAS 
 
Neuroblastoma Ras viral oncogene homolog (NRAS) is a member of RAS 
family. Along with KRAS and BRAF, NRAS has also been evaluated recently as 
a potential predictive marker in metastatic colorectal cancer. The most 
frequently reported NRAS mutations are observed in codons 12, 13, 61, 117 
and 146 (D. Lambrechts, 2009). Recently in a retrospective study the predictive 
value of NRAS was evaluated in KRAS wild type metastatic colorectal cancer 
patients. As opposed to KRAS mutations, the NRAS mutation frequency was 
low (3-5%). In the pooled retrospective analysis led by the European 
Consortium, the rates of response to cetuximab in a large cohort of patients 
were lower in patients with KRAS wild-type tumors bearing NRAS mutations 
(De Roock et al., 2010). The only randomized dataset available demonstrates a 
numeric lack of benefit from panitumumab, another EGFR-targeted monoclonal 
antibody, for the NRAS mutant population, but trying to extract statistical 
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significance from findings obtained in a 14-patient population is not feasible. In 
one recent study, it was observed that in metastatic colorectal cancer the Q61K 
NRAS mutation had a favorable response to bevacizumab (Janku et al., 2013). 
These results suggest that NRAS mutations merits further investigation as a 
potential biomarker predicting the efficacy of bevacizumab-based treatment. 
2.8.3.4 PIK3CA 
 
Phosphatidylinositide-3-kinases (PIK3) are lipid kinases that are divided in three 
classes, I, II and III. Only the a-type isoform of the catalytic subunit, PI3KCA, 
harbors oncogenic mutations that are present in 15–20% of all colorectal 
cancers(Jehan et al., 2009). PIK3CA mutations occurring in the “hotspots” 
located in exon 9 (E542K, E545K) and exon 20 (H1047R) (Samuels et al., 
2005). It has been demonstrated that PIK3CA mutations confer resistance to 
apoptosis, whilst enhancing invasion capacity and metastatic potential. Several 
studies have demonstrated that PIK3CA mutations do not respond to anti-
EGFR therapy and these mutant colorectal cancer patients have shorter 
progression free survival than wild type patients (Lièvre et al., 2010). The 
findings of a European consortium suggest that response to EGFR treatment 
can be predicted only if specific PIK3CA mutation status is co-evaluated with 
KRAS status (De Roock et al., 2010). These investigations suggest that 
combining mutational analysis for KRAS and PIK3CA could identify up to 70% 
patients with metastatic colorectal cancer who are unlikely to respond to 
treatment with an EGFR targeted monoclonal antibody (Sartore-Bianchi et al., 
2009). In one of the recent studies a contradictory evidence was reported in 
which it was found that there was no strong rationale for using PIK3CA 
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mutations as a single marker for sensitivity to cetuximab in chemotherapy 
refractory metastatic colorectal cancer (Prenen et al., 2009). Since tumors with 
oncogenic PIK3CA are likely to be driven by PI3K as the primary source of 
growth, proliferation and survival, the use of selective PI3K inhibitors is being 
tested in ongoing trials. Several PI3K inhibitors are progressing from pre-clinical 
studies to phase I trials. These include XL147,GDC-0941,BGT226, XL765 and 
NVP-BEZ235 (Yuan and Cantley, 2008). This data from various trials needs to 
be validated in clinical applications in larger study groups due to occurrence of 
low frequency of PIK3CA mutations. 
2.8.3.5 PTEN 
Phosphatase and tensin homolog (PTEN) acts as a tumor suppressor gene 
through the action of its phosphatase protein product. This phosphatase is 
involved in the regulation of the cell cycle, preventing cells from growing and 
dividing too rapidly (Chu and Tarnawski, 2004). It negatively regulates 
intracellular levels of phosphatidylinositol-3,4,5-trisphosphate in cells and 
functions as a tumor suppressor by negatively regulating Akt/PKB signaling 
pathway. PTEN loss or inactivation leads to hyperactivation of the PI3K 
signaling pathway. Loss of PTEN expression occurs in 30% of sporadic CRCs 
(Thomas and Grandis, 2004). There are only few studies which have 
demonstrated that loss of PTEN expression may be useful in predicting 
response to cetuximab. Frattini et al. reported that none of 11 patients with 
tumor PTEN loss responded to cetuximab-based treatment, whereas 10 (63%) 
of 16 patients with intact PTEN protein expression were partial responders 
(Frattini et al., 2007, Sartore-Bianchi et al., 2009). Further studies are required 
to confirm these findings. 
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Figure 2.21: Estimated Response Rate to EGFR inhibitors in Western 
population with activating mutations in KRAS, BRAF, NRAS and PIK3CA Data 
according to -(Frattini et al., 2007). 
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2.8.3.6 TP53 
 
The TP53 gene encodes a tumor suppressor protein p53 which is one of the 
most frequently mutated genes in human cancer. Activated p53 binds to the 
regulatory sequences of a number of target genes to initiate a program of cell 
cycle arrest, DNA repair, apoptosis, and angiogenesis (Vogelstein et al., 2000). 
Loss of function of TP53 is critical in tumorigenesis, and mutations which result 
in overexpression of the protein are frequent events in colorectal cancer. p53 
alterations are more frequent in tumors that are aneuploid, non-mucinous, and 
do not show any MSI or CIMP molecular phenotypes (Westra et al., 2005).  
 
Associations of TP53 tumor alterations with patient prognosis and response to 
adjuvant chemotherapy have been widely studied. The majority of translational 
studies carried out which aimed at determining whether TP53 mutation and 
overexpression of p53 have prognostic value in colorectal cancer (Popat et al., 
2006). Few studies in colon cancer patients failed to demonstrate correlations 
between TP53 alterations and benefit from adjuvant therapy (Allegra et al., 
2003). Similarly, a subset of functionally inactive mutations in TP53 predict poor 
survival in late stage colorectal cancer (Iacopetta et al., 2006). Oden- Gangloff 
et al. suggests that TP53 mutations may be predictive of increased likelihood of 
response to cetuximab treatment, particularly in patients with wild-type KRAS 
status (Slevin et al., 2008).  
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2.9 Predictive and prognostic biomarkers in development 
2.9.1  Micro RNAs  
MicroRNAs (miRNAs) are small non-coding RNA molecules involved in the 
post-transcriptional and translational regulation of gene expression. miRNAs are 
emerging as ideal disease biomarkers for diagnosis as well as therapeutics in 
CRC patients. Several studies have demonstrated that the expression of 
various miRNAs in plasma may be indicative of presence of CRC. High plasma 
miR-29a and miR-92a expression are useful non-invasive biomarkers to 
distinguish CRC from healthy controls. Studies have shown a total of 362 
differentially expressed miRNAs in colorectal cancer of which 242 are 
upregulated and 120 are down regulated (Ma et al., 2012). miRNAs have also 
been evaluated as therapeutic targets. Two general strategies for miRNA-based 
therapeutics are seen: blocking oncogenic miRNAs and restoration of tumor-
suppressor miRNAs. Blocking of oncogenic miRNAs by anti-miRNAs has 
suppressed cell proliferation and has enhanced chemo sensitivity (Akao et al., 
2011). Similarly, studies have shown that restoration of miR-143 using miR-143 
precursor has reduced tumor growth (Ng et al., 2009). 
 
2.9.2   Cell free nucleic acid  
Circulating cell free nucleic acids has been reported in blood, stool and urine of 
colorectal cancer patients in higher levels in comparison to healthy individuals. 
Hence, presence of circulating DNA or RNA expression can provide valuable 
molecular information about the tumor. It has been shown that cfDNA levels 
decreased after tumor resection and increased in patients with recurrence and 
metastasis (Frattini et al., 2008). More studies are required to evaluate cfNA 
Chapter 2. Literature Review 
 86 
levels in same cohort and different sample types to select the best possible 
panel for diagnosis. 
2.9.3  Circulating tumor cells  
Circulating tumor cells (CTC) levels in peripheral blood have shown a significant 
correlation with more advanced disease. CTC detection is significantly 
associated with depth of tumor invasion, venous invasion, lymph node 
metastasis, liver metastasis and stage (Iinuma et al., 2006).Metastatic 
colorectal cancer patients with liver metastasis and poorer performance had 
higher baseline CTC levels. Baseline CTC is an independent prognostic factor 
in metastatic colorectal cancer. Patients with unfavorable levels of CTCs at 
baseline had significantly shorter median disease-free and overall survival than 
patients with fewer CTCs (Aggarwal et al., 2012). Also, patients with low 
baseline and post-treatment CTC counts had longer progression-free and 
overall survival than patients with an initially high baseline CTC count which 
decreased after chemotherapy. Hence, in multiple studies CTCs have shown to 
be prognostic and predictive biomarker. 
2.9.4  Protein Biomarkers 
Due to limited clinical applicability of CEA and CA19-9, additional proteins have 
been proposed as colorectal cancer protein markers. These include TIMP-1, 
MAPKAPK3, ACVR2B, CCSA-2, CCSA-3, CCSA-4 and matrix 
metalloproteinase 9, S100A8, and S100A9. These proteins show very 
promising results as CRC diagnostic biomarkers. However, these proposed 
biomarkers need to be validated individually or in panel so as to make it 
clinically relevant diagnostic tool (García-Bilbao et al., 2012).  
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2.9.5  Cancer stem cells  
Recently, compelling evidence has emerged in support of the cancer stem cell 
(CSC) hypothesis in several solid organ epithelial malignancies including CRC. 
CSC's are responsible for tumor initiation, metastases and resistance to 
treatment leading to disease relapse following surgery and/or chemo 
radiotherapy. As CSC have a potential to self-renew, capacity to differentiate 
and initiate tumor and also allow asymmetric cell division via non-random 
chromosomal co-segregation researchers have used these properties to isolate 
colorectal cancer stem cells (Langan et al., 2013). Till date various putative 
CRC stem cell  markers have been identified- CD133, CD24, CD29, CD44, 
CD166 (ALCAM), EpCAM, Lgr5, ALDH1A1 and ALDH1B1. These CSC markers 
have shown to predict disease progression, and identify patients at risk for 
recurrence. However, their prognostic significance as not been effectively 
evaluated(Lugli et al., 2010). Further as reviewed by Lagan et al, 2013 in order 
to translate the CSC based findings into clinical practice, comprehensive 
analysis of a panel of CSC expression in large groups of colorectal cancer 
patients is crucial. 
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Table 2.4: Summary of Biomarker based studies in CRC (Patil et al., 2016) 
 
Type Biomarker Biological Role Clinical use References 
C
h
e
m
o
th
e
ra
p
y
 
TS : Thymidylate 
Synthetase 
Response to 5-
Fluorouracil 
Predictive (Choueiri et 
al., 2015) 
Nuclear excision repair 
pathway -  ERCC1 
expression 
Absence or low 
expression, prolonged 
disease free survival with 
Cisplatin based adjuvant 
chemotherapy 
Prognostic (Choueiri et 
al., 2015) 
DPD : Dihydropyrimidine 
dehydrogenase 
5-FU Prognostic (Falvella et 
al., 2015) 
TP : Thymidine 
Phosphorylase 
High expression, poor 
prognosis with 
Capecitabine  
Prognostic (Bai et al., 
2015) 
MTHFR : 
Methylenetetrahydrofola
te Reductase 
Genetic polymorphisms; 
low risk to CRC 
Prognostic (Zhao et 
al., 2013) 
UGT1A1 : Uridine 
diphosphate 
glucuronosyl transferase 
1A1 
Genetic polymorphisms ; 
predicting toxicity to 
Irinotecan 
Prognostic (Lu et al., 
2015, 
Hirose et 
al., 2012) 
GSTP1 : Glutathione S-
transferase P1 
Genetic polymorphism 
Ile105Val ,increased risk 
to CRC 
Prognostic (Song et 
al., 2014) 
T
a
rg
e
te
d
 t
h
e
ra
p
y
 
KRAS : v-ki-ras2 Kristen 
rat sarcoma viral 
oncogene homologue 
Genetic mutations in 
exon2, 3 and 4. Predicting 
resistance to anti-EGFR 
moAB 
Predictive (Allegra et 
al., 2015) 
BRAF : V-raf murine Genetic mutations in exon Prognostic (Fransen et 
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sarcoma viral oncogene 
homologue B1 
15 V600 E, poor 
prognosis 
al., 2004) 
NRAS : Neuroblastoma 
Ras viral oncogene 
homolog 
Genetic mutations in 
exon2, 3 and 4. Predicting 
resistance to anti-EGFR 
moAB 
Predictive (De Roock 
et al., 2010) 
PI3K: 
Phosphatidylinositide-3-
kinases 
Genetic mutations. 
Predicting resistance to 
anti-EGFR moAB 
Predictive (Jehan et 
al., 2009) 
PTEN : Phosphatase 
and tension homolog 
Loss of expression. 
Predicting response to 
anti-EGFR moAB 
Predictive (Thomas 
and 
Grandis, 
2004) 
TP53 Genetic mutations. 
Predicting response to 
anti-EGFR moAB 
Predictive (Slevin et 
al., 2008) 
E
p
ig
e
n
e
ti
c
 m
a
rk
e
rs
 
MSI : Microsatellite 
Instability 
Lynch Syndrome Prognostic (Lech et al., 
2016) 
COX2 : Cyclooxegenase 
-COX2 
COX2 inhibitors 
associated with worst 
outcome to treatment and 
low risk to CRC 
Prognostic (Rahman et 
al., 2012) 
CIMP : CpG island 
methylator phenotype 
Methylation of CpG 
islands. Indicator of poor 
prognosis 
Prognostic (Bae et al., 
2013) 
18q LOH : 18q loss of 
heterogeneity 
Allelic loss of 18 q, poor 
prognosis 
Prognostic (Colussi et 
al., 2013) 
CIN : Chromosomal 
instability 
Abnormal chromosome 
number, poor prognosis 
Prognostic (Reimers et 
al., 2013) 
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P
ro
te
in
 m
a
rk
e
rs
 
CEA : Carcinoembryonic 
antigen 
Monitoring therapy and 
prognosis 
Prognostic (García-
Bilbao et 
al., 2012) 
CA19-9  : Cancer 
antigen 19-9 
Monitoring therapy and 
prognosis 
Prognostic (García-
Bilbao et 
al., 2012) 
TIMP : Tissue Inhibitors 
of Metalloproteinases 
Monitoring therapy and 
prognosis 
Prognostic (García-
Bilbao et 
al., 2012) 
B
io
m
a
rk
e
rs
 I
n
 d
e
v
e
lo
p
m
e
n
t 
Micro RNA (miRNA) Regulating gene 
expression, poor 
prognosis 
Predictive and 
prognostic 
(Akao et 
al., 2011) 
Cell free nucleic acid High levels of cfNA, poor 
outcome 
Predictive and 
prognostic 
(Frattini et 
al., 2008) 
Circulating tumor cells High CTC, poor outcome Predictive and 
prognostic 
(Aggarwal 
et al., 2012) 
Cancer stem cells Predict disease 
progression and risk of 
reoccurrence 
Predictive and 
prognostic 
(Lugli et al., 
2010) 
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In summary as reviewed in this chapter, over the past decade significant 
advances have been made in the management of colorectal cancer. Various 
genes and pathways have been identified in colorectal cancer and extensive 
knowledge has been gained about initiation and progression of the disease. 
These recent advancements have attributed to an increase in overall survival of 
metastatic colorectal cancer patients, with current overall survival averaging at 
approximately 2 years. Advances in the development of chemotherapy and 
biological agents to treat colorectal cancer have resulted in incremental gains 
for patients survival (Table 2.5).  
Recently several dynamic predictive markers have been identified which partly 
solve the challenge of selecting patients who will respond to the high cost 
targeted therapy (Table 2.4). However, currently there are only a few predictive 
tools which are available to select patients who would best respond to specific 
tumor treatments. Hence, there is a strong need to develop and validate more 
biomarkers to assist with clinical decision making.  
Population based studies are required to assess the most recent benefits of 
clinical trials and also to determine the meaningful survival improvements in 
colorectal cancer. With the recent genomic profiling of colorectal cancer and the 
development of new proteomic and modeling studies, selecting and stratifying 
colorectal cancer patients based on their molecular profile will be improved, 
resulting in better patient management and individualized and personalized 
health care. 
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Table 2.5: Biological agents in clinical trials 
 
Biological Agent Clinical Trial Stage Biological Agent Clinical Trial Stage 
Edrecolomab Phase III-Completed MEHD7945A Phase I-Recruiting 
Adecatumumab Phase II-Completed R05083945 Phase II 
Cixutumumab Phase II-Completed OMP-21M18 Phase I-Active not 
recruiting Conatumumab Phase II-Recruiting MGA271 Phas  I-Recruiting 
Figitumumab Phase II-Completed Dalotuzumab Phase II-Completed 
Ganitumab Phase II Drozitumab Phase Ib 
Necitumumab Phase II-Completed Ensituximab Phase I-Recruiting 
Nimotuzumab Phase II-Terminated Etaracizumab Phase I-Completed 
Trastuzumab Phase II-Completed Ramucirumab Phase II-Completed 
Tremelimumab Phase II-Completed Tigatuzimab Phase II 
Zalutumumab Phase II-Terminated CDX-1127 Phase I-Recruiting 
AMG386 Phase I-Completed CEP37250/KHK280
4 
Phase I-Active not 
recruiting 
CNTO328 Phase I/II-Completed Hu3S193 Phase I-Completed 
CT011 Phase II-Completed ING-1 Phase I-Completed 
GS-6624 Phase II-Recruiting KRN330 Phase  I/II-Completed 
IMC18F1 Phase II-Active not 
recruiting 
MDX-1105 Phase I-Active not 
recruiting 
IVIG Phase II-Unknown MDX-1106 Phase I-Completed 
L19 Phase II-Completed MGA-271 Phase I-Recruiting 
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2.10 Molecular Pathology Epidemiology: Emerging discipline to help in 
optimizing disease prevention and treatment strategies  
Molecular Pathological Epidemiology (MPE) or Molecular Pathologic 
Epidemiology is a promising interdisciplinary research field that deals with the 
integration of molecular signatures with epidemiological studies to elucidate 
disease aetiologies. Its concept was consolidated in the year 2010 by Ogino 
and Stampfer (Ogino and Stampfer, 2010), and has been designed to reveal 
how various lifestyle exposures affect initiation, transformation and progression 
of neoplasia (Ogino and Stampfer, 2010, Ogino et al., 2016).  
 
CRC comprises of heterogeneous group of diseases with varied genetic and 
epigenetic alterations. With the introduction of MPE, interactive effect of 
molecular features of the tumor and lifestyle or other exposure factors on 
prognosis and clinical outcome can be examined. In traditional epidemiological 
studies, the risk of developing CRC in accordance with the different genetic, 
environmental or lifestyle related factors was examined. However, MPE 
investigates   the genetic or molecular variation in population, its interaction with 
lifestyle or environmental factors to evaluate possible causative links by 
encompassing Genome wide association studies (GWAS) (Figure 2.22).  
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Figure 2.22: Difference between traditional epidemiological studies and 
Molecular pathologic epidemiology (MPE) (Image Source-Ogino et. al., Gut, 
2011). 
 
 
As mentioned by Ogino and co-workers, there are three approaches to 
investigate exposure and molecular change- Case-Case approach, Case-
Control Study and Prospective Cohort Study (Ogino et al., 2011). The same has 
been demonstrated in Figure 2.23. There is one more approach as mentioned 
by Ogino et. al. which is known as Interventional Cohort study. This approach is 
considered as a ‘gold standard’, however, no data has been published yet. 
  
Chapter 2. Literature Review 
 95 
 
Figure 2.23: Three approaches of MPE (Image source-Ogino et.al., Gut, 2011). 
 
In ‘case- case’ approach, the tumor is classified according to the subtypes and 
the effect of the variable of interest is compared amongst the different subtypes. 
The limitation of this approach is that the direction of any association between 
the exposure variable and the molecular subtype cannot be ascertained. Like 
for example as provided by Ogino et al, if smoking an exposure variable is 
studied along with KRAS mutations which acts as molecular subtype, then in 
case- case approach it cannot be ascertained if smoking protects form KRAS 
mutations or causes KRAS mutations. 
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The second approach is ‘Case-Control’ approach. In this approach the 
distribution of the exposure variable is studied in the cases with specific genetic 
or epigenetic alterations as well as in the control cases without those 
alterations.The third approach of Prospective cohort study combines case-case 
and case-control approach. This approach requires substantial number of 
participants, frequent follow up time, large funding and substantial efforts by 
researchers. 
Hence, MPE with its distinctive strengths can provide insights into the 
pathogenic process of a disease and help optimize personalized therapy and 
prevention. 
 
However, there are few challenges of MPE such as sample size limitations, 
validations of assays and study findings, paucity of interdisciplinary experts and 
standardized guidelines (Ogino et al., 2015). To overcome these challenges, 
Professor Shuji Ogino has taken an initiative and has introduced International 
MPE meeting series since April 2013.He has also started many projects like- 
Strengthening the Reporting of Observational Studies in Epidemiology-MPE 
guideline project and ongoing efforts for multidisciplinary consortium projects. 
These approaches are similar to other existing initiatives like Big Data to 
Knowledge (BD2K), Genetic Associations and Mechanisms in Oncology 
(GAME-ON), and Precision Medicine initiatives. Hence, in oncology, MPE, a 
different approach  from traditional epidemiological studies, has led to address 
the interactive effect of exposure factors and molecular changes on the tumor 
aggressiveness.MPE will in future help in providing substantial insights in 
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carcinogenic processes and will also help in optimizing prevention and 
treatment strategies. 
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Chapter 3     Materials and Methods 
 
3.1 Study Population 
A total of 203 formalin fixed paraffin embedded (FFPE) colorectal cancer tissue 
samples of patients from Indian origin were analyzed for mutations in KRAS, 
BRAF, NRAS and PIK3CA genes.  
 
The age range for males was 21-90 years and of females was 27-76 years and 
median age was 54 years. These samples were resected at various hospitals all 
over India and were sent to us for testing during January 2013 till June 2016. 
 
Demographic and clinicopathological features were obtained along with the test 
requisition form. Each sample has been designated with a unique accession 
number. The project has been approved by scientific committee of Reliance Life 
Sciences. The samples were processed according to guidelines of College of 
American Pathologists (CAP) and National Accreditation Board for testing and 
calibration Laboratory (NABL) and the samples were collected from patients 
with informed consent. 
 
3.2 Methods 
The detection of mutations in KRAS exons 2 and 3, BRAF exon 15, NRAS 
exons 2 and 3 and PIK3CA exons 9 and 20 was developed and standardized 
in-house for PCR amplification and direct nucleotide sequencing of PCR 
products. The assay was validated in order to comply with the guidelines of 
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National Accreditation Board for testing and calibration Laboratory (NABL), 
India and College of American Pathologists (CAP), USA. The validation 
parameters included sensitivity, specificity, repeatability and reproducibility as 
defined below. The performance characteristics were determined at Molecular 
Medicine Group, Reliance Life Sciences Pvt. Ltd., Navi Mumbai, India, after the 
completion of validation of the assay. 
 
Sensitivity: Analytical sensitivity represents ability of the assay to consistently 
detect presence or absence of mutations in minimum percentage of tumor 
present in the sample and also to detect the mutant allele burden in normal 
allele. 
 
Specificity: Analytical specificity represents ability of the assay to consistently 
amplify only specific exons or regions of the mentioned genes and absence of 
non-specific additional fragments. 
 
Repeatability: The agreement in the results of an assay performed by the same 
analyst on two different occasions in independent assay is defined as 
repeatability of the assay. 
 
Reproducibility: The agreement in results of an assay performed by different 
analysts on different occasions in independent assay is defined as 
reproducibility of the assay. 
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The mutation detection assays for KRAS, BRAF, NRAS and PIK3CA were 
based on six major processes outlined below. 
1. Haematoxylin and eosin (H&E) analysis for histological assessment of 
tumor in FFPE tissue samples. 
2. Specimen preparation: DNA extraction from FFPE tissues, quality check 
and quantification of the DNA. 
3. PCR amplification of exon 2 and exon 3 for KRAS, exon 15 for BRAF, 
exon 2 and exon3 for NRAS and exon 9 and exon 20 for PIK3CA genes. 
4. Detection of amplified products by agarose gel electrophoresis. 
5. Direct sequencing of the amplified products. 
6. In-silico data analysis for mutation screening. 
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Flow chart of Methodology 
 
Formalin Fixed Paraffin Embedded Tissue (FFPE) specimen collection (n=203) 
(Demographic and clinico-pathological details) 
 
 
Immunohistochemistry (Tumor % + Tumor grading) 
 
 
DNA isolation from FFPE samples 
 
 
PCR assay standardization, validation and set up for all four genes (KRAS, 
BRAF, NRAS and PIK3CA genes) 
 
 
Sequencing and analysis for mutation profiling of four genes  
 
 
Correlation between mutations and clinico-pathological characteristics 
 
 
Survival Analysis 
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3.2.1 Haematoxylin and eosin (H&E) Analysis 
H & E staining is an essential first step to confirm the presence of 
representative tumor tissue before further analysis can be started. It is the gold 
standard and allows the typing and grading of tumors as well as gauging the 
extent of tissue involvement by tumor. 
 
3.2.1.1 Principle 
Tissue processing leaves the tissue structurally enabled to undergo 
downstream processes of sectioning and staining for diagnostic purpose. The 
H&E is the most widely used stain for histopathology in which nuclei is stained 
by oxidized haematoxylin (haematin) through mordant bonds such as aluminum 
followed by counter-staining by xanthene dye eosin, which colors in various 
shades the different tissue fibers and cytoplasm. Haematoxylin is basic in 
nature and binds to basophilic substances i.e. DNA or RNA, whereas eosin is 
acidic in nature and binds to acidophilic substances like amino acid side chains. 
 
3.2.1.2 Method 
Pre-cooled FFPE block was immobilized on a microtome. The angle of high 
profile microtome blade was adjusted. Trimming of the paraffin blocks was done 
on 10 µM. Then microtome setting was adjusted for section thickness of 3-4 
µM. Ribbons of tissue sections taken and were layered on a floatation water 
bath (temperature = 50° C) from where they were mounted on egg albumin 
coated ordinary double frosted slide for H & E analysis. 
Slides were then placed in oven at 60°C overnight and then transferred into 
xylene bath and three serial changes were performed at an interval of 5 min. 
Rehydration of slides was done using 100 % ethanol in two changes at 5 min 
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interval and then the slides were placed in freshly prepared 90 % ethanol for 5 
min followed by 70% and 50%. Slides were gently rinsed under tap water for 5 
min and were kept in Harris haematoxylin solution for 10 min followed by gentle 
wash under tap water for 5 min. The slides were then dipped in 1% acid alcohol 
for differentiation and then gently rinsed under tap water followed by treatment 
with 1% ammonia solution with single change followed by gentle wash under 
tap water. These slides were then placed in 70% ethanol followed by absolute 
ethanol for 30 s each and were then dipped in Eosin stain for one min. Slides 
were dehydrated in two changes of fresh 100% ethanol for 5 min each followed 
by blot drying and were kept in xylene overnight and mounted in DPX. These 
were then reviewed by the pathologist for tumor content and grading. 
  
Chapter 3. Materials and Methods 
 104 
Figure 3.1: H&E stained tissue samples 
  A
  B 
Figure Legend: 
A Representative H&E photomicrograph of colorectal cancer tissue sample with well 
differentiated adenocarcinoma, WHO grade I; 
B  H&E photomicrographs of normal tissue. 
 
3.2.2 DNA extraction 
3.2.2.1 Principle 
The PureLink Genomic DNA kits (Invitrogen, Cat No. K1820-02, Carlsbad, CA, 
USA) are based on the selective binding of DNA to silica-based membrane in 
the presence of chaotropic salts. The lysate was prepared from a variety of 
starting material such as tissues. The cells were digested with Proteinase K at 
55C using an optimized digestion buffer formulation that aids in protein 
denaturation and enhances Proteinase K activity. Any residual RNA was 
removed by digestion with RNase A prior to binding samples to the silica 
membrane. The lysate was mixed with ethanol and Purelink Genomic Binding 
Buffer that allows high DNA binding Purelink Spin Column (Mini kit). The DNA 
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binds to the silica based membrane in the column and impurities were removed 
by thorough washing with Wash Buffers. The genomic DNA was then eluted in 
low salt Elution Buffer. 
 
3.2.2.2 Methodology 
The protocol was followed as per the manufactures instructions (Invitrogen, Cat 
No. K1820-02, Carlsbad, CA, USA) 
 
1. Specimen preparation 
Four sections each of 8 µM of FFPE tissue specimen were taken in 1.5 ml 
microfuge tube. Tumor sections having 20% tumor content, as assessed by the 
pathologist, were processed further for macrodissection. Sections on the slide 
containing tumor were marked by the pathologist which were further scraped 
and taken for DNA extraction. One ml xylene was added followed by vortex for 
10 s and centrifugation at 13000 rpm for 3 min. The supernatant was removed 
and the xylene wash was repeated again to remove paraffin from the tissue. 
Then 1 ml of absolute ethanol was added to the tube followed by vortexing for 
10 s and centrifugation at 13000 rpm for 3 min. The supernatant was removed 
and the ethanol wash step was repeated again. Supernatant was removed and 
the tube with open lid was placed at 37 °C dry block until all residual ethanol 
was evaporated. Pellet was re-suspended in 180 µl digestion buffer and 20 µl 
Proteinase K followed by incubation at 50° C overnight. 
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2. DNA extraction 
After overnight incubation, the lysate was centrifuged at 13000 rpm for 3 min. 
The supernatant was transferred to 1.5 ml micro centrifuge tube. 20 ul of RNase 
A solution was added followed by one min incubation at RT.200 µl of 
Lysis/Binding buffer and 200 µl of ethanol was added to the lysate, vortexed to 
yield a homogenous solution and spun briefly. The 620 µl solution was then 
layered on Purelink spin column and centrifuged at 10000 rpm for 1 min. The 
spin column was then transferred to fresh collection tube. Wash Buffer WB1 
500 µl was added to the spin column and centrifuged at 10000 rpm for 1 min. 
The column was then placed in fresh collection tube and 500 µl of Wash Buffer 
WB2 was added and centrifuged at 13000 rpm for 3 min. The column was then 
placed in 1.5 ml microfuge tube and 50 µl of elution buffer was added to the 
center of the column, incubated for 1 min at RT followed by centrifugation at 
10000 rpm for 1 min. The spin column was discarded and the DNA was 
collected in 1.5 ml tube. 
The extracted DNA was quantified by Nanodrop spectrophotometer using the 
Nanodrop 26 ND-1000 spectrophotometer (Nanodrop Technologies Inc. 
Wilmington, NC, USA). Purified DNA with the A260/A280 ratio of 1.7-1.9 and 
absorbance scans with symmetric peak at 260 nm confirmed the purity of the 
DNA. 
The DNA was further processed for PCR amplification followed by nucleotide 
sequencing. 
3.2.3 Primer selection for Polymerase Chain Reaction (PCR) 
The primers were selected from literature survey for amplification of KRAS exon 
2 and exon 3, BRAF exon 15, NRAS exon 2 and exon 3 and PIK3CA exon 9 
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and exon 20. The described primers were modified , when necessary using 
Primer Express software (Applied Bio systems, Foster City, USA) to check the 
secondary structure and critical parameters like primer length, melting 
temperature (Tm), specificity, complimentary primer sequences, G/C content 
polypyrimidine (T,C) or polypurine (A,G) stretches, 3’- end sequence, primer-
dimer formation. 
 
3.2.3.1 PCR Assay Optimization 
PCR assay optimization for KRAS, BRAF, NRAS and PIK3CA mutation 
detection included optimization of DNA concentration, tumor percentage, and 
Taq polymerase, MgCl2, DMSO and BSA. The PCR conditions including 
temperature and time for denaturation, annealing and extension were 
standardized and were finalized on observation of the PCR products on 
agarose gel electrophoresis. 
The nested PCR was standardized for all four genes.  Table 3.1 and 3.2 
summarize the thermal cycling conditions:  
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Table 3.1: Master mixture for first round of PCR for KRAS, BRAF, NRAS and 
PIK3CA. 
 
Stock Solution 1 reaction (µl) 
Sterile MilliQ water 11.7 
5 X Buffer (Promega) 10 
2mM d NTPs (Takara) 5 
25mM MgCl2 (Promega) 3 
DMSO (Sigma) 3 
0.1% BSA (Sigma) 5 
Forward Primer (Sigma) 1 
Reverse Primer (Sigma) 1 
Taq DNA Polymerase (5U/µl) Promega 0.3 
Total Volume 40 
10 µl of extracted DNA was added to the reaction mix. Each assay had an 
amplification control, and reaction control to check the assay validity. 
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Table 3.2: Master mixture preparation for nested PCR for KRAS, BRAF, NRAS 
and PIK3CA. 
Stock Solution 1 reaction (µl) 
Sterile MilliQ water 7.7 
5 X Buffer (Promega) 5 
2mM d NTPs (Takara) 2.5 
25mM MgCl2 (Promega) 1.5 
DMSO (Sigma) 1.5 
0.1% BSA (Sigma) 2.5 
Forward Primer (Sigma) 1 
Reverse Primer (Sigma) 1 
Taq DNA Polymerase (5U/µl) Promega 0.3 
Total Volume 23 
About 2 µl of the first round product was added to the reaction mix 
Thermal cycling conditions are given in Table 3.3 - Table 3.11. 
 
Table 3.3: KRAS exons 2 and 3 mutation detection assay. 
Initial denaturation 94°C- 5 min 
Denaturation 94°C – 30sec 
Annealing 52°C – 30sec 
Extension 72°C – 30sec 
Number of cycles 35 
Final extension  72°C – 7min 
Hold 15°C - ∞ 
First round and Nested PCR for KRAS exons 2 and 3 have same conditions. 
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Table 3.4: BRAF exon 15 mutation detection assay- First round PCR. 
Initial denaturation 94°C- 5 min 
Denaturation 94°C – 30sec 
Annealing 58°C – 30sec 
Extension 72°C – 30sec 
Number of cycles 22 
Final extension  72°C – 7min 
Hold 15°C - ∞ 
 
Table 3.5: BRAF exon 15 mutation detection assay- Nested PCR. 
Initial denaturation 94°C- 5 min 
Denaturation 94°C – 30sec 
Annealing 58°C – 30sec 
Extension 72°C – 30sec 
Number of cycles 35 
Final extension  72°C – 7min 
Hold 15°C - ∞ 
 
Table 3.6 NRAS exon 2 mutation detection assay- First round and Nested PCR. 
Initial denaturation 94°C- 5 min 
Denaturation 94°C – 30sec 
Annealing 58°C – 30sec 
Extension 72°C – 30sec 
Number of cycles 35 
Final extension  72°C – 7min 
Hold 15°C - ∞ 
First round and Nested PCR for NRAS exons 2 and 3 have same conditions.  
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Table 3.7: NRAS exon 3 mutation detection assay- First round PCR. 
Initial denaturation 94°C- 5 min 
Denaturation 94°C – 30sec 
Annealing 60°C – 30sec 
Extension 72°C – 30sec 
Number of cycles 35 
Final extension  72°C – 7min 
Hold 15°C - ∞ 
 
Table 3.8: NRAS exon 3 mutation detection assay- Nested PCR. 
Initial denaturation 94°C- 5 min 
Denaturation 94°C – 30sec 
Annealing 53°C – 30sec 
Extension 72°C – 30sec 
Number of cycles 35 
Final extension  72°C – 7min 
Hold 15°C - ∞ 
 
Table 3.9: PIK3CA exon 9 mutation detection assay- First round and Nested 
PCR. 
Initial denaturation 95°C- 5 min 
Denaturation 95°C – 30sec 
Annealing 60°C – 30sec 
Extension 72°C – 1min 
Number of cycles 35 
Final extension  72°C – 7min 
Hold 15°C - ∞ 
First round and Nested PCR for PIK3CA exon 9 have same conditions.  
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Table 3.10: PIK3CA exon 20 mutation detection assay- First round PCR. 
Initial denaturation 94°C- 5 min 
Denaturation 94°C – 30sec 
Annealing 55°C – 30sec 
Extension 72°C – 1min 
Number of cycles 35 
Final extension  72°C – 7min 
Hold 15°C - ∞ 
 
Table 3.11: PIK3CA exon 20 mutation detection assay- Nested PCR 
Initial denaturation 94°C- 5 min 
Denaturation 94°C – 30sec 
Annealing 64°C – 30sec 
Extension 72°C – 30sec 
Number of cycles 35 
Final extension  72°C – 7min 
Hold 15°C - ∞ 
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Primer Details: 
Gene Primer Name 
 
 
Primer sequence 5'-3' Base 
pairs 
        
KRAS KRAS E2-FP TACTGGTGGAGTATTTGATAGTG 23 
  KRAS E2-RP TGTATCAAAGAATGGTCCTG 20 
  KRAS-E2IF TAGTGTATTAACCTTATGTGTGAC 24 
  KRAS-E2IR ACCTCTATTGTTGGATCATATTC 23 
        
  KRAS-E3 F AAGGTGCACTGTAATAATCCA 21 
  KRAS-E3 R CATGGCATTAGCAAAGACTC 20 
  KRAS-E3IF AATCCAGACTGTGTTTCTCC 20 
  KRAS-E3IR TTTAAACCCACCTATAATGG 20 
  (Patil et al., 2013)     
BRAF BRAFEX15F1 CATAATGCTTGCTCTGATAGG 21 
  BRAFEX15R1 GGCCAAAAATTTAATCAGTGGA 22 
  BRAFEX15F2 CATAATGCTTGCTCTGATAGG 21 
  BRAFEX15R2 TAGCCTCAATTCTTACCATC 20 
   (Houben et al., 2004)     
NRAS NRAS2F1 TAATCCGGTGTTTTTGCGTTCTC 23 
  NRAS2R1 GCTACCACTGGGCCTCACCTCTA 23 
  NRAS2F2 AGTACTGTAGATGTGGCTCGC 21 
  NRAS2R2 ACTGGGCCTCACCTCTATG 19 
        
  NRAS3F1 CCCCCTTACCCTCCACACC 19 
  NRAS3R1 GAGGTTAATATCCGCAAATGACTT 24 
  NRAS3F2 GATTCTTACAGAAAACAAGTG 21 
  NRAS3R2 ATGACTTGCTATTATTGATGG 21 
   (Houben et al., 2004)     
PIK3CA PIKEX9 P1 TTGCTTTTCTGTAAATCATCTGTG 24 
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  PIKEX9 P2 GGGAAAAATATGACAAAGAAAGC 23 
  PIKEX9 P3 GAATCTCCATTTTAGCACTTACCTG
TGACT 
30 
        
  PIKEX20 P1 TTTTCTCAATGATGCTTGGC 20 
  PIKEX20 P2 GGATTGTGCAATTCCTATGC 20 
  PIKEX20 P3 AATCTTTTGATGACATTGCATACAT
TCG 
28 
  PIKEX20 P4 
(Bisht et al., 2014) 
TCAGTTATCTTTTCAGTTCAATGCA
TG 
27 
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3.2.4 Detection of PCR products by agarose gel electrophoresis 
3.2.4.1 Method 
The agarose was made in 1X TBE buffer after initial homogenization in 
microwave. After cooling to 55°C, Ethidium bromide (0.5µg/ml) was added to 
agarose, mixed thoroughly and poured in Bio-Rad gel casting tray (Bio-Rad 
Laboratories Inc., Hercules, USA) and the gel was allowed to solidify. 
About 10 µl of PCR product is loaded into the wells of the gel along with 4 µl of 
DNA ladder. The gel was run at 200 volts with 30-35 min run time and 
visualized under Gel Documentation system (Amersham Pharmacia Biotech, 
Sweden). Image was captured and saved as *tif file and documented. 
 
3.2.5 Sequencing of PCR products for Detection of mutations 
Direct Nucleotide Sequencing, the gold standard for detection of mutations was 
used to determine the mutations in KRAS, BRAF, NRAS and PIK3CA genes. 
3.2.5.1 Principle 
Sanger dideoxy sequencing method, developed by Nobel Laureate Fredrick 
Sanger, is an enzymatic procedure in which DNA synthesis is carried out by 
DNA polymerase. DNA polymerase requires both a primer, to which nucleotides 
are added and a template strand to guide selection of each nucleotide. The 
primer binds to the 3’hydroxyl group of the DNA to be synthesized. The 3’ end 
of the primer reacts with the incoming deoxynucleoside phosphates (dNTPs). In 
Sanger sequencing procedure dideoxynucleoside triphosphate (ddNTP) 
analogues are used to interrupt DNA synthesis as these lack 3’-hydroxyl group 
needed for addition of subsequent nucleotide. Thus, these ddNTPS prematurely 
terminate the reaction. This process synthesizes DNA strands of varying length. 
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Each of the resulting fragment is analyzed by electrophoresis and a base 
sequence is elucidated from the results. 
3.2.5.2 Method 
Five major processes are involved in nucleotide sequencing 
1. Pre sequencing clean up 
2. Sequencing clean up 
3. Post sequencing clean up 
4. Capillary electrophoresis 
5. In-Silico Data Analysis 
 
1. Pre sequencing clean up: 
After the PCR amplification was completed, unincorporated primers, excess 
dNTPs interfere with subsequent sequencing reaction. For removing these 
contaminants pre sequencing clean-up was carried out before setting up 
sequencing reaction. The volume of PCR products to be sequenced was 
adjusted to 100 µl by MilliQ and was layered on Millipore Montage µPCR 96 
cleanup plate. These plates incorporate Millipore’s size exclusion technology for 
sample clean-up. The plate having PCR product was then placed on a vacuum 
manifold and vacuum of 20 inches of Hg was applied for 5 min. The products 
were subsequently washed with 50 µl MilliQ water at same vacuum pressure for 
5 min. In the dried well the 25 µl of MilliQ was added and the purified PCR 
products were retrieved from each well by pipetting. 
 
2. Sequencing PCR: 
The purified PCR products were subjected to cycle sequencing using Big Dye 
Terminator v3.1 Cycle sequencing kit. The PCR included initial denaturation at 
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96°C for 10 sec, 50° C for 5 sec and 60° C for 4 min. The reaction was carried 
out in 10 µl volume, containing 1 µl of BigDye Terminator, 3 µl of 2.5X 
sequencing buffer, 4 µl of MilliQ water, 1 µl each of primer and template. 
 
3. Post sequencing clean-up: 
Unincorporated fluorescence dye terminators in the sequencing reaction 
interfere with the quality of sequence by forming unwanted dye blobs in the 
sequence read. Hence, it is important to remove these from the reaction before 
loading it ABI Prism 3100 Genetic Analyzer. 
Sequencing reaction cleanup was carried using Montage SEQ 96 sequencing 
reaction clean up kit. Each cycle sequencing product was mixed with 30 ul of 
injection solution provided in the kit and transferred to Montage SEQ 96 plate. 
Vacuum pressure of 20 inches of Hg was applied until wells become dry. The 
wash was given again with 30 µl of injection solution at same vacuum pressure. 
The purified sequencing products were re-suspended n 25 µl of injection 
solution and were transferred to ABI 96 well Optical plates. 
 
4. Capillary electrophoresis: 
The 96 well ABI Optical plate having purified products was loaded on the BI 
3100 Genetic analyzer. Electro kinetic injection was done at 1kv for 22 sec, 
voltage of 12.2 kV was applied and 50°C constant temperature was maintained 
in the oven throughout the run time of 2 hrs. 22 min. For correct data collection, 
analysis and extraction, following settings were made in the software. Run 
module: StdSeq50_POP6_1 Default Module, Dye set Z-BigDyeV3, Analysis 
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Protocol: 3100POP6_BDTv-3-kb-dEnOvO_V5.1, Base Caller KB.bcp, Mobility 
File: KB_3100_POP6_BDTv3.mob. 
After the run was completed, the data was extracted and analyzed 
automatically by the software provided with the instrument. 
 
5. In-silico Sequence Analysis: 
The sequences of KRAS, BRAF, NRAS and PIK3CA genes obtained were 
aligned with respective exonic sequences obtained from NCBI to screen for 
mutations using BioEdit software.  
 
6. Statistical analysis: 
Statistical analysis was performed using GraphPad and GraphPad Prism 
software. The comparative distribution of mutations in all four genes was 
studied and its correlation with clinico-pathological parameters was analyzed. 
Chi square test was employed and a finding of p<0.05 was considered as 
statistically significant. 
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Chapter 4     Assay Validation 
 
According to National Accreditation Board for testing and calibration Laboratory 
(NABL), India and College of American Pathologists (CAP), USA. Guidelines, 
assay validation involves three critical components- Assay development, Assay 
validation and Validation retention system. 
Figure 4.1: Components of Assay Validation. 
 
 
Assay development phase involves performing a thorough background search, 
developing a rationale, aims and objectives. The key assay requirements which 
should be taken in consideration include-Pre analytical, Analytical and Post 
analytical components. The Pre-analytical component includes- Specimen Type 
and tumor content which includes parameters like Frozen tissue or FFPE tissue, 
primary or metastatic tissue, necrotic or inflammatory and if there is any need 
for macro dissection. Analytical phase includes methodology i.e in-house 
developed or kit based, assay validation includes sensitivity, robustness and 
reproducibility of the assay and spectrum of mutations covered. The post 
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analytical parameter includes the cost of testing i.e. the reagent and labor cost 
and the report content. The assay requirements are summarized in Figure 4.2. 
Figure 4.2: Key assay considerations (Image Source-Steven Anderson, Expert 
Rev Mol Diagn, 2011). 
 
 
 
Further, assay validation involves four parameters – Specificity, Sensitivity, 
Reproducibility and Repeatability. Then comes the assay validation retention, 
which comprises of monitoring and maintenance of the assay. 
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4.1 Validation parameters: 
4.1.1 Specificity 
Specificity is primarily a function of primer selection in PCR assays. Twenty 
samples and ten plasmid DNA samples were tested to establish that the assay 
did not generate false-positive reactions. Cross contamination concerns were 
addressed by testing the panel containing alternating panel of the plasmid DNA 
to be tested after every two human DNA samples. The PCR products were 
loaded on 2% agarose gel along with a 100 bp molecular weight marker and 
reaction controls. The results were observed, and recorded. All the positive 
samples were subjected to nucleotide sequencing for the critical point mutations 
at exons 2 and 3 for KRAS and NRAS, exon 15 for BRAF and exons 9 and 20 
for PIK3CA and the sequences were analyzed. 
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4.1.2 Sensitivity 
The detection limit of the qualitative assay must account for the detection of 
gene mutation in excess of normal DNA. The positive cut-off point was the 
minimum percentage of malignant cells in the tissue as visualized in H&E 
staining of the tissue sample, for detection of mutation in the tissue sample. The 
test was performed on 20 samples with malignant cell percentages ranging from 
80% to 10%. The PCR products were observed visually on gel documentation 
system and gel images recorded. The positive PCR products were sequenced 
on ABI 3100 Genetic Analyzer, and analyzed with Sequence Analysis Software 
version 5.1.1. The allelic sensitivity was also established using commercially 
available standards each of 50% allele burden from Horizon Diagnostics. The 
nucleotide sequences obtained were screened for mutations. The sequences 
were aligned using BioEdit tool against respective exonic sequences of 
reference sequence. 
 
4.1.3 Repeatability 
Twenty samples comprising wild-type and mutated were analyzed for specific 
exons of all four genes, on two different days in independent assays, by two 
different analysts. The results were recorded. 
 
4.1.4 Reproducibility 
Twenty samples comprising wild-type and mutated were analyzed for specific 
exons of all four genes, twice on different days in independent assays, by the 
same analyst. The results were recorded. 
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4.2 Validation of KRAS exon 2 and exon 3 (codons 12, 13 and 61) 
mutation detection assay 
 
4.2.1 Specificity 
Twenty samples comprising wild-type and mutated used for specificity assay 
showed specific amplimers for exons 2 and 3 of K-ras gene. The ten plasmid 
DNA samples did not show amplification in exons 2 or 3. The nucleotide 
sequences showed >99% homology with the reference sequence of K-ras 
(Accession No: NC_000012) indicating 100% specificity of the assay. The 
variations obtained were due to mutations. The results are shown in Figures 
4.3A and 4.3B and the description for the same is mentioned in Table 
4.1.Figure 4.4 is the ClustalW of KRAS exon 2, codons 12 and 13. 
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Figure 4.3A and 4.3B: Specificity experiment for KRAS mutation detection 
assay.  
 
Figure 4.3A 
  
Figure 4.3B 
Figure Legend (4.3A and 4.3B): Twenty samples were analysed using PCR followed 
by Sanger sequencing along with ten plasmid DNA samples having insert other than 
KRAS gene. The samples showed amplification whereas the plasmid DNA samples did 
not show any amplification. Two bands were observed in few sample lanes like lane 
nos. 7, 14, 16, 17 of Figure 4.3A and lane nos.2, 7, 11, 13, 14, 16 in Figure 4.3B which 
could be due to non specific amplification. This non specific amplification was 
overcome by increasing the annealing temperature to 52°C.The loading pattern is 
mentioned in Table 4.1. 
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Table 4.1: Loading pattern for Figures 4.3A and 4.3B. 
 
Figure 4.3A: KRAS Spec 1 Figure 4.3B:  KRAS Spec 2 
Lane 
No. 
Sample Lane No. Sample 
1 100 bp Ladder 1 100 bp Ladder 
2 Positive Control 2 Positive Control 
3 Reaction Control 3 Reaction Control 
4 7C40344 4 7C51922 
5 7C49157 5 7C47808 
6 Plasmid 1 6 Plasmid 6 
7 7C49142 7 7C47583 
8 7C42607 8 7C50956 
9 Plasmid 2 9 Plasmid 7 
10 7C49133 10 7C47333 
11 7C49132 11 7B35583 
12 Plasmid 3 12 Plasmid 8 
13 7C50984 13 7C47933 
14 7C51169 14 7C43426 
15 Plasmid 4 15 Plasmid 9 
16 7C47888 16 7C49168 
17 7C43404 17 7C43424 
18 Plasmid 5 18 Plasmid 10 
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Figure 4.4: Clustal W for KRAS exon 2 codon 12 and 13 for specificity 
parameter.  
Codon 12/13 
KRAS_E2            GTTGGAGCTG GTGGCGTAGG CAAGAGTGCC TTGACGATAC AGCTAATTCA  85   
7C40344_K2F        GTTGGAGCTG GTGGCGTAGG CAAGAGTGCC TTGACGATAC AGCTAATTCA 100  
7C49157_K2F        GTTGGAGCTG RTGGCGTAGG CAAGAGTGCC TTGACGATAC AGCTAATTCA  92   
7C49142_K2F        GTTGGAGCTG GTGGCGTAGG CAAGAGTGCC TTGACGATAC AGCTAATTCA  92   
7C42607_K2F        GTTGGAGCTG GTGGCGTAGG CAAGAGTGCC TTGACGATAC AGCTAATTCA  80   
7C49133_K2F        GTTGGAGCTG GTGGCGTAGG CAAGAGTGCC TTGACGATAC AGCTAATTCA  98   
7C49132_K2F        GTTGGAGCTG GTGGCGTAGG CAAGAGTGCC TTGACGATAC AGCTAATTCA  91   
7C50984_K2F        GTTGGAGCTG GTGGCGTAGG CAAGAGTGCC TTGACGATAC AGCTAATTCA  92   
7C51169_K2F        GTTGGAGCTG GTGGCGTAGG CAAGAGTGCC TTGACGATAC AGCTAATTCA  79   
7C47888_K2F        GTTGGAGCTG GTGGCGTAGG CAAGAGTGCC TTGACGATAC AGCTAATTCA  85   
7C43404_K2F        GTTGGAGCTG GTGGCGTAGG CAAGAGTGCC TTGACGATAC AGCTAATTCA  84   
7C51922_K2F        GTTGGAGCTG GTGGCGTAGG CAAGAGTGCC TTGACGATAC AGCTAATTCA  92   
7C47808_K2F        GTTGGAGCTG GTGGCGTAGG CAAGAGTGCC TTGACGATAC AGCTAATTCA  85   
7C47583_K2F        GTTGGAGCTK GTGGCGTAGG CAAGAGTGCC TTGACGATAC AGCTAATTCA  98   
7C50956_K2F        GTTGGAGCTK GTGGCGTAGG CAAGAGTGCC TTGACGATAC AGCTAATTCA  92   
7C47333_K2F        GTTGGAGCTG GTGGCGTAGG CAAGAGTGCC TTGACGATAC AGCTAATTCA  92   
7B35583_K2F        GTTGGAGCTG GTGGCGTAGG CAAGAGTGCC TTGACGATAC AGCTAATTCA  89   
7C47933_K2F        GTTGGAGCTG GTGGCGTAGG CAAGAGTGCC TTGACGATAC AGCTAATTCA  92   
7C43426_K2F        GTTGGAGCTG GTGGCGTAGG CAAGAGTGCC TTGACGATAC AGCTAATTCA  98   
7C49168_K2F        GTTGGAGCTG GTGGCGTAGG CAAGAGTGCC TTGACGATAC AGCTAATTCA  98   
7C43424_K2F        GTTGGAGCTG GTGGCGTAGG CAAGAGTGCC TTGACGATAC AGCTAATTCA  91   
Clustal Consensus  *********   ********* ********** ********** **********  77   
Figure Legend: The PCR amplified samples were sequenced and aligned with the 
reference sequence using BioEdit software. The highlighted nucleotides  in the box 
correspond to codon 12 (GGT) and codon 13 (GGC) and the heterozygous G/A is 
depicted by R and heterozygous G/T is depicted by K. 
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4.2.2 Sensitivity 
The test was performed on 20 samples with malignant cell percentages ranging 
from 80% to 20%, for exon 2, codons 12/13 and exon3, codon 61. The PCR 
products are observed visually on gel documentation system and gel images 
recorded. The KRAS positive PCR products are sequenced on ABI 3100 
Genetic Analyzer, and analyzed with Sequence Analysis Software version 
5.1.1. The nucleotide sequences obtained were screened for mutations at 
exon2, codons12/13 and/or exon3, codon 61. The sequences are aligned using 
BioEdit tool against respective exonic sequences of reference sequence of 
KRAS gene (Accession No: NC_000012). 
The minimum percentage of malignant cells in the tissue as visualized in H&E 
staining, for detection of KRAS mutation in the tissue sample was found to be 
20%. The results are shown in Figures 4.5 and 4.6 and the description for the 
same is mentioned in Table 4.2. Clustal W for KRAS is shown in Figure 4.7 for 
sensitivity parameter. 
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Figure 4.5: KRAS Sensitivity 1  
 
   
 
 
Figure 4.6: KRAS Sensitivity 2 
 
 
 
Figure Legend: Figure 4.5 and 4.6: Sensitivity experiment for KRAS mutation 
detection assay. Twenty samples with malignant cell percentage from 20 to 80% were 
analysed using PCR. The amplified products were further sequenced. The loading 
pattern is mentioned in Table 4.2. 
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Table 4.2:  Loading pattern on agarose gel electrophoresis for figures 4.5 and 
4.6 
 
Figure 4.5: KRAS Sensitivity 1 Figure 4.6: KRAS Sensitivity 2 
Lane 
No. 
Sample % 
Tumor 
Lane 
No. 
Sample % 
Tumor 
1 100 bp Ladder   1 100 bp Ladder   
2 Positive Control   2 Positive Control   
3 Reaction Control   3 Reaction Control   
4 7C55300 80 4 7C43458  60 
5 7C61089 70 5 7C59701 50 
6 7C58028 70 6 7C60972 50 
7 7C58014 70 7 7C46780 50 
8 7C49157  70 8 7B35569  50 
9 7C49110  70 9 7C61075 40 
10 7C42621  70 10 7C58194 40 
11 7C60966 60 11 7C58062 30 
12 7C52618 60 12 7C61886 20 
      13 7C52160 20 
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Figure 4.7: Clustal W for KRAS exon 2, codons 12 and 13 for sensitivity 
parameter. 
 
KRAS_E2            AGTTGGAGCT GGTGGCGTAG GCAAGAGTGC CTTGACGATA CAGCTAATTC  84   
7C55300_k2f        AGTTGGAGCT GRTGGCGTAG GCAAGAGTGC CTTGACGATA CAGCTAATTC 100  
7C61089_k2f        AGTTGGAGCT GKTGGCGTAG GCAAGAGTGC CTTGACGATA CAGCTAATTC  99   
7C58028_k2f        AGTTGGAGCT GRTGGCGTAG GCAAGAGTGC CTTGACGATA CAGCTAATTC  83   
7C58014_k2f        AGTTGGAGCT KGTGGCGTAG GCAAGAGTGC CTTGACGATA CAGCTAATTC  61   
7C49157_k2f        AGTTGGAGCT GRTGGCGTAG GCAAGAGTGC CTTGACGATA CAGCTAATTC  99   
7C49110_k2f        AGTTGGAGCT GKTGGCGTAG GCAAGAGTGC CTTGACGATA CAGCTAATTC  92   
7C42621_k2f        AGTTGGAGCT GKTGGCGTAG GCAAGAGTGC CTTGACGATA CAGCTAATTC  92   
7C60966_k2f        AGTTGGAGCT GRTGGCGTAG GCAAGAGTGC CTTGACGATA CAGCTAATTC  91   
7C52618_k2f        AGTTGGAGCT KGTGGCGTAG GCAAGAGTGC CTTGACGATA CAGCTAATTC 100  
7C43458_K2F        AGTTGGAGCT GSTGGCGTAG GCAAGAGTGC CTTGACGATA CAGCTAATTC  91   
7C59701_k2f        AGTTGGAGCT GSTGGCGTAG GCAAGAGTGC CTTGACGATA CAGCTAATTC  78   
7C60972_k2f        AGTTGGAGCT GRTGGCGTAG GCAAGAGTGC CTTGACGATA CAGCTAATTC  83   
7C46780_K2F        AGTTGGAGCT KGTGGCGTAG GCAAGAGTGC CTTGACGATA CAGCTAATTC  79   
7B35569_K2F        AGTTGGAGCT GGTGRCGTAG GCAAGAGTGC CTTGACGATA CAGCTAATTC  63   
7C61075_K2F        AGTTGGAGCT GRTGGCGTAG GCAAGAGTGC CTTGACGATA CAGCTAATTC  64   
7C58194_k2f        AGTTGGAGCT RGTGGCGTAG GCAAGAGTGC CTTGACGATA CAGCTAATTC 100  
7C58062_K2F        AGTTGGAGCT GKTGGCGTAG GCAAGAGTGC CTTGACGATA CAGCTAATTC  60   
7C61886_K2F        AGTTGGAGCT GRTGGCGTAG GCAAGAGTGC CTTGACGATA CAGCTAATTC  62   
7C52160_K2F        AGTTGGAGCT KGTGGCGTAG GCAAGAGTGC CTTGACGATA CAGCTAATTC  91   
Clustal Consensus  **********   ** ***** ********** ********** **********  57   
 
 
Figure Legend: The PCR amplified samples were sequenced and aligned with the 
reference sequence using BioEdit software. The highlighted nucleotides in the box 
correspond to codon 12 (GGT) and codon 13 (GGC). The mutation was observed in 
the sample with 20% malignant cells (Sample accession no.7C52160) indicating the 
sensitivity as 20%.The heterozygous G/A is depicted by R, heterozygous G/T is 
depicted by K and heterozygous G/C is depicted by S. 
  
Chapter 4. Assay Validation 
 131 
4.2.3 Reproducibility 
Twenty samples comprising wild-type and mutated were analysed for codons 
12/13 and 61 mutations at exons 2 and 3 of KRAS gene, on two different days 
in independent assays, by two different analysts, using KRAS gene mutation at 
codons 12/13 and 61 testing protocol. Detection of KRAS gene mutation at 
codons 12/13 and 61 was observed to be 100% reproducible assay as, all the 
samples showed same nucleotide sequence when performed by two different 
analysts (Table 4.3). 
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Table 4.3: Results of samples analysed by two different analysts for 
reproducibility. 
 
Accession No Test Result Mutation 
Detected 
Test Result Mutation 
Detected 
Analyst 1 Analyst 2 
7C42621  Detected GGT ; GTT Detected GGT ; GTT 
7C46549  Detected GGT ; GTT Detected GGT ; GTT 
7C49823  Detected GGT ; GAT Detected GGT ; GAT 
7C50956  Detected GGT ; TGT Detected GGT ; TGT 
7C58194  Detected GGT ; AGT Detected GGT ; AGT 
7C52484 Detected GGT : GAT Detected GGT : GAT 
7C52681 Detected GGT ; TGT Detected GGT ; TGT 
7C43458 Detected GGT ; GCT Detected GGT ; GCT 
7A12168 Not Detected - Not Detected - 
7C46456 Not Detected - Not Detected - 
7C46867  Not Detected - Not Detected - 
7B35559 Not Detected - Not Detected - 
7B35575 Not Detected - Not Detected - 
7B35583  Not Detected - Not Detected - 
7C27862 Not Detected - Not Detected - 
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Figure 4.8: Clustal W for KRAS for reproducibility parameter. 
 
 
KRAS_E2            AGTTGGAGCT GGTGGCGTAG GCAAGAGTGC CTTGACGATA CAGCTAATTC  84   
7c42621_k2f        AGTTGGAGCT GKTGGCGTAG GCAAGAGTGC CTTGACGATA CAGCTAATTC  77   
7c46549_k2f        AGTTGGAGCT GKTGGCGTAG GCAAGAGTGC CTTGACGATA CAGCTAATTC  78   
7c47823_k2f        AGTTGGAGCT GRTGGCGTAG GCAAGAGTGC CTTGACGATA CAGCTAATTC  83   
7C50956_K2F        AGTTGGAGCT KGTGGCGTAG GCAAGAGTGC CTTGACGATA CAGCTAATTC  88   
7c58194_k2f        AGTTGGAGCT RGTGGCGTAG GCAAGAGTGC CTTGACGATA CAGCTAATTC  82   
7c52484_k2f        AGTTGGAGCT GRTGGCGTAG GCAAGAGTGC CTTGACGATA CAGCTAATTC  92   
7C52618_k2f        AGTTGGAGCT KGTGGCGTAG GCAAGAGTGC CTTGACGATA CAGCTAATTC  98   
7C43458_K2F        AGTTGGAGCT GSTGGCGTAG GCAAGAGTGC CTTGACGATA CAGCTAATTC  61   
7A12168_k2f        AGTTGGAGCT GGTGGCGTAG GCAAGAGTGC CTTGACGATA CAGCTAATTC  99   
7c46456_k2f        AGTTGGAGCT GGTGGCGTAG GCAAGAGTGC CTTGACGATA CAGCTAATTC  61   
7c46867_k2f        AGTTGGAGCT GGTGGCGTAG GCAAGAGTGC CTTGACGATA CAGCTAATTC 100  
7B35559_k2f        AGTTGGAGCT GGTGGCGTAG GCAAGAGTGC CTTGACGATA CAGCTAATTC  91   
7c35575_K2F        AGTTGGAGCT GGTGGCGTAG GCAAGAGTGC CTTGACGATA CAGCTAATTC  64   
7B35583_K2F        AGTTGGAGCT GGTGGCGTAG GCAAGAGTGC CTTGACGATA CAGCTAATTC  79   
7c47087_k2f        AGTTGGAGCT GGTGGCGTAG GCAAGAGTGC CTTGACGATA CAGCTAATTC  92   
7c27862_k2f        AGTTGGAGCT GGTGGCGTAG GCAAGAGTGC CTTGACGATA CAGCTAATTC  83   
Clustal Consensus  **********   ******** ********** ********** **********  59   
 
 
Figure Legend: The samples were processed independently by two analyst to validate 
the reproducibility parameter and the results were concordant. The highlighted 
nucleotides in the box correspond to codon 12 (GGT) and codon 13 (GGC). R depicts 
the heterozygous G/A, K depicts heterozygous G/T and S depicts heterozygous G/C. 
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4.2.4 Repeatability 
Twenty samples comprising wild-type and mutated were analyzed for codons 
12/13 and 61 mutations at exons 2 and 3 of KRAS gene, twice on different days 
in independent assays, by the same analyst, using KRAS gene mutation at 
codons 12/13 and 61 testing protocol. The samples showed identical nucleotide 
sequences in two independent assays, by the same analyst, indicating 100% 
repeatability (Table 4.4).   
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Table 4.4: Results of samples analysed by two different analysts for 
repeatability. 
 
Accession No Test Result Mutation 
Detected 
Test Result Mutation 
Detected 
Analyst 1 Analyst 1 
7C42621  Detected GGT ; GTT Detected GGT ; GTT 
7C46549  Detected GGT ; GTT Detected GGT ; GTT 
7C49823  Detected GGT ; GAT Detected GGT ; GAT 
7C50956  Detected GGT ; TGT Detected GGT ; TGT 
7C58194  Detected GGT ; AGT Detected GGT ; AGT 
7C52484 Detected GGT : GAT Detected GGT : GAT 
7C52681 Detected GGT ; TGT Detected GGT ; TGT 
7C43458 Detected GGT ; GCT Detected GGT ; GCT 
7A12168 Not Detected - Not Detected - 
7C46456 Not Detected - Not Detected - 
7C46867  Not Detected - Not Detected - 
7B35559 Not Detected - Not Detected - 
7B35575 Not Detected - Not Detected - 
7B35583  Not Detected - Not Detected - 
7C27862 Not Detected - Not Detected - 
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Figure 4.9: Clustal W for KRAS for repeatability parameter. 
 
 
KRAS_E2            AGTTGGAGCT GGTGGCGTAG GCAAGAGTGC CTTGACGATA CAGCTAATTC  84   
7c42621_k2f        AGTTGGAGCT GKTGGCGTAG GCAAGAGTGC CTTGACGATA CAGCTAATTC  83   
7c46549_k2f        AGTTGGAGCT GKTGGCGTAG GCAAGAGTGC CTTGACGATA CAGCTAATTC  99   
7c49823_k2f        AGTTGGAGCT GRTGGCGTAG GCAAGAGTGC CTTGACGATA CAGCTAATTC  61   
7c50956_k2f        AGTTGGAGCT KGTGGCGTAG GCAAGAGTGC CTTGACGATA CAGCTAATTC  91   
7c58194_k2f        AGTTGGAGCT RGTGGCGTAG GCAAGAGTGC CTTGACGATA CAGCTAATTC  92   
7c52484_k2f        AGTTGGAGCT GRTGGCGTAG GCAAGAGTGC CTTGACGATA CAGCTAATTC  83   
7c52618_k2f        -GTTGGAGCT KGTGGCGTAG GCAAGAGTGC CTTGACGATA CAGCTAATTC  49   
7c43458_k2f        AGTTGGAGCT GSTGGCGTAG GCAAGAGTGC CTTGACGATA CAGCTAATTC  92   
7a12168_k2f        AGTTGGAGCT GGTGGCGTAG GCAAGAGTGC CTTGACGATA CAGCTAATTC 100  
7c46456_k2f        AGTTGGAGCT GGTGGCGTAG GCAAGAGTGC CTTGACGATA CAGCTAATTC 100  
7c46867_K2F        AGTTGGAGCT GGTGGCGTAG GCAAGAGTGC CTTGACGATA CAGCTAATTC  64   
7b35559_K2F        AGTTGGAGCT GGTGGCGTAG GCAAGAGTGC CTTGACGATA CAGCTAATTC  63   
7B35575_K2F        AGTTGGAGCT GGTGGCGTAG GCAAGAGTGC CTTGACGATA CAGCTAATTC  62   
7B35583_K2F        AGTTGGAGCT GGTGGCGTAG GCAAGAGTGC CTTGACGATA CAGCTAATTC  91   
7C47087_K2F        AGTTGGAGCT GGTGGCGTAG GCAAGAGTGC CTTGACGATA CAGCTAATTC  79   
7c27862_K2F        AGTTGGAGCT GGTGGCGTAG GCAAGAGTGC CTTGACGATA CAGCTAATTC  60   
Clustal Consensus   *********   ******** ********** ********** **********  47   
 
Figure Legend: To validate the repeatability parameter of the KRAS assay, the same 
analyst processed the samples used in reproducibility assay on two different days and 
concordant results were observed. The highlighted nucleotides in the box correspond 
to codon 12 (GGT) and codon 13 (GGC). R depicts the heterozygous G/A, K depicts 
heterozygous G/T and S depicts heterozygous G/C. 
 
Thus, a nested PCR protocol was used to amplify exons 2 and 3 of KRAS gene 
with specific primers. Annealing temperature used for both the rounds of PCR 
was 52° C. Base pair size for KRAS exon 2 is 189 bp and for exon 3 is 218 bp. 
The agarose gel images after optimization of the assay for each exon fragments 
is given in Fig. 4.10. A representative electropherogram obtained after 
sequencing of the amplified product is shown in Figure 4.11, 4.12 and 4.13. 
Hence, the data suggests the KRAS gene mutation at codons 12/13 and 61 
testing protocol showed 100% specificity, 100% reproducibility and 100% 
repeatability and lower detection limit of 20% tumor involvement, in the samples 
studied. 
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Figure 4.10: Agarose gel electrophoresis of exon2 and exon3 of KRAS gene 
after optimization   of the assay. 
 
 
  
 
 
 
Figure Legend: KRAS mutation detection assay was optimised at 52°C annealing 
temperature with a nested PCR protocol complying all the validation parameter 
requirements of specificity, sensitivity, reproducibility and repeatability. The base pair 
size of exon 2 amplified product was 189 bp and for exon 3 -218 bp. Lane 1-100 bp 
molecular weight ladder, lane 2-amplification control for KRAS exon 2, lane 3- reaction 
control, lane 4 till lane 10- KRAS exon 2 PCR amplified samples, lane 11-blank well, 
lane 12-amplification control for KRAS exon 3, lane 13- reaction control, lane14till lane 
18-KRAS exon 3 PCR amplified samples. 
 
  
100 bp ladder 
Exon 2(189 bp) Exon 3(218bp) 
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Figure 4.11: Electropherogram of KRAS exon 2 with no mutations detected. 
 
 
Figure Legend: Highlighted region is codon 12 –GGT at position 84, 85 and 86 and 
codon 13- GGC at position 87, 88 and 89 on the electropherogram.  
  
Chapter 4. Assay Validation 
 139 
Figure 4.12:  Electropherogram of KRAS exon 2 with codon 12 mutation 
(GGT;GAT) Glycine to Aspartic acid substitution. 
 
 
 
Figure Legend: Highlighted region is codon 12 –GGT at position 83, 84 and 85 and 
codon 13- GGC at position 86, 87 and 88 on the electropherogram. R depicts the 
heterozygous G/A change in the system as seen at the position number 84. This 
change results in Glycine (GGT) to Aspartic acid (GAT) substitution. 
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Figure 4.13: Electropherogram of KRAS exon 3 with no mutations detected. 
 
 
Figure Legend: Highlighted region is codon 61 –CAA at position 96, 95 and 94 on the 
electropherogram. The sample is sequenced using reverse primer. 
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Mutations of clinical significance for KRAS: 
According to published findings critical KRAS mutations at codon 12/13, and 
one at codon 61 have been associated with resistance to anti-EGFR therapy, 
as tabulated:  
Exon Codon Nucleotide Change Amino acid change 
2 12 GGT - GAT Gly - Asp 
2 12 GGT - GTT Gly - Val 
2 12 GGT - CGT Gly - Arg 
2 12 GGT - GCT Gly - Ala 
2 12 GGT - AGT Gly - Ser 
2 12 GGT - TGT Gly - Cys 
2 13 GGC - GAC Gly - Asp 
2 13 GGC-TGC Gly - Cys 
3 61 CAA - CAC Gln - His 
3 61 CAA- AAA Gln - Lys 
3 61 CAA- GAA Gln - Glu 
3 61 CAA- CTA Gln - Leu 
3 61 CAA- CCA Gln - Pro 
3 61 CAA- CGA Gln - Arg 
3 61 CAA-CAT Gln - His 
Presence of the above mentioned mutations indicate resistance to anti-EGFR 
therapy. Absence of the mutations indicates wild-type allele indicating 
responsiveness to anti-EGFR therapy. 
Establishment of allelic sensitivity on Sanger sequencer 
Commercially available standards for KRAS G12D and NRAS G12V each of 
50% allele burden from Horizon Diagnostics’ were mixed with wild type genomic 
DNA to obtain 50%, 25%, 20%, 10% and 5% tumor DNA content. PCR was set 
up followed by Sanger sequencing. Samples were processed in triplicates. 
Sanger sequencing yielded an optimum sensitivity of 20%. Representative 
electropherograms of KRAS G12D allelic sensitivity establishment experiment 
are shown below.  
Chapter 4. Assay Validation 
 142 
Figure 4.13 A: KRAS-G12D Original-50% 
 
 
Figure Legend: An electropherogram of the original sample received from Horizon 
Diagnostics’ having 50% allele burden for the mutation KRAS G12D having Glycine 
(GGT) to Aspartic acid (GAC) substitution. The G/A substitution is marked with R, 
highlighted in red, on the electropherograms at position 84. 
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Figure 4.13 B: KRAS-G12D 25% 
 
 
Figure Legend: An electropherogram obtained after titration of KRAS G12D reference 
sample received from Horizon Diagnostics’ having 50% allele burden with wild type 
genomic DNA to obtain 25% allele burden. The G/A substitution is marked with R, 
highlighted in red, on the electropherograms at position 87. 
  
Chapter 4. Assay Validation 
 144 
Figure 4.13 C: KRAS-G12D 20% 
 
 
 
Figure Legend: An Representative electropherogram obtained after titration of KRAS 
G12D reference sample received from Horizon Diagnostics’ having 50% allele burden 
with wild type genomic DNA to obtain 20% allele burden. The G/A substitution is 
marked with R, highlighted in red, on the electropherograms at position 86. 
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Figure 4.13 D: KRAS-G12D 10% 
 
 
 
Figure Legend: An electropherogram obtained after titration of KRAS G12D reference 
sample received from Horizon Diagnostics’ having 50% allele burden with wild type 
genomic DNA to obtain 10% allele burden. The G/A substitution is marked with R, 
highlighted in red, on the electropherograms at position 87. 
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4.3 Validation of BRAF exon 15 codon 600 mutation detection assay 
4.3.1 Specificity 
Twenty samples and ten plasmid DNA samples with no BRAF insert were used 
to test BRAF specificity. All the 20 samples showed specific amplimers for exon 
15 of BRAF gene. Ten plasmid DNA samples did not show amplification in exon 
15. The nucleotide sequences showed >99% homology with the reference 
sequence of BRAF (Accession No: NG_007378) indicating 100% specificity of 
the assay. The variations obtained were due to mutations. 
Figure 4.14: Clustal W for BRAF for specificity parameter 
 
 
 
BRAF_EX15        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGTGGGTC CCGATCAGTT 179  
7D67172_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGTGGGTC CCGATCAGTT  64  
7D86257_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGGGGGTC CCGATCAGTT  65  
7D86258_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGTGGGTC CCGATCAGTT  65  
7D97202_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGGGGGTC CCGATCAGTT  71  
7D95188_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGTGGGTC CCGATCAGTT  75  
7D96711_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGGGGGTC CCGATCAGTT  64  
7E00488_F        AAAATAGGTG ATTTTGGTCT AGCTACAGKG AAATCTCGAT GGAGTGGGTC CCGATCAGTT  68  
7D95189_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGGGGGTC CCGATCAGTT  60  
7D91488_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGGGGGTC CCGATCAGTT  70  
7E01934_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGTGGGTC CCGATCAGTT  66  
7C82482_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGTGGGTC CCGATCAGTT  72  
7D95360_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGGGGGTC CCGATCAGTT  80  
7D67181_F        AAAATAGGTG ATTTTGGTCT AGCTACAGKG AAATCTCGAT GGAGGGGGTC CCGATCAGTT  82  
7D97108_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGTGGGTC CCGATCAGTT  64  
7D86665_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGGGGGTC CCGATCAGTT  72  
7D95218_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGTGGGTC CCGATCAGTT  96  
7D86359_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGGGGGTC CCGATCAGTT  64  
7D95373_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGGGGGTC CCGATCAGTT  85  
7D86360_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGGGGGTC CCGATCAGTT  71  
Clustal Consens  ********** ********** ******** * ********** ********** **********  82  
 
Figure Legend: The PCR amplified samples were sequenced and aligned with the 
reference sequence using BioEdit software. The highlighted nucleotides in the box 
correspond to codon 600 of exon 15 and the K depicts the heterozygous G/T on the 
sequence. 
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4.3.2 Sensitivity 
The minimum percentage of malignant cells in the tissue as visualized in HNE 
staining, for detection of BRAF mutation in the tissue sample was found to be 
20%. 
 
Table 4.5: Results of samples analyzed for sensitivity parameter for BRAF 
assay. 
 
Sample % Tumor Sample % Tumor 
7D83666 80 7D28772 60 
7D92670 70 7D28773 50 
7E01745 70 7D87169 50 
7D87179 70 7A15581 50 
7E01761  70 7E01840  50 
7D92584 70 7D83668 40 
7E04378 70 7D52242 40 
7D52160 60 7A15506 30 
7D97202 60 7D71912 20 
    7D97108 10 
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Figure 4.15: Clustal W for BRAF for sensitivity parameter. 
 
 
 
BRAF_EX15        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGTGGGTC CCGATCAGTT 180  
7D83666_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGTGGGTC CCGATCAGTT  78  
7D92670_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGGGGGTC CCGATCAGTT  80  
7E01745_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGTGGGTC CCGATCAGTT  85  
7D87179_F        AAAATAGGTG ATTTTGGTCT AGCTACAGKG AAATCTCGAT GGAGGGGGTC CCGATCAGTT  90  
7E01761_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGTGGGTC CCGATCAGTT  95  
7D92584_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGGGGGTC CCGATCAGTT 100  
7E04378_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGTGGGTC CCGATCAGTT  85  
7D52160_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGGGGGTC CCGATCAGTT  75  
7D97202_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGGGGGTC CCGATCAGTT  90  
7D28772_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGTGGGTC CCGATCAGTT  75  
7D28773_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGTGGGTC CCGATCAGTT  77  
7D87169_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGGGGGTC CCGATCAGTT  69  
7A15581_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGGGGGTC CCGATCAGTT  75  
7E01840_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGTGGGTC CCGATCAGTT  85  
7D83668_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGGGGGTC CCGATCAGTT  88  
7D52242_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGTGGGTC CCGATCAGTT  76  
7A15506_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGGGGGTC CCGATCAGTT  80  
7D71912_F        AAAATAGGTG ATTTTGGTCT AGCTACAGKG AAATCTCGAT GGAGGGGGTC CCGATCAGTT  85  
7D97108_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGGGGGTC CCGATCAGTT  92  
Clustal Consens  ********** ********** ******** * ********** ********** **********  76 
 
Figure Legend: The PCR amplified samples were sequenced and aligned with the 
reference sequence using BioEdit software. The highlighted nucleotides in the box 
correspond to codon 600 in exon 15. The mutation was observed in the sample with 
20% malignant cells (Sample accession no.7D71912) indicating the sensitivity as 20%. 
K depicts the heterozygous G/T. 
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4.3.3 Reproducibility 
The reproducibility of the assay, as observed in 15 samples was 100% 
concordance in two independent assays by two analysts. The results in both the 
assays were identical, indicating 100% reproducible.  
Table 4.6: Results of clinical samples analyzed by two different analysts for 
reproducibility. 
 
Accession No 
  
Test Result Mutation 
Detected 
Test Result Mutation 
Detected 
Analyst 1 Analyst 2 
7D83668  Detected GTG ; GAG Detected GTG ; GAG 
7D83666  Not Detected - Not Detected - 
7D96917 Detected GTG ; GAG Detected GTG ; GAG 
7E01702 Not Detected - Not Detected - 
7E01703  Detected GTG ; GAG Detected GTG ; GAG 
7D28772  Not Detected - Not Detected - 
7D87169 Detected GTG ; GAG  Detected GTG ; GAG  
7D52242  Not Detected - Not Detected - 
7D28773  Not Detected - Not Detected - 
7D92760 Not Detected - Not Detected - 
7D91871 Not Detected - Not Detected - 
7D52160 Not Detected - Not Detected - 
7D71911 Not Detected - Not Detected - 
7D94781 Not Detected - Not Detected - 
7E00505 Not Detected - Not Detected - 
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Figure 4.16: Clustal W for BRAF for reproducibility parameter. 
 
 
BRAF_EX15        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGTGGGTC CCGATCAGTT 179  
7D83668_F        AAAATAGGTG ATTTTGGTCT AGCTACAGKG AAATCTCGAT GGAGTGGGTC CCGATCAGTT  65  
7D83666_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGGGGGTC CCGRKCAGTT  69  
7D96917_F        AAAATAGGTG ATTTTGGTCT AGCTACAGKG AAATCTCGAT GGAGTGGGTC GATCAGTTTT  75  
7E01702_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGGGGGTC CCGATCAGTT  78  
7E01703_F        AAAATAGGTG ATTTTGGTCT AGCTACAGKG AAATCTCGAT GGAGTGGGTC CCGATCAGTT  71  
7D28772_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGGGGGTC CCGATCAGTT  80  
7D87169_F        AAAATAGGTG ATTTTGGTCT AGCTACAGKG AAATCTCGAT GGAGTGGGTC CCGRTCAGTT  86  
7D52242_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGGGGGTC CCGRTCAGTT  83  
7D28773_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGGGGGTC CCGATCAGTT  71  
7D92760_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGTGGGTC CCGATCAGTT  80  
7D91871_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGTGGGTC CCGATCAGTT  71  
7D52160_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGGGGGTC CCGRKCAGTT  75  
7D71911_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGGGGGTC CCGATCAGTT  88  
7D94781_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGTGGGTC CCGATCAGTT  75  
7E00505_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGGGGGTC CCGATCAGTT  79  
Clustal Consens  ********** ********** ******** * ********** ********** **********  80  
Figure Legend: The samples were processed independently by two analyst to validate 
the reproducibility parameter and the results were concordant. The PCR amplified 
samples were sequenced and aligned with the reference sequence using BioEdit 
software. The highlighted nucleotides in the box correspond to codon 600 (GTG) in 
exon 15. K depicts the heterozygous G/T. 
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4.3.4 Repeatability 
The repeatability of the assay, as observed in 15 samples was 100% 
concordance in the independent assays by the same analyst. The results in 
both the assays were identical, indicating 100% repeatability. 
 
 
Table 4.7: Results of clinical samples analyzed by two different analysts for 
repeatability. 
 
Accession No Test Result Mutation 
Detected 
Test Result Mutation 
Detected 
  Analyst 1: HP Analyst 1: HP 
7D83668  Detected GTG ; GAG Detected GTG ; GAG 
7D83666  Not Detected - Not Detected - 
7D96917 Detected GTG ; GAG Detected GTG ; GAG 
7E01702 Not Detected - Not Detected - 
7E01703  Detected GTG ; GAG Detected GTG ; GAG 
7D28772  Not Detected - Not Detected - 
7D87169 Detected GTG ; GAG  Detected GTG ; GAG  
7D52242  Not Detected - Not Detected - 
7D28773  Not Detected - Not Detected - 
7D92760 Not Detected - Not Detected - 
7D91871 Not Detected - Not Detected - 
7D52160 Not Detected - Not Detected - 
7D71911 Not Detected - Not Detected - 
7D94781 Not Detected - Not Detected - 
7E00505 Not Detected - Not Detected - 
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Figure 4.17: Clustal W for BRAF for repeatability parameter. 
 
 
BRAF_EX15        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGTGGGTC CCGATCAGTT 179  
7D83668_F        AAAATAGGTG ATTTTGGTCT AGCTACAGKG AAATCTCGAT GGAGTGGGTC CCGATCAGTT  57  
7D83666_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGGGGGTC CCGATCAGTT  61  
7D96917_F        AAAATAGGTG ATTTTGGTCT AGCTACAGKG AAATCTCGAT GGAGTGGGTC GATCAGTTTT  75  
7E01702_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGGGGGTC CCGATCAGTT  52  
7E01703_F        AAAATAGGTG ATTTTGGTCT AGCTACAGKG AAATCTCGAT GGAGTGGGTC CCGATCAGTT  57  
7D28772_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGGGGGTC CCGATCAGTT  60  
7D87169_F        AAAATAGGTG ATTTTGGTCT AGCTACAGKG AAATCTCGAT GGAGTGGGTC CCGRTCAGTT  57  
7D52242_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGGGGGTC CCGRTCAGTT  65  
7D28773_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGGGGGTC CCGATCAGTT  75  
7D92760_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGTGGGTC CCGATCAGTT  75  
7D91871_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGTGGGTC CCGATCAGTT  57  
7D52160_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGGGGGTC CCGATCAGTT  67  
7D71911_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGGGGGTC CCGATCAGTT  57  
7D94781_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGTGGGTC CCGATCAGTT  76  
7E00505_F        AAAATAGGTG ATTTTGGTCT AGCTACAGTG AAATCTCGAT GGAGGGGGTC CCGATCAGTT  74  
Clustal Consens  ********** ********** ******** * ********** ********** **********  71  
Figure Legend: To validate the repeatability parameter of the BRAF assay, the same 
analyst processed the samples used in reproducibility assay on two different days and 
concordant results were observed. The PCR amplified samples were sequenced and 
aligned with the reference sequence using BioEdit software. The highlighted 
nucleotides in the box correspond to codon 600 (GTG) in exon 15. K depicts the 
heterozygous G/T. 
 
Thus, a nested PCR protocol is used to amplify exon 15 of BRAF gene with 
specific primers. Annealing temperature used for both the rounds of PCR is 55° 
C. Base pair size for BRAF exon 15 is 228 bp. The agarose gel image after 
optimization of the assay for exon 15 fragment is given in Fig. 4.18. A 
representative electropherogram obtained after sequencing of the amplified 
product is shown in Fig.4.19 ClustalW of the sequenced product is shown in Fig 
4.20. 
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Figure 4.18: Agarose gel electrophoresis of exon15 of BRAF gene after 
optimization of the BRAF assay 
      
  
  
Figure Legend: BRAF mutation detection assay was optimised using nested PCR 
protocol complying all the validation parameter requirements of specificity, sensitivity, 
reproducibility and repeatability. The base pair size of exon 15 amplified product was 
228 bp. Lane 1-100 bp molecular weight ladder, lane 2-amplification control for BRAF 
exon 15, lane 3- reaction control, lane 4 till lane 8- BRAF exon 15 PCR amplified 
samples. 
 
 
  
100 base pair (bp) ladder 
228 bp 
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Figure 4.19: Electropherogram of BRAF exon 15 with no mutations detected. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure Legend: Highlighted region is codon 600(GTG) of exon 15 at position 90, 91 
and 92 on the electropherograms. 
 
Figure 4.20: ClustalW of exon15 of BRAF gene after sequencing. 
 
Figure Legend: The highlighted nucleotides in the box correspond to codon 600 
(GTG) in exon 15.  
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Hence, the data suggests the BRAF gene mutation at codons 12/13 and 61 
testing protocol showed 100% specificity, 100% reproducibility and 100% 
repeatability and lower detection limit of 20% tumor involvement, in the samples 
studied. 
 
Mutation of clinical significance 
V600E, GTG - GAG (Valine to Glutamic Acid) 
Presence of the above mentioned mutations indicate resistance to anti-EGFR 
therapy. Absence of the mutations indicates wild-type allele indicating 
responsiveness to anti-EGFR therapy (Di Nicolantonio et al., 2008). 
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4.4 Validation of NRAS exon 2 and exon 3 (codons 12, 13 and 61) 
mutation detection assay 
4.4.1 Specificity 
Twenty samples used for specificity assay showed specific amplimers for exons 2 and 
3 of NRAS gene. The ten plasmid DNA samples did not show amplification in exons 2 
or 3. The nucleotide sequences showed >99% homology with the reference sequence 
of NRAS (Accession No: NG_007572.1) indicating 100% specificity of the assay. The 
variations obtained were due to mutations. 
Figure 4.21: Representative Agarose gel electrophoresis of NRAS gene exon 
2. 
 
Figure Legend: NRAS 
specific amplification was 
observed in genomic DNA 
samples (lanes 4-8) however 
plasmid DNA samples did not 
show any amplification (lanes 
9-13) showing specificity of 
primers used for NRAS 
amplification. 
 
  
Lane No. Sample 
1 100 bp Ladder 
2 Amplification control 
3 Reaction control 
4 7G23701(60%tumor) 
5 7G23702(70%tumor) 
6 7G23703(30%tumor) 
7 7G23704(50%tumor) 
8 7G23705(70%tumor) 
9 Plasmid 1 
10 Plasmid 2 
11 Plasmid 3 
12 Plasmid 4 
13 Plasmid 5 
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Figure 4.22: ClustalW of NRAS gene after sequencing for specificity. 
 
 
Figure Legend: The PCR amplified samples were sequenced and aligned with the 
reference sequence using BioEdit software. The highlighted nucleotides in the box 
correspond to codons 12 (GGT) and 13 (GGT) of exon 2. 
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4.4.2 Sensitivity 
The detection limit of the qualitative assay must account for the detection of 
NRAS gene mutation in excess of normal DNA. The positive cut-off point is the 
minimum percentage of malignant cells in the tissue as visualized in HNE 
staining of the tissue sample, for detection of NRAS mutation in the tissue 
sample. The test was performed on 20 samples with malignant cell percentages 
ranging from 80% to 10%, for exon 2, codons 12/13 and exon3, codon 61. The 
PCR products are observed visually on gel documentation system and gel 
images recorded. The NRAS positive PCR products are sequenced on ABI 
3100 Genetic Analyzer, and analyzed with Sequence Analysis Software version 
5.1.1. The nucleotide sequences obtained were screened for mutations at 
exon2, codons12/13 and/or exon3, codon 61. The sequences are aligned using 
BioEdit tool against respective exonic sequences of reference sequence of 
NRAS gene (Accession No: NG_007572.1). 
The minimum percentage of malignant cells in the tissue as visualized in HNE 
staining, for detection of NRAS mutation in the tissue sample was found to be 
20%. 
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4.4.3 Reproducibility 
Twenty samples were analyzed for codons 12/13 and 61 mutations at exons 2 
and 3 of NRAS gene, on two different days in independent assays, by two 
different analysts, using NRAS gene mutation at codons 12/13 and 61 testing 
protocol. Detection of NRAS gene mutation at codons 12/13 and 61 is 100% 
reproducible assay as, all the samples showed same nucleotide sequence 
when performed by two different analysts. 
 
Table 4.8: Results of clinical samples analysed by two different analysts for 
reproducibility for NRAS codon 12/13 
 
Sample  Codon Test Result 
(Analyst 1) 
Test Result 
(Analyst 2) 
7G15477 12/13 Not Detected Not Detected 
7G15474 12/13 Not Detected Not Detected 
7G23703 12/13 Not Detected Not Detected 
7G01373 12/13 Not Detected Not Detected 
7G15453 12/13 Not Detected Not Detected 
7G23730 12/13 Not Detected Not Detected 
7G23729 12/13 Not Detected Not Detected 
7G23731 12/13 Not Detected Not Detected 
7G23732 12/13 Not Detected Not Detected 
7G23733 12/13 Not Detected Not Detected 
7G23701 12/13 Not Detected Not Detected 
7G23702 12/13 Not Detected Not Detected 
7G23703 12/13 Not Detected Not Detected 
7G23704 12/13 Not Detected Not Detected 
7G23705 12/13 Not Detected Not Detected 
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Figure 4.23: ClustalW of NRAS gene after sequencing for reproducibility. 
 
 
 
Figure Legend: The samples were processed independently by two analyst to validate 
the reproducibility parameter and the results were concordant. The highlighted 
nucleotides in the box correspond to codon 12 (GGT) and codon 13 (GGT).  
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NRAS EXON 3  
Table 4.9: Results of clinical samples analysed by two different analysts for 
reproducibility for NRAS codon 61. 
 
Sample    Codon Test Result 
(Analyst 1) 
Test Result 
(Analyst 2) 
7G15477 61 Not Detected Not Detected 
7G15474 61 Not Detected Not Detected 
7G23703 61 Not Detected Not Detected 
7G01373 61 Not Detected Not Detected 
7G15453 61 Not Detected Not Detected 
7G23730 61 Not Detected Not Detected 
7G23729 61 Not Detected Not Detected 
7G23731 61 Not Detected Not Detected 
7G23732 61 Not Detected Not Detected 
7G23733 61 Not Detected Not Detected 
7G23701 61 Not Detected Not Detected 
7G23702 61 Not Detected Not Detected 
7G23703 61 Not Detected Not Detected 
7G23704 61 Not Detected Not Detected 
7G23705 61 Not Detected Not Detected 
 
  
Chapter 4. Assay Validation 
 162 
Figure 4.24: ClustalW of nras exon 3 gene after sequencing for reproducibility. 
 
 
 
Figure Legend: The samples were processed independently by two analyst to validate 
the reproducibility parameter and the results were concordant. The highlighted 
nucleotides in the box correspond to codon 61 (CAA).  
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4.4.4 Repeatability 
Twenty samples comprising wild-type and mutated were analysed for codons 
12/13 and 61 mutations at exons 2 and 3 of NRAS gene, twice on different days 
in independent assays, by the same analyst, using NRAS gene mutation at 
codons 12/13 and 61 testing protocol. The samples showed identical nucleotide 
sequences in two independent assays, by the same analyst, indicating 100% 
repeatability.   
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NRAS EXON 2    
Table 4.10: Results of clinical samples analyzed by two different analysts for 
repeatability. 
 
Sample    Codon Test Result 
(Analyst 1) 
Test Result 
(Analyst 2) 
7G15477   12/13 Not Detected Not Detected 
7G15474   12/13 Not Detected Not Detected 
7G23703   12/13 Not Detected Not Detected 
7G01373   12/13 Not Detected Not Detected 
7G15453   12/13 Not Detected Not Detected 
7G23730   12/13 Not Detected Not Detected 
7G23729   12/13 Not Detected Not Detected 
7G23731   12/13 Not Detected Not Detected 
7G23732   12/13 Not Detected Not Detected 
7G23733   12/13 Not Detected Not Detected 
7G23701   12/13 Not Detected Not Detected 
7G23702   12/13 Not Detected Not Detected 
7G23703   12/13 Not Detected Not Detected 
7G23704   12/13 Not Detected Not Detected 
7G23705   12/13 Not Detected Not Detected 
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Figure 4.25: ClustalW of NRAS gene after sequencing for repeatability 
 
  
 
Figure Legend: To validate the repeatability parameter of the NRAS assay, the same 
analyst processed the samples used in reproducibility assay on two different days and 
concordant results were observed. The PCR amplified samples were sequenced and 
aligned with the reference sequence using BioEdit software. The highlighted 
nucleotides in the box correspond to codon 12 (GGT) and codon 13 (GGT) in exon 2.  
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NRAS EXON 3  
Table 4.11: Results of clinical samples analysed by two different analysts for 
repeatability for NRAS codon 61. 
 
Sample    Codon Test Result (Analyst 
1) 
Test Result 
(Analyst 2) 
7G15477 61 Not Detected Not Detected 
7G15474 61 Not Detected Not Detected 
7G23703 61 Not Detected Not Detected 
7G01373 61 Not Detected Not Detected 
7G15453 61 Not Detected Not Detected 
7G23730 61 Not Detected Not Detected 
7G23729 61 Not Detected Not Detected 
7G23731 61 Not Detected Not Detected 
7G23732 61 Not Detected Not Detected 
7G23733 61 Not Detected Not Detected 
7G23701 61 Not Detected Not Detected 
7G23702 61 Not Detected Not Detected 
7G23703 61 Not Detected Not Detected 
7G23704 61 Not Detected Not Detected 
7G23705 61 Not Detected Not Detected 
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Figure 4.26: ClustalW of NRAS gene after sequencing for repeatability 
 
 
 
Figure Legend: To validate the repeatability parameter of the NRAS assay, the same 
analyst processed the samples used in reproducibility assay on two different days and 
concordant results were observed. The PCR amplified samples were sequenced and 
aligned with the reference sequence using BioEdit software. The highlighted 
nucleotides in the box correspond to codon 61 (CAA) in exon 3.  
 
Thus, a nested PCR protocol is used to amplify exon 2 and 3 of NRAS gene 
with specific primers. Annealing temperature used for both the rounds of PCR is 
58 ° C. Base pair size for NRAS exon 2 is 192 bp and for exon 3 is 157 bp. The 
agarose gel images after optimization of the assay for each exon fragments is 
given in Figure 4.27. ClustalW of the sequenced product is shown in Figure 
4.28.  
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Hence, the data suggests the NRAS gene mutation at codons 12/13 and 61 
testing protocol showed 100% specificity, 100% reproducibility and 100% 
repeatability and lower detection limit of 20% tumor involvement, in the samples 
studied. 
Figure 4.27: Agarose gel electrophoresis of exon2 and exon 3 of NRAS gene 
after optimization of the   NRAS assay.  
 
 
 
 
 
Figure Legend: NRAS mutation detection assay was optimised at 58°C annealing 
temperature with a nested PCR protocol complying all the validation parameter 
requirements of specificity, sensitivity, reproducibility and repeatability. The base pair 
size of exon 2 amplified product was 197 bp and for exon 3 -157 bp. Lane 1-100 bp 
molecular weight ladder, lane 2-amplification control for NRAS exon 2, lane 3- reaction 
control, lane 4 till lane 9- NRAS exon 2 PCR amplified samples, lane 10-amplification 
control for NRAS exon 3, lane 11- reaction control, lane12 till lane 17-NRAS exon 3 
PCR amplified samples. 
  
100 bp ladder 
NRAS exon2 (192bp) NRAS exon3 (157 bp) 
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Figure 4.28: ClustalW of exon 2 and 3 of NRAS gene after sequencing. 
 
 
 
 
 
Figure Legend: The PCR amplified samples were sequenced and aligned with the 
reference sequence using BioEdit software. The highlighted nucleotides in the box 
correspond to codon 12 (GGT), codon 13 (GGT) and codon 61 (CAA).  
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Mutations of clinical significance 
According to published findings critical NRAS mutations at codon 12/13, and 
one at codon 61 have been associated with resistance to anti-EGFR therapy, 
as tabulated below.  
 
Exon Codon Nucleotide Change Amino acid change 
2 12 GGT - GAT Gly - Asp 
2 12 GGT - GTT Gly - Val 
2 12 GGT - CGT Gly - Arg 
2 12 GGT - GCT Gly - Ala 
2 12 GGT - AGT Gly - Ser 
2 12 GGT - TGT Gly - Cys 
2 13 GGT - GAT Gly - Asp 
2 13 GGT - GTT Gly - Val 
2 13 GGT - CGT Gly - Arg 
2 13 GGT - GCT Gly - Ala 
2 13 GGT - AGT Gly - Ser 
2 13 GGT - TGT Gly - Cys 
3 61 CAA - CAC Gln - His 
3 61 CAA- AAA Gln - Lys 
3 61 CAA- GAA Gln - Glu 
3 61 CAA- CTA Gln - Leu 
3 61 CAA- CCA Gln - Pro 
3 61 CAA- CGA Gln - Arg 
3 61 CAA-CAT Gln - His 
 
Presence of the above mentioned mutations indicate resistance to anti-EGFR 
therapy. Absence of the mutations indicates Wild-type allele indicating 
responsiveness to anti-EGFR therapy. 
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4.5 Validation of PIK3CA exon 9 and exon 20 (codon 545 and codon 
1047) mutation detection assay 
4.5.1 Specificity 
Twenty samples used for specificity assay showed specific amplimers for exons 
9 and 20 of PIK3CA gene. The ten plasmid DNA samples did not show 
amplification in exon 2 or 3. The nucleotide sequences showed >99% homology 
with the reference sequence of PIK3CA (Accession No: NG_012113.2) 
indicating 100% specificity of the assay. The variations obtained were due to 
mutations. 
 
4.5.2 Sensitivity 
The test was performed on 20 samples with malignant cell percentages ranging 
from 80% to 10%, for exon 9, codon 545 and exon 20, codon 1047. The PCR 
products are observed visually on gel documentation system and gel images 
recorded. The PIK3CA positive PCR products are sequenced on ABI 3100 
Genetic Analyzer, and analyzed with Sequence Analysis Software version 
5.1.1. The nucleotide sequences obtained were screened for mutations at 
exon9, codon 545 and/or exon20, codon 1047. The sequences are aligned 
using BioEdit tool against respective exonic sequences of reference sequence 
of PIK3CA gene (Accession No: NG_012113.2). 
The minimum percentage of malignant cells in the tissue as visualized in H&E 
staining, for detection of PIK3CA mutation in the tissue sample was found to be 
20%. 
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4.5.3 Reproducibility 
Twenty samples were analysed for codons 12/13 and 61 mutations at exons 9 
and 20 of PIK3CA gene, on two different days in independent assays, by two 
different analysts, using PIK3CA gene mutation at codons 545 and 1047 testing 
protocol. Detection of PIK3CA gene mutation at codons 545 and 1047 is 100% 
reproducible assay as, all the samples showed same nucleotide sequence 
when performed by two different analysts. 
Table 4.12: Results of clinical samples analysed by two different analysts for 
reproducibility for PIK3CA. 
 
Accession 
No 
Test Result Mutation 
Detected 
Test Result Mutation 
Detected 
Analyst 1 Analyst 2 
7D83668 Detected GGT ; GAT Detected GGT ; GAT 
7D83666 Not Detected - Not Detected - 
7D96917 Detected GGT ; GAT Detected GGT ; GAT 
7E01702 Not Detected - Not Detected - 
7E01703 Detected CAA - CAG Detected CAA - CAG 
7D28772 Not Detected - Not Detected - 
7D87169 Detected GGT ; GAT Detected GGT ; GAT 
7D52242 Not Detected - Not Detected - 
7D28773 Not Detected - Not Detected - 
7D92760 Not Detected - Not Detected - 
7D91871 Not Detected - Not Detected - 
7D52160 Not Detected - Not Detected - 
7D71911 Not Detected - Not Detected - 
7D94781 Not Detected - Not Detected - 
7E00505 Not Detected - Not Detected - 
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Figure 4.29: ClustalW of PIK3CA gene after sequencing for reproducibility. 
 
 
PIK3_EX09        AAAATAGGTG ATTTTGGTCT AGCTACAGGT AAATCTCGAT GGAGTGGGTC CCGATCAGTT 179  
7D83668_F        AAAATAGGTG ATTTTGGTCT AGCTACAGRT AAATCTCGAT GGAGTGGGTC CCGATCAGTT  64  
7D83666_F        AAAATAGGTG ATTTTGGTCT AGCTACAGGT AAATCTCGAT GGAGGGGGTC CCGATCAGTT  65  
7D96917_F        AAAATAGGTG ATTTTGGTCT AGCTACAGRT AAATCTCGAT GGAGTGGGTC CCGATCAGTT  65  
7D97202_F        AAAATAGGTG ATTTTGGTCT AGCTACAGGT AAATCTCGAT GGAGGGGGTC CCGATCAGTT  71  
7D95188_F        AAAATAGGTG ATTTTGGTCT AGCTACAGGT AAATCTCGAT GGAGTGGGTC CCGATCAGTT  75  
7D96711_F        AAAATAGGTG ATTTTGGTCT AGCTACAGGT AAATCTCGAT GGAGGGGGTC CCGATCAGTT  64  
7E00488_F        AAAATAGGTG ATTTTGGTCT AGCTACAGRT AAATCTCGAT GGAGTGGGTC CCGATCAGTT  68  
7D95189_F        AAAATAGGTG ATTTTGGTCT AGCTACAGGT AAATCTCGAT GGAGGGGGTC CCGATCAGTT  60  
7D91488_F        AAAATAGGTG ATTTTGGTCT AGCTACAGGT AAATCTCGAT GGAGGGGGTC CCGATCAGTT  70  
7E01934_F        AAAATAGGTG ATTTTGGTCT AGCTACAGGT AAATCTCGAT GGAGTGGGTC CCGATCAGTT  66  
7C82482_F        AAAATAGGTG ATTTTGGTCT AGCTACAGGT AAATCTCGAT GGAGTGGGTC CCGATCAGTT  72  
7D95360_F        AAAATAGGTG ATTTTGGTCT AGCTACAGGT AAATCTCGAT GGAGGGGGTC CCGATCAGTT  80  
7D67181_F        AAAATAGGTG ATTTTGGTCT AGCTACAGGT AAATCTCGAT GGAGGGGGTC CCGATCAGTT  82  
7D97108_F        AAAATAGGTG ATTTTGGTCT AGCTACAGGT AAATCTCGAT GGAGTGGGTC CCGATCAGTT  64  
7D86665_F        AAAATAGGTG ATTTTGGTCT AGCTACAGGT AAATCTCGAT GGAGGGGGTC CCGATCAGTT  72  
7D95218_F        AAAATAGGTG ATTTTGGTCT AGCTACAGGT AAATCTCGAT GGAGTGGGTC CCGATCAGTT  96  
7D86359_F        AAAATAGGTG ATTTTGGTCT AGCTACAGGT AAATCTCGAT GGAGGGGGTC CCGATCAGTT  64  
7D95373_F        AAAATAGGTG ATTTTGGTCT AGCTACAGGT AAATCTCGAT GGAGGGGGTC CCGATCAGTT  85  
7E00505_F        AAAATAGGTG ATTTTGGTCT AGCTACAGGT AAATCTCGAT GGAGGGGGTC CCGATCAGTT  71  
Clustal Consens  ********** ********** ******** * ********** ********** **********  82  
 
Figure Legend: The samples were processed independently by two analyst to validate 
the reproducibility parameter and the results were concordant. The PCR amplified 
samples were sequenced and aligned with the reference sequence using BioEdit 
software. The highlighted nucleotides in the box correspond to codon 545 (GGT) in 
exon 15. R depicts the heterozygous G/A. 
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4.5.4 Repeatability 
Twenty samples comprising wild-type and mutated were analysed for codons 
545 and 1047 mutations at exons 9 and 20 of PIK3CA gene, twice on different 
days in independent assays, by the same analyst, using PIK3CA gene mutation 
at codons 545 and 1047 testing protocol. The samples showed identical 
nucleotide sequences in two independent assays, by the same analyst, 
indicating 100% repeatability.   
Table 4.13: Results of clinical samples analysed by two different analysts for 
repeatability for PIK3CA. 
 
Accession 
No 
Test Result Mutation 
Detected 
Test Result Mutation 
Detected 
Analyst 1 Analyst 2 
7D83668  Detected GGT ; GAT Detected GGT ; GAT 
7D83666  Not Detected - Not Detected - 
7D96917 Detected GGT ; GAT Detected GGT ; GAT 
7E01702 Not Detected - Not Detected - 
7E01703  Detected CAA - CAG Detected CAA - CAG 
7D28772  Not Detected - Not Detected - 
7D87169 Detected GGT ; GAT Detected GGT ; GAT 
7D52242  Not Detected - Not Detected - 
7D28773  Not Detected - Not Detected - 
7D92760 Not Detected - Not Detected - 
7D91871 Not Detected - Not Detected - 
7D52160 Not Detected - Not Detected - 
7D71911 Not Detected - Not Detected - 
7D94781 Not Detected - Not Detected - 
7E00505 Not Detected - Not Detected - 
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Figure 4.30: ClustalW of PIK3CA gene after sequencing for repeatability 
 
PIK3_EX09        AAAATAGGTG ATTTTGGTCT AGCTACAGGT AAATCTCGAT GGAGTGGGTC CCGATCAGTT 179  
7D83668_F        AAAATAGGTG ATTTTGGTCT AGCTACAGRT AAATCTCGAT GGAGTGGGTC CCGATCAGTT  64  
7D83666_F        AAAATAGGTG ATTTTGGTCT AGCTACAGGT AAATCTCGAT GGAGGGGGTC CCGATCAGTT  65  
7D96917_F        AAAATAGGTG ATTTTGGTCT AGCTACAGRT AAATCTCGAT GGAGTGGGTC CCGATCAGTT  65  
7D97202_F        AAAATAGGTG ATTTTGGTCT AGCTACAGGT AAATCTCGAT GGAGGGGGTC CCGATCAGTT  71  
7D95188_F        AAAATAGGTG ATTTTGGTCT AGCTACAGGT AAATCTCGAT GGAGTGGGTC CCGATCAGTT  75  
7D96711_F        AAAATAGGTG ATTTTGGTCT AGCTACAGGT AAATCTCGAT GGAGGGGGTC CCGATCAGTT  64  
7E00488_F        AAAATAGGTG ATTTTGGTCT AGCTACAGRT AAATCTCGAT GGAGTGGGTC CCGATCAGTT  68  
7D95189_F        AAAATAGGTG ATTTTGGTCT AGCTACAGGT AAATCTCGAT GGAGGGGGTC CCGATCAGTT  60  
7D91488_F        AAAATAGGTG ATTTTGGTCT AGCTACAGGT AAATCTCGAT GGAGGGGGTC CCGATCAGTT  70  
7E01934_F        AAAATAGGTG ATTTTGGTCT AGCTACAGGT AAATCTCGAT GGAGTGGGTC CCGATCAGTT  66  
7C82482_F        AAAATAGGTG ATTTTGGTCT AGCTACAGGT AAATCTCGAT GGAGTGGGTC CCGATCAGTT  72  
7D95360_F        AAAATAGGTG ATTTTGGTCT AGCTACAGGT AAATCTCGAT GGAGGGGGTC CCGATCAGTT  80  
7D67181_F        AAAATAGGTG ATTTTGGTCT AGCTACAGGT AAATCTCGAT GGAGGGGGTC CCGATCAGTT  82  
7D97108_F        AAAATAGGTG ATTTTGGTCT AGCTACAGGT AAATCTCGAT GGAGTGGGTC CCGATCAGTT  64  
7D86665_F        AAAATAGGTG ATTTTGGTCT AGCTACAGGT AAATCTCGAT GGAGGGGGTC CCGATCAGTT  72  
7D95218_F        AAAATAGGTG ATTTTGGTCT AGCTACAGGT AAATCTCGAT GGAGTGGGTC CCGATCAGTT  96  
7D86359_F        AAAATAGGTG ATTTTGGTCT AGCTACAGGT AAATCTCGAT GGAGGGGGTC CCGATCAGTT  64  
7D95373_F        AAAATAGGTG ATTTTGGTCT AGCTACAGGT AAATCTCGAT GGAGGGGGTC CCGATCAGTT  85  
7E00505_F        AAAATAGGTG ATTTTGGTCT AGCTACAGGT AAATCTCGAT GGAGGGGGTC CCGATCAGTT  71  
Clustal Consens  ********** ********** ******** * ********** ********** **********  82  
 
Figure Legend: To validate the repeatability parameter of the PIK3CA assay, the 
same analyst processed the samples used in reproducibility assay on two different 
days and concordant results were observed. The PCR amplified samples were 
sequenced and aligned with the reference sequence using BioEdit software. The 
highlighted nucleotides in the box correspond to codon 545 (GGT) in exon 15. R 
depicts the heterozygous G/A. 
 
 
Thus, a nested PCR protocol was used to amplify exon 9 and 20 of PIK3CA 
gene with specific primers. Annealing temperature used for both the rounds of 
PCR is 56 ° C. Base pair size for PIK3CA exon 9 was 197 bp and for exon 20 
was 225 bp. The agarose gel images after optimization of the assay for each 
exon fragments is given in Figure 4.31. A representative electropherogram 
obtained after sequencing of the amplified product is shown in Figure 4.32 and 
Figure 4.33. ClustalW of the sequenced product is shown in Figure 4.34.  
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Figure 4.31: Agarose gel electrophoresis of exon 9 and exon 20 of PIK3CA 
gene after optimization of the assay. 
 
 
  
 
 
 
Figure Legend: PIK3CA mutation detection assay was optimised at 56°C annealing 
temperature with a nested PCR protocol complying all the validation parameter 
requirements of specificity, sensitivity, reproducibility and repeatability. The base pair 
size of exon 9 amplified product was 197 bp and for exon 20 -225 bp. Lane 1-100 bp 
molecular weight ladder, lane 2-amplification control for PIK3CA exon 9, lane 3- 
reaction control, lane 4 till lane 10- PIK3CA exon 9 PCR amplified samples, lane 11-
blank well, lane 12-amplification control for PIK3CA exon 20, lane 13- reaction control, 
lane14till lane 18- PIK3CA exon 20 PCR amplified samples. 
 
 
Hence, the data suggests the PIK3CA gene mutation at codons 545 and 1047 
testing protocol showed 100% specificity, 100% reproducibility and 100% 
repeatability and lower detection limit of 20% tumor involvement, in the samples 
studied. 
  
100 bp ladder Exon 9(197 bp) Exon 20(225bp) 
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Mutations of clinical significance 
According to published findings critical PIK3CA mutations at codon 545 and one 
at codon 1047 have been associated with resistance to anti-EGFR therapy, as 
tabulated below. : 
 
  Exon Codon Nucleotide 
Change 
Amino acid 
change 
9 545 GGT - GAT Gly - Asp 
20 1047 CAA - CAG His – Arg 
20 1047 CAA - CAT His - Leu 
 
Presence of the above mentioned mutations indicate resistance to anti-EGFR 
therapy. Absence of the mutations indicates Wild-type allele indicating 
responsiveness to anti-EGFR therapy. 
 
4.6 Laboratory methods used for detection of mutations 
World wide a variety of laboratory methods have been used for detection of 
mutations in KRAS, BRAF, NRAS and PIK3CA genes like, Allele specific PCR, 
ARMS PCR, Realtime PCR, Sanger Sequencing, Pyrosequencing, Multiplex 
PCR etc. each having  specific characteristics and sensitivity as mentioned in 
Figure 4.32. 
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Figure 4.32: Key features of different methodologies used for mutation analysis 
(Image Source-Steven Anderson, Expert Rev Mol Diagn, 2011). 
 
 
 
To provide a cost effective solution to CRC patients Sanger sequencing was 
used in this study. The sensitivity of Sanger sequencing was established as 
20% with a broad spectrum of mutations being detected in comparison to kit 
based assays wherein the sensitivity is higher than Sanger sequencing 
however the spectrum of mutation detection is limited. Also the reagent and 
labor cost is minimal in case of Sanger Sequencing. The comparison of different 
methodologies used recently is shown in Figure 4.33. More recently, with the 
advent of Next generation sequencing (NGS) platform the mutation analysis 
would be more cost efficient and time efficient however, larger studies are 
required to assess its use in routine clinical setting. 
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Figure 4.33: Comparison of properties of different methodologies used for 
mutation analysis. 
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Chapter 5  
Correlation of KRAS, BRAF, NRAS and PIK3CA mutation 
profiling with clinicopathological features of CRC patients  
 
5.1 Introduction 
As reviewed in Chapter 2, genetic alterations in KRAS, NRAS, BRAF and PIK3CA 
have an important role in colorectal cancer evolution. Mutations in KRAS exons 2 
and 3, BRAF exon 15, NRAS exons 2 and 3 and PIK3CA exon 9 and 20 are the 
most frequently mutated hotspots. These alterations lead to tumorigenesis and 
cause resistance to the targeted therapy.  
 
The aim of this chapter was to screen for mutations in these four oncogenes 
in Indian CRC patients (n=203) and to study the correlation with different 
clinicopathological features.  
 
As per the COSMIC database, the hotspot mutations analysed for KRAS in the 
current study account for 99% of all KRAS mutation found in CRC. Similarly V600E 
mutations of BRAF accounts for 98%, 9 mutations of NRAS account for 99% and 3 
hotspot mutations of PIK3CA, two in exon 9 and one in exon 20 accounts for 77% 
of all mutations observed in CRC. This information is summarised in the table 
given below (Table 5.1). 
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Table 5.1: Frequency of mutations in Catalogue of Somatic Mutations In Cancer 
(COSMIC) database. 
 
Gene Mutation COSMIC Database Frequency 
 
KRAS 
 
G12D 12.5% 
 
G12V 8.0% 
 
G12S 2.2% 
 
G12C 3.0% 
 
G12R 0.5% 
 
G12A 2.3% 
 
G13D 7.1% 
 
G13C 0.2% 
 
    
NRAS G12D 3.0% 
 
G13D 0.9% 
 
   
BRAF V600E 10.1% 
 
    
PIK3CA E545K 4.1% 
 
E542K 2.2% 
 
H1047R 3.2% 
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5.2 Methodology 
In summary, a total of 203 Indian CRC patient samples were analysed for KRAS, 
BRAF, NRAS and PIK3CA mutation status. 
Formalin-fixed, paraffin-embedded tissue blocks were cut at 4μm thicknesses and 
stained with haematoxylin and eosin (HE) for histopathological examination as 
mentioned in Chapter 3, section 3.2.1. Histological examination was carried out to 
ensure the tumor percentage was greater than 20% in the sections analysed. All 
tissue samples were analyzed for their tumor content by NABL certified internal 
pathologists. The tumor was further classified in poorly differentiated, well 
differentiated and moderately differentiated tumor according to the WHO 
classification (Jass and SOBIN, 2012). Mucinous and signet ring tumors were 
classified separately. Subsequently for DNA extraction, 10μm section of tumor 
tissue was used. DNA was extracted by using Purelink DNA extraction kit (Life 
Technologies, Carlsbad, California, USA) according to manufacturer’s protocol as 
described in Chapter 3, section 3.2.2.  
In total, 25–50 ng of DNA was added to a volume of 2 mM deoxynucleotide 
triphosphates (Takara Bio.Inc, Shinga, Japan), 10 pmol of each primer, 5U of DNA 
polymerase (Promega, Madison, WI, USA), 0.1 % BSA (Sigma Aldrich, Missouri, 
USA) , 6 % dimethylsulfoxide, 25 mM MgCl2 and 5X polymerase chain reaction 
(PCR) buffer (Promega, Madison, WI, USA). The cycling conditions and primer 
details for KRAS (exon 2 and 3), BRAF (exon 15), NRAS (exon 2 and 3) and 
PIK3CA (exon 9 and 20) are mentioned in Chapter 3, section 3.2.3. The PCR 
products were electrophoresed on 2 % agarose gels, visualized in Gel-
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Documentation system (Amersham Pharmacia Biotech, Uppsala, Sweden) and 
recorded as described in Chapter 3, section 3.2.4. The PCR product obtained after 
amplification was subjected to nucleotide sequencing. The sequencing reactions 
used 5 pmol of forward and reverse primers, 10l volume and Big Dye Terminator 
v.3.3 cycle sequencing kit and analysed after sequencing using ABI 3100 
Genetic Analyzer (Life Technologies, Carlsbad, CA, USA) refer Chapter 3, section 
3.2.5.  
The chi-square test using GraphPad Software was performed to examine statistical 
differences between mutation distribution and clinicopathological data. It was also 
used to compare the mutation frequency found in other studies to that in our 
present study. P<0.05 was considered significant. 
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5.3 Clinicopathological characteristics of CRC samples 
The clinicopathological characteristics of collected 203 CRC patient samples from 
Indian population are detailed in the Table 5.2. 
Table 5.2: The clinicopathological characteristics of Indian colorectal cancer 
samples (n=203). 
 
Characteristics Total Samples Percentage 
Age ≤50 64 31.5 
>50 139 68.5 
        
Gender Males 138 68.0 
Females 65 32.0 
        
Geographical location East  8 3.9 
West 119 58.6 
North 38 18.7 
South 38 18.7 
        
Primary or Metastatic Primary 129 63.5 
Metastatic 74 36.5 
        
Type of tumor Adenocarcinoma 174 85.7 
Mucinous 19 9.4 
Signet ring 10 4.9 
        
Tumor Differentiation MDA 111 54.7 
WDA 41 20.2 
PDA 51 25.1 
        
pT T1 3 1.5 
T2 12 5.9 
T3 136 67.0 
T4 52 25.6 
        
Lymph Node Metastasis Yes 152 74.9 
No 51 25.1 
        
Anatomic Site Colon 147 72.4 
Rectum 56 27.6 
MDA-Moderately differentiated adenocarcinoma, WDA-Well differentiated adenocarcinoma 
and PDA-Poorly differentiated adenocarcinoma, pT-extent of primary tumor. 
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In these CRC samples analysed, it was observed that the frequency of CRC 
tumors was higher in patients with age above 50 years (68.5%). The frequency 
was more in males (68%) as compared to females (32%) (Table 5.2). Figures 5.1 
and 5.2 further show the distribution of samples as per the clinicopathological 
features.  
According to geographical location of India, 58.6% cases were from West followed 
by 18.7% cases from North and South and 3.9% cases from East. With regards to 
the malignancy status 63.5% cases were of primary tumor and 36.5% were 
metastatic cases. When these samples were subtyped histologically, the tumor 
samples were distributed as – 85.7% adenocarcinoma, 9.4% mucinous 
adenocarcinoma and 4.9% signet ring carcinoma. The tumor samples were also 
classified as moderately differentiated adenocarcinomas (MDA) (n=111, 54.7%), 
well differentiated adenocarcinoma (WDA) (n=41, 20.2%) and poorly differentiated 
adenocarcinoma (PDA) (n=51, 25.1%).  
 
According to AJCC/UICC TNM staging system, these tumors were classified as T1 
(1.5%), T2 (5.9%), T3 (67%) and T4 (25.6%). Lymph node metastasis was also 
investigated in this study and 74.9% cases had lymph node metastasis and 25.1% 
cases did not show any lymph node metastasis (Table 5.2 and Figure 5.1). On the 
basis of anatomic location of tumors (colon or rectum) 72.4% cases were from 
colon and 27.6% cases from rectum. The distribution of cases as per the anatomic 
location is shown in Figure 5.2. 
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Figure 5.1: Clinicopathological and demographic characteristics of the CRC 
patient cohort employed in this study (n=203). 
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Figure Legend: The CRC cohort included in this study was investigated according to age, 
gender, geographical location, tumour differentiation, lymph node metastasis and tumour 
stage. MDA-Moderately differentiated adenocarcinoma, WDA-Well differentiated 
adenocarcinoma and PDA-Poorly differentiated adenocarcinoma  
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Figure 5.2: Distribution of CRC tumor samples according to the anatomic location. 
 
 
Figure Legend: In this study 35% of cases were from colon followed by 28% cases from 
rectum and 20% from sigmoid. Rest of the cases belonged to caecum, transverse colon, 
ascending colon, descending colon, appendix and jejunum. 
 
 
Figure 5.3 shows the overall mutation frequency of KRAS, BRAF, NRAS and 
PIK3CA genes in the CRC samples was found to be 36%.  KRAS showed the 
highest mutation rate (24%), followed by BRAF (6%) and PIK3CA (4%) while 
NRAS gene had the lowest frequency rate (2%). 
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Figure 5.3: Overall mutation frequency rate of four genes (KRAS, BRAF, NRAS 
and PIK3CA) in Indian CRC patient samples (n=203). 
 
 
 
 
Figure Legend: Out of the 203 CRC samples, 36% of cases had mutation in either of the 
four genes studied. KRAS mutation frequency was highest with 24% of cases having 
KRAS mutation followed by BRAF, PIK3CA and NRAS.  
 
 
 
The overall mutation rate was further represented in detail as a Venn diagram 
(Figure 5.4) 
 
 
 
 
 
 
 
 
KRAS, 24%
BRAF, 6%
NRAS, 2%
PIK3CA, 4%
Overall mutation frequency
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Figure 5.4: Venn Diagram showing overall mutation distribution in CRC patient 
samples (n=203). 
 
 
Figure Legend: Out of the 203 CRC samples, 49 cases (24%) harboured KRAS mutation, 
12 cases  (6%) harboured BRAF mutation, PIK3CA mutations were observed in 8 cases 
(4%) and 4 cases (2%) had NRAS mutations. BRAF, NRAS and KRAS mutations were 
mutually exclusive. 3 cases harboured both KRAS and PIK3CA mutations. 
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KRAS Mutant
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5.3.1 KRAS mutations 
KRAS mutational status tested by Sanger Sequencing showed that 49 cases out of 
a total of 203 (24.1%) harboured KRAS mutation and the spectrum of these 
mutations in KRAS gene is further analysed and summarised in Table 5.3. In these 
49 samples, KRAS codon 12 mutations were most frequent (20.2%) followed by 
codon 13 (3.9%). The most frequent mutation was Glycine to Aspartic acid 
substitution G12D (6.9%) followed by Glycine to Valine substitution G12V (6.4%). 
Other mutations observed in codon 12 were Glycine to Alanine G12A (3.94%), 
Glycine to Cysteine G12C (2.46%) and Glycine to Serine substitution G12S 
(0.49%). At codon 13, only one substitution i.e. Glycine to Aspartic acid G13D 
(3.9%) was observed. Thus, in KRAS predominantly G>A transition mutations were 
observed followed by G>T transversions. All mutations observed were in 
heterozygous state. None of the concomitant mutations in codon 12 and 13 were 
observed. Representative sequencing electropherograms are further shown below 
in Figure 5.5. 
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Table 5.3: Spectrum of KRAS mutations in 203 CRC cases determined by Sanger 
sequencing. 
 
 Codons 
 
Type of 
mutation 
No. of 
patients (%) 
Wild Type 
codon (amino 
acid) 
Mutated 
codon 
(amino acid) 
KRAS cd12 G>A 14 (6.9)  
GGT (Gly) (G) 
 
GAT (Asp) (D) 
1 (0.49) AGT (Ser) (S) 
    
G>T 13 (6.4) GTT (Val) (V) 
5 (2.46) TGT (Cys) ( C) 
    
G>C 8 (3.94) GCT (Ala) (A) 
KRAS cd13 G>A 8 (3.94) GGC (Gly) (G) GAC (Asp) (D) 
Gly glycine, asp aspartic acid, ser serine, val valine, cys cysteine, ala alanine, arg arginine,  
his histidine,  
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Figure 5.5: Representative Sequencing electropherograms of KRAS  showing 
KRAS codon 12 and codon 13.  
 
a-KRAS Wild type 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b-KRAS G12V 
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c-KRAS G12D 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 d-KRAS G12A 
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e-KRAS G12C 
 
 
f-KRAS G12S 
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g- KRAS G13D 
 
Figure Legend: Figure a- KRAS Wild type with no mutation, Figure b-KRAS Glycine 
(GGT) to Valine (GTT) substitution G12V, Figure c-KRAS Glycine (GGT) to Aspartic acid 
(GAT) substitution G12D, Figure d-KRAS Glycine (GGT) to Alanine (GCT) substitution 
G12A, Figure e-KRAS Glycine (GGT) to Cysteine (TGT) substitution G12C and Figure f-
KRAS Glycine (GGT) to Serine (AGT) substitution G12SD and Figure g-KRAS Glycine 
(GGC) to Aspartic acid (GAC) substitution at codon 13 G13D. Highlighted regions on the 
electropherograms correspond to codon 12 (GGT) and codon 13(GGC).R depicts the 
heterozygous G/A substitution, K depicts the heterozygous G/T substitution, S depicts 
heterozygous G/C substitution on the electropherograms. 
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Figure 5.6 (a-f): Representative Sequencing electropherograms of NRAS, 
BRAF and PIK3CA showing Wild type and mutant sequences. 
 
a-NRAS Wild Type 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b-NRAS G12V 
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c-BRAF Wild Type 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
d-BRAF V600E 
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 e- PIK3CA exon 9 – Wild Type 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 f- PIK3CA exon 20 – Wild Type 
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Figure Legend: a- Representative electropherogram of NRAS Wild type with no mutation, 
b-NRAS Glycine (GGT) to Valine (GTT) substitution G12V, c-BRAF Wild type with no 
mutation, d-BRAF Valine (GTG) to Glutamic acid (GAG) substitution V600E, e-PIK3CA 
exon 9 wild type with no mutation for codon 545- (GAG) and f- PIK3CA exon 20 wild type 
with no mutation for codon 1047-Histidine (CAT). Highlighted regions on the 
electropherograms correspond to respective codon positions of NRAS, BRAF and 
PIK3CA. R depicts the heterozygous G/A substitution, K depicts the heterozygous G/T 
substitution, W depicts heterozygous A/T substitution on the electropherograms. 
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Table 5.4: Correlation of mutation frequency in KRAS gene with clinicopathological factors of colorectal cancer patients (n=203). 
Characteristics Total 
Samples 
% Total 
Detected 
% KRAS 
Detected 
Codon12 
KRAS 
Detected 
Codon13 
Total 
KRAS 
Detected 
% Not 
detec
ted 
% p 
value 
Age ≤50 64 31.5 20 9.9 9 2 9 4.4 55 27.1 0.02* 
>50 139 68.5 53 26.1 32 6 40 19.7 99 48.8   
Gender Males 138 68.0 53 26.1 30 6 36 17.7 102 50.2 0.38 
Females 65 32.0 20 9.9 11 2 13 6.4 52 25.6   
Geographical 
location 
East  8 3.9 2 1.0 0 2 2 1.0 6 3.0 0.84 
West 119 58.6 47 23.2 27 3 30 14.8 89 43.8   
North 38 18.7 11 5.4 6 1 7 3.4 31 15.3   
South 38 18.7 13 6.4 8 2 10 4.9 28 13.8   
Primary or Metastatic 
tumor 
Primary 129 63.5 45 22.2 26 5 31 15.3 98 48.3 0.99 
Metastatic 74 36.5 28 13.8 15 3 18 8.9 56 27.6   
Mucinous or Adeno 
or Signet 
Adeno 174 85.7 66 32.5 38 7 45 22.2 129 63.5 0.35 
Mucinous 19 9.4 5 2.5 2 1 3 1.5 16 7.9   
Signet ring 10 4.9 2 1.0 1 0 1 0.5 9 4.4   
Differentiation status MDA 111 54.7 43 21.2 18 6 33 16.3 78 38.4 0.04* 
WDA 41 20.2 19 9.4 14 1 10 4.9 31 15.3   
PDA 51 25.1 11 5.4 9 1 6 3.0 45 22.2   
Stage T1 3 1.5 1 0.5 1 0 1 0.5 2 1.0 0.98 
T2 12 5.9 3 1.5 2 1 3 1.5 9 4.4   
T3 136 67.0 49 24.1 27 6 33 16.3 103 50.7   
T4 52 25.6 20 9.9 9 1 12 5.9 40 19.7   
Lymph Node 
Metastasis 
Yes 152 74.9 61 30.0 32 7 39 19.2 113 55.7 0.45 
No 51 25.1 12 5.9 9 1 10 4.9 41 20.2   
Site Colon 147 72.4 51 25.1 28 7 35 17.2 112 55.2 0.86 
Rectum 56 27.6 22 10.8 13 1 14 6.9 42 20.7   
* statistically significant 
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Statistical analysis of KRAS gene mutational status with clinico-pathological data 
revealed that KRAS mutations were significantly higher in patients above 50 years 
of age (p<0.05) (Table 5.4). KRAS mutations were more frequent in males (17.7%) 
as compared to females (6.4%), however, this association  was not statistically 
significant (p=0.38). Furthermore there was no significant correlation seen between 
KRAS mutations and geographical location of India.  
 
In correlation with tumor differentiation, KRAS gene mutations were significantly 
higher in moderately differentiated and poorly differentiated tumors (p<0.05). Also, 
KRAS mutations were seen to be more frequent in Adenocarcinoma (22.17%), T3 
stage (16.26%) and colon as the anatomic site (17.24%), however, no this 
association was not statistically significant. 
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5.3.2 BRAF 
In this study, 5.9% (12/203) cases showed presence of BRAF gene mutations. All 
these 12 samples showed presence of codon 600 GTG to GAG substitution 
resulting in Valine to Glutamic acid substitution V600E. None of the mutations in 
BRAF gene were overlap with KRAS, NRAS or PIK3CA mutations. All these BRAF 
mutations were present in heterozygous state. Representative electropherograms 
are shown in Figure 5.6. 
In regards with clinicopathological status BRAF mutation frequency was similar in 
patients above and below 50 years of age (3% each). Frequency of BRAF 
mutations was higher in Western region of India (55.2%); however, there was no 
significant association between the geographical location and BRAF mutations. In 
correlation with tumor differentiation status, BRAF mutations were significantly 
associated with moderately differentiated and poorly differentiated 
adenocarcinomas (p>0.05). No significant association was observed in BRAF and 
other clinico-pathological features like type of tumor, T stage, lymph node 
metastasis and site of tumor (Table 5.5). 
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Table 5.5: Clinicopathological characteristics’ correlation with mutation frequency in BRAF gene in colorectal cancer 
patients (n=203). 
Characteristics Total Samples % Total Detected % Detected % Not 
detected 
% p value 
Age ≤50 64 31.5 20 9.9 6 3.0 58 28.6 0.2 
>50 139 68.5 53 26.1 6 3.0 133 65.5   
Gender Males 138 68.0 53 26.1 8 3.9 130 64.0 0.99 
Females 65 32.0 20 9.9 4 2.0 61 30.0   
Geographical location East  8 3.9 2 1.0 0 0.0 8 3.9 0.44 
West 119 58.6 47 23.2 7 3.4 112 55.2   
North 38 18.7 11 5.4 4 2.0 34 16.7   
South 38 18.7 13 6.4 1 0.5 37 18.2   
Primary or Metastatic 
tumor 
Primary 129 63.5 45 22.2 8 3.9 121 59.6 0.99 
Metastatic 74 36.5 28 13.8 4 2.0 70 34.5   
Mucinous or Adeno 
or Signet 
Adeno 174 85.7 66 32.5 9 4.4 165 81.3 0.55 
Mucinous 19 9.4 5 2.5 2 1.0 17 8.4   
Signet ring 10 4.9 2 1.0 1 0.5 9 4.4   
Differentiation status MDA 111 54.7 43 21.2 4 2.0 107 52.7 0.02* 
WDA 41 20.2 19 9.4 6 3.0 35 17.2   
PDA 51 25.1 11 5.4 2 1.0 49 24.1   
Stage T1 3 1.5 1 0.5 0 0.0 3 1.5 0.74 
T2 12 5.9 3 1.5 0 0.0 12 5.9   
T3 136 67.0 49 24.1 8 3.9 128 63.1   
T4 52 25.6 20 9.9 4 2.0 48 23.6   
Lymph Node 
Metastasis 
Yes 152 74.9 61 30.0 10 4.9 142 70.0 0.73 
No 51 25.1 12 5.9 2 1.0 49 24.1   
Site Colon 147 72.4 51 25.1 8 3.9 139 68.5 0.74 
Rectum 56 27.6 22 10.8 4 2.0 52 25.6   
* Statistically significant 
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5.3.3 NRAS 
Out of 203 cases, NRAS mutations were observed in only 4 patients accounting to 
1.9%. Three of the NRAS mutations were observed in codon 12 and one was seen 
in codon 13. All of the codon 12 mutations were G12V substitutions and in codon 
13 was G13D substitution. Representative electropherograms for these changes in 
the gene are shown in Figure 5.6. All these NRAS mutations were observed in 
adenocarcinomas, metastatic lymph nodes and colon; however, the presence was 
not statistically significant. There was no statistically significant correlation between 
other clinicopathological and demographic features (Table 5.6) ; such as primary 
or metastatic tumor, tumor staging, distant metastasis or anatomical site. 
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Table 5.6: Correlation of mutation frequency in NRAS gene with clinicopathological characteristics in CRC cases (n=203). 
 
Characteristics Total 
Samples 
% Total 
Detecte
d 
% Detected 
Codon 12 
Detected 
Codon 61 
Total 
Detected 
% Not 
detected 
% p 
value 
Age ≤50 64 31.5 20 9.9 1 1 2 1.0 62 30.5 0.59 
>50 139 68.5 53 26.1 2 0 2 1.0 137 67.5   
Gender Males 138 68.0 53 26.1 2 0 2 1.0 136 67.0 0.59 
Females 65 32.0 20 9.9 1 1 2 1.0 63 31.0   
Geographical 
location 
East  8 3.9 2 1.0 0 0 0 0.0 8 3.9 0.75 
West 119 58.6 47 23.2 3 0 3 1.5 116 57.1   
North 38 18.7 11 5.4 0 0 0 0.0 38 18.7   
South 38 18.7 13 6.4 0 1 1 0.5 37 18.2   
Primary or 
Metastatic 
tumor 
Primary 129 63.5 45 22.2 2 0 2 1.0 127 62.6 0.62 
Metastatic 74 36.5 28 13.8 1 1 2 1.0 72 35.5   
Mucinous or 
Adeno or Signet 
Adeno 174 85.7 66 32.5 3 1 4 2.0 170 83.7 0.71 
Mucinous 19 9.4 5 2.5 0 0 0 0.0 19 9.4   
Signet ring 10 4.9 2 1.0 0 0 0 0.0 10 4.9   
Differentiation 
status 
MDA 111 54.7 43 21.2 1 0 1 0.5 110 54.2 0.43 
WDA 41 20.2 19 9.4 0 1 1 0.5 40 19.7   
PDA 51 25.1 11 5.4 2 0 2 1.0 49 24.1   
Stage T1 3 1.5 1 0.5 0 0 0 0.0 3 1.5 0.95 
T2 12 5.9 3 1.5 0 0 0 0.0 12 5.9   
T3 136 67.0 49 24.1 3 0 3 1.5 133 65.5   
T4 52 25.6 20 9.9 0 1 1 0.5 51 25.1   
Lymph Node 
Metastasis 
Yes 152 74.9 61 30.0 3 1 4 2.0 148 72.9 0.57 
No 51 25.1 12 5.9 0 0 0 0.0 51 25.1   
Site Colon 147 72.4 51 25.1 3 1 4 2.0 143 70.4 0.57 
Rectum 56 27.6 22 10.8 0 0 0 0 56 27.6   
Chapter 5. Correlation of KRAS, BRAF, NRAS and PIK3CA mutation profiling with 
clinicopathological features of CRC patients 
 207 
5.3.4 PIK3CA 
PIK3CA mutations were seen in 3.9% cases (8/203) in the current study. Seven of 
the PIK3CA mutations were observed in exon 9 and all were GAG to AAG 
substitution i.e. E545K mutation. One mutation was observed in exon 20 namely 
H1047R resulting in CAT to CGT substitution. It was also observed that 3 
mutations of exon 9 were overlap with KRAS mutant cases. This suggests that 
KRAS and PIK3CA mutations can occur in the overlapping form in colon cancer. 
No such concomitant mutations were observed in PIK3CA and NRAS and BRAF 
suggesting that these mutations occur in exclusive manner. Interestingly, no 
significant correlation was observed in PIK3CA mutations and any of the 
clinicopathological characteristics (Table 5.7). 
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Table 5.7: Correlation of mutation frequency in PIK3CA gene with clinicopathological characteristics in colorectal cancer 
cases (n=203). 
Characteristics Total 
Samples 
% Total 
Detected 
% Detected 
exon 9 
Detected 
exon 20 
Total 
Detected 
% Not 
detect
ed 
% p 
value 
Age ≤50 64 31.5 20 9.9 2 0 3 1.5 61 30.0 0.71 
>50 139 68.5 53 26.1 5 1 5 2.5 134 66.0   
Gender Males 138 68.0 53 26.1 5 1 7 3.4 131 64.5 0.44 
Females 65 32.0 20 9.9 2 0 1 0.5 64 31.5   
Geographical 
location 
East  8 3.9 2 1.0 0 0 0 0.0 8 3.9 0.36 
West 119 58.6 47 23.2 6 1 7 3.4 112 55.2   
North 38 18.7 11 5.4 0 0 0 0.0 38 18.7   
South 38 18.7 13 6.4 1 0 1 0.5 37 18.2   
Primary or 
Metastatic 
tumor 
Primary 129 63.5 45 22.2 4 0 4 2.0 125 61.6 0.46 
Metastatic 74 36.5 28 13.8 3 1 4 2.0 70 34.5   
Mucinous or 
Adeno or 
Signet 
Adeno 174 85.7 66 32.5 7 1 8 3.9 166 81.8 0.49 
Mucinous 19 9.4 5 2.5 0 0 0 0.0 19 9.4   
Signet ring 10 4.9 2 1.0 0 0 0 0.0 10 4.9   
Differentiation 
status 
MDA 111 54.7 43 21.2 5 0 5 2.5 106 52.2 0.69 
WDA 41 20.2 19 9.4 1 1 2 1.0 39 19.2   
PDA 51 25.1 11 5.4 1 0 1 0.5 50 24.6   
Stage T1 3 1.5 1 0.5 0 0 0 0.0 3 1.5 0.78 
T2 12 5.9 3 1.5 0 0 0 0.0 12 5.9   
T3 136 67.0 49 24.1 4 1 5 2.5 131 64.5   
T4 52 25.6 20 9.9 3 0 3 1.5 49 24.1   
Lymph Node 
Metastasis 
Yes 152 74.9 61 30.0 7 1 8 3.9 144 70.9 0.21 
No 51 25.1 12 5.9 0 0 0 0.0 51 25.1   
Site Colon 147 72.4 51 25.1 4 0 4 2.0 143 70.4 0.22 
Rectum 56 27.6 22 10.8 3 1 4 2.0 52 25.6   
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Table 5.8: Multivariate Logistic Regression Analysis for the correlation between gene mutations and clinicopathological 
features in Indian CRC patients (n=203) 
Clinico-
pathological 
features 
KRAS BRAF NRAS PIK3CA 
OR 95%CI P OR 95%CI P OR 95%CI P OR 95%CI P 
Age 2.4691 1.1154 - 
5.4660 
0.018* 0.4361 0.1350 - 
1.4091 
0.17 0.4526 0.0623 - 
3.2869 
0.439 0.7587 0.1757 - 
3.2768 
0.715 
Gender 0.7083 0.3459 - 
1.4505 
0.339 1.0656 0.3089 - 
3.6754 
0.92 2.1587 0.2973, 
15.6757 
0.452 0.2924 0.0352 - 
2.4276 
0.191 
Geographic 
location 
0.9777 0.6654 - 
1.4366 
0.909 0.9667 0.4791 - 
1.9506 
0.925 0.968 0.2940 - 
3.1870 
0.957 0.6283 0.2346 - 
1.6826 
0.327 
Primary or 
metastatic 
1.0161 0.5214 - 
1.9802 
0.963 0.8643 0.2512 - 
2.9741 
0.816 1.7639 0.2433 - 
12.7904 
0.577 1.7857 0.4332 - 
7.3616 
0.425 
Mucinous or 
Adeno or 
Signet 
0.5534 0.2409 - 
1.2712 
0.123 1.5807 0.6332 - 
3.9458 
0.36 The model could not be fit.# The model could not be fit.#  
Differentiation 0.5921 0.3852 - 
0.9102 
0.012* 1.2045 0.6163 - 
2.3539 
0.59 2.077 0.6516 - 
6.6208 
0.206 0.7196 0.2835 - 
1.8268 
0.471 
Stage 0.911 0.5293 - 
1.5681 
0.737 1.7155 0.6019 - 
4.8890 
0.304 1.284 0.2274 - 
7.2593 
0.775 1.9522 0.5421 - 
7.0306 
0.297 
Lymph Node 
Mets 
0.7067 0.3236 - 
1.5435 
0.375 0.5796 0.1227 - 
2.7376 
0.468 The model could not be fit.# The model could not be fit.#  
Site 1.0667 0.5223 - 
2.1785 
0.86 1.3365 0.3861 - 
4.6269 
0.652 The model could not be fit.# 2.75 0.6635 - 
11.3973 
0.171 
             
#Maximum likelihood estimates of parameters may not exist due to quasi-complete separation of data points.  
*-Statistically significant p<0.05 
OR-Odds ratio, 95%CI-95% Confidence interval 
In the multivariate logistic regression analysis it was observed that mutant KRAS was directly associated with increased 
age i.e above 50 years (p=0.018) and greater differentiation (p=0.012) as seen in Table 5.8.  
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5.4 Discussion 
In this phase of the study, the mutation frequencies in KRAS, BRAF, NRAS and 
PIK3CA genes in 203 Indian colorectal cancer patients was examined and also the 
correlation between clinicopathological features of CRC patients with these 
mutations was further investigated. To the best of my knowledge, the present study 
is the first study to determine collectively the mutation status of KRAS, BRAF, 
NRAS and PIK3CA genes along with clinicopathological and geographical 
incidence in a cohort of 203 Indian CRC patients. 
The estimated incidence of CRC worldwide is 1.3 million (Ferlay et al., 2015). 
Incidence of CRC in India has been estimated as 4.2 and 3.2 per 100,000 in males 
and females, respectively. Population based time trend studies show a rising trend 
in incidence of CRC in India (Ferlay et al., 2015).  
 
Significant developments have been made in the recent  past in the field of treating 
CRC with the use of monoclonal antibodies targeting Epidermal growth factor 
receptor (EGFR) such as cetuximab and panitumumab (Velho et al., 2009). EGFR 
pathway plays a very critical role in tumorigenesis and progression of CRC. EGFR 
initiates cascade of downstream signalling pathways such as RAS-RAF-MAPK and 
PIK3-AKT pathways, which are responsible for, cell proliferation, differentiation and 
survival (Patil et al., 2016). However, these anti-EGFR monoclonal antibodies are 
effective against a small subset of CRC patients. This is due to the presence of 
activating oncogenic mutations downstream of EGFR like KRAS, BRAF, NRAS 
and PIK3CA, which negatively predict the response to anti-EGFR therapy. Studies 
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have identified KRAS, BRAF, NRAS and PIK3CA gene mutations as predictive 
biomarkers in response to anti-EGFR antibody therapy (D. Lambrechts, 2009, De 
Roock et al., 2010). 
 
 
The overall frequency of mutations  in current study from 203  Indian CRC cases,  
revealed the presence of one of at least gene mutation in 36% cases and 
remaining 64% of cases did not have any mutations in the four genes tested. The 
prevalence of KRAS, BRAF, NRAS and PIK3CA mutations in this Indian cohort 
cases was 24%, 6%, 2% and 4%, respectively. Hence, it can be seen further that 
12% of KRAS wild type CRC patients had mutations in NRAS, BRAF or PIK3CA 
genes. 
 
5.4.1 KRAS 
KRAS mutation frequency varies from 14% to 67% worldwide as seen in Table 5.8. 
In the present study, the KRAS mutation frequency was observed to be 24%. In 
Western countries such as USA, UK, France, Italy, Lithuania, Germany, Russia 
and Australia, KRAS frequency ranges from 13%-67% where as in Asian countries 
such as China, Korea, India, Japan and Taiwan it varies from 20%-66% as 
mentioned in Table 5.8. The KRAS mutation frequency of 24% seen in the present 
study is thus similar to those reported from our group as well as from Bagadi et.al. 
and Bhist et.al. (20%-24%) (Patil et al., 2013, Bagadi et al., 2012, Bisht et al., 
2014) (Table 5.9). The variations seen in KRAS mutation frequency could be 
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attributed to ethnicity, geographical location, sample size, and techniques used and 
other etiological factors. 
 
In the current study, mutations in KRAS codons 12, 13 and 61 were evaluated. 
From the past studies, it has been observed that point mutations in KRAS codon 
12 are most common mutations in CRC (Vaughn et al., 2011). KRAS G12D is the 
most frequent change observed which is trailed by G12V, G12C, G12S and G12A 
(Vaughn et al., 2011, Neumann et al., 2009). In agreement with this, in present 
study, codon 12 mutations were observed in 20.2% cases followed by codon 3.9% 
in codon 13. No mutation was observed in codon 61.  
 
The glycine residue at codon 12 has a very critical role in normal functioning of ras 
protein. Hence, the single base substitutions that occur at this position cause 
GTPase formation, which further gets locked at the activating site (Arrington et al., 
2012). In the current study, G12D substitution was the most frequent followed by 
G12V, G12A, G12C and G12S. Similarly, G13D is the most frequent mutation 
observed in codon 13, which was also seen as the only mutation observed in this 
study in codon 13. (Vaughn et al., 2011)  
 
Correlation of clinico-pathological characteristics was further investigated with 
respect to KRAS mutations. It was observed that there was a significant positive 
association between KRAS mutations and age of a CRC patient (p<0.05). Mutation 
rate in patients with above 50 years of age was higher as compared to the patients 
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younger than 50 years. Furthermore, KRAS mutations were significantly 
associated with tumor differentiation status and significantly associated 
(moderately and poorly differentiated adenocarcinoma as compared to well-
differentiated adenocarcinoma (p<0.05) (Table 5.4). This observation is in 
agreement with the previous reports (Zhang et al., 2015a). In present study, it was  
further seen that KRAS mutations were more frequent in adenocarcinomas than in 
mucinous or signet ring carcinoma, which is also interestingly observed in an 
earlier study, however, statistically significant association was not observed in the 
current study (Li et al., 2011). Other clinico-pathological characteristics showed no 
significant association with KRAS mutations (p>0.05) which is in concordance with 
the recent reports of Indian population study based data (Bisht et al., 2014). 
 
5.4.2 BRAF 
BRAF is a member of the serine-threonine protein kinase family i.e. RAF family. It 
plays a very crucial role downstream of EGFR signalling pathway. The codon 600 
Valine to Glutamic acid substitution is the most frequent alteration observed in 
many human cancers including CRC (Di Nicolantonio et al., 2008). The BRAF 
mutation frequency ranges from 0.2% to 25% worldwide. In the present study the 
BRAF frequency is seen to be 5.9% which is in concordance with Asian studies 
(Table 5.9). As mentioned earlier geographical location, etiological factors, genetic 
makeup have an important role in these variations. 
 
BRAF codon 600 V600E was the only mutation observed in our study. Other 
mutations of BRAF i.e. V600K, V600Q or V600L were not observed which have 
Chapter 5. Correlation of KRAS, BRAF, NRAS and PIK3CA mutation profiling with 
clinicopathological features of CRC patients 
 214 
been reported in Western population (Mao et al., 2012b). Also, there was no 
presence of concomitant BRAF mutation with KRAS mutant cases. This lies in 
concordance with previous studies which show that BRAF and KRAS mutations 
are mutually exclusive (Di Nicolantonio et al., 2008). 
 
However, till today there is insufficient data to justify the predictive role of BRAF for 
benefit from anti-EGFR monoclonal antibody therapy in KRAS wild type cases. 
Few studies in past have shown worst outcome in case of BRAF mutant cases(Di 
Fiore et al., 2010). In the recent past few studies have evaluated anti-BRAF/EGFR 
combination regimes to elucidate the best treatment outcome (Connolly et al., 
2013, Yaeger et al., 2015). This combinatorial approach would emerge as a 
potential strategy for future cancer treatment. 
 
 
In the present study, it was seen that BRAF mutations were significantly observed 
in moderately differentiating and poorly differentiating adenocarcinomas than in 
well-differentiated adenocarcinomas. Presence of BRAF mutations in poorly 
differentiated adenocarcinomas is similar to findings of previously reported studies 
(Shen et al., 2013). No significant association was observed in BRAF mutations 
and other clinico-pathological features which supports the reported studies (Li et 
al., 2011, Mao et al., 2012b, Bisht et al., 2014).  
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5.4.3 NRAS 
In human cancers RAS proto-oncogenes, KRAS and NRAS, are found mostly in 
mutant oncogenic forms. In case of CRC unlike KRAS, which are most frequently 
mutated, NRAS mutations are rare (Irahara et al., 2010). The mutation frequency 
for NRAS in CRC varies from 2%-10% (Table 5.9). In the present study, NRAS 
mutations were observed in 1.9% which lies in concordance with previously 
reported studies from Asian countries (Bagadi et al., 2012, Zhang et al., 2015a). 
There was no coexistence of KRAS , BRAF and NRAS mutations in the study. No 
significant association was observed between NRAS mutations and patient 
demographics. 
 
5.4.4 PIK3CA 
 
Alterations in phosphoinositide-3-kinase catalytic alpha; a catalytic domain in PIK3, 
is seen in many cancers. In CRC these mutations range from 1%-37% and majority 
of mutations are observed in exon 9 and exon 20 (Table 5.9). There are two hot 
spot regions in exon 9 –codon 542 and codon 545 and one in exon 20-codon 1047. 
Recently, PIK3CA has been observed as a potential predictive marker for targeted 
therapy in CRC. A low response rate has been observed in patients having 
PIK3CA mutations (De Roock et al., 2011). In the present study, the frequency of 
PIK3CA mutations was found to be 3.9% similar to other Asian studies (Zhang et 
al., 2015a, Bisht et al., 2014, Hsieh et al., 2012). Higher percentage of mutations 
were observed in exon 9 which is similar to Western population (Palomba et al., 
2012). Further current study data shows that mutations were seen in exon 9 only 
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E545K and in exon 20 H1047R while other mutations of exon 9 namely E542K and 
H1047L in exon 20 were absent. Mutations in exon 9 and 20 may affect differently 
the response to anti-EGFR therapy. Mutations in exon 20 are associated with lower 
response rates as seen in the study done by Mao et.al (Mao et al., 2012b, De 
Roock et al., 2010).  
 
It was also seen in the present study results that 3 cases showed overlapping 
mutations in KRAS and PIK3CA. Such coexistence of KRAS and PIK3CA 
mutations has been reported earlier in few studies (Mao et al., 2012b). However, 
no significant correlation was seen in clinico-pathological characteristics and 
PIK3CA mutations which corresponds to previous studies of Asian countries (Mao 
et al., 2012b, Bisht et al., 2014) . 
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Table 5.9: KRAS, NRAS, BRAF and PIK3CA mutation frequencies in reported studies worldwide. 
Study Sample 
size 
Method Target Population KRAS 
% 
NRAS 
% 
BRAF 
% 
PIK3C
A % 
(Baltruškevičienė et al., 
2016) 
55 Sanger sequencing KRAS exons 2,3 and 4 
NRAS exons 2,3 and 4 
BRAF exon 15 
PIK3CA exons 9 and 20 
Lithuania 67.3 0 1.8 5.5 
(Zhang et al., 2015a) 1110 RT PCR and Sanger sequencing KRAS exons 2,3 and 4 
NRAS exons 2,3 and 4 
BRAF exon 15 
PIK3CA exon 9 
China 45.4 3.9 3.1 3.5 
(Foltran et al., 2015) 194 Pyro sequencing KRAS exons 2 and 3 
BRAF exon 15 
NRAS exons 2 and 3 
PIK3CA exons 9 and 20 
Italy 47.4 3.6 5.2 16.5 
(Kawazoe et al., 2015) 264 Luminex assay KRAS exons 2,3 and 4 
NRAS exons 2 and 3 
BRAF exon 15 
PIK3CA exons 9 and 20 
Japan 34.1 4.2 5.4 6.4 
(Normanno et al., 2015)  182 Next Generation Sequencing KRAS exons 2,3 and 4 
NRAS exons 2,3 and 4 
BRAF exon 15 
PIK3CA exons 9 and 20 
Italy 24.7 7.1 8.2 13.2 
(Kriegsmann et al., 2015) 93 Mass spectrometry KRAS exons 2,3 and 4 
NRAS exons 2,3 and 4 
BRAF exon 15 
Germany 49 2 1 Not 
done 
(Negru et al., 2014) 2071 Sanger sequencing KRAS exons 2,3 and 4 
NRAS exons 2,3 and 4 
Greek 46.56 9 14.4 Not 
done 
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BRAF exon 15, 
(Negru et al., 2014) 2071 Sanger sequencing KRAS exons 2,3 and 4 
NRAS exons 2,3 and 4 
BRAF exon 15 
Romania 46.3 10.3 10.2 Not 
done 
(Bisht et al., 2014) 204 DNA sequencing KRAS exons 2 and 3 
NRAS exons 2 and 3 
BRAF exon 15 
PIK3CA exons 9 and 20 
India 23.5 Not 
done 
9.8 5.9 
(Guedes et al., 2013) 212 High resolution melting analysis KRAS exons 2,3 and 4 
BRAF exon 15 
PIK3CA exons 9 and 20 
Portugal 44.1 Not 
done 
18.3 37.3 
(Rosty et al., 2013) 757 HRM and Sanger sequencing KRAS exons 2 and 3 
BRAF exon 15 
PIK3CA exons 9 and 20 
Australia 28.4 Not 
done 
15.9 14 
(Patil et al., 2013) 1323 DNA sequencing KRAS exons 2 and 3 India 20.5 Not 
done 
Not 
done 
Not 
done 
(Sinha et al., 2013) 62 DNA sequencing KRAS exons 2 and 3 India 62.1 Not 
done 
Not 
done 
Not 
done 
(Malhotra et al., 2013) 30 PCR Restriction digestion KRAS exons 2 and 3 India 26.7 Not 
done 
Not 
done 
Not 
done 
(Smith et al., 2013) 1976 Mass spectrometry and pyro 
sequencing 
KRAS exons 2 and 3 
BRAF exon 15 
PIK3CA exons 9 and 20 
UK 42.3 Not 
done 
9 12.7 
(Yanus et al., 2013) 195 HRM/COLDPCR/Allele Specific 
PCR and Sequencing 
KRAS exons 2 and 3 
NRAS exons 2 and 3 
BRAF exon 15 
PIK3CA exons 9 and 20 
Russia 35.9 4.1 4.1 12.3 
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(Derbel et al., 2013) 98 DNA sequencing KRAS exons 2 and 3 
BRAF exon 15 
PIK3CA exon 9 and 20 
France 23.5 Not 
done 
2 4 
(Neumann et al., 2013) 171 Pyro sequencing KRAS exon 2, 
BRAF exon 15 
PIK3CA exons 9 and 20 
Germany 40.9 Not 
done 
11.1 18.7 
(Yip et al., 2013) 44 KRAS-DNA sequencing, BRAF-
Real Time 
KRAS exons 2 and 3 
BRAF exon 15 
Malaysia 25 Not 
done 
2.3 Not 
done 
(Nakanishi et al., 2013) 254 DNA sequencing KRAS exon 2, 
BRAF exon 15 
Japan 33.5 Not 
done 
6.7 Not 
done 
(Soeda et al., 2013) 43 DNA sequencing KRAS exons 2 and 3, 
BRAF exon 15 
PIK3CA exons 9 and 20 
Japan 27.9 Not 
done 
4.7 4.7 
(Mao et al., 2012a) 69 Sanger sequencing KRAS codons 12,13,14 
BRAF codon 600 
PIK3CA exons 9 and 20 
China 43.9 Not 
done 
25.4 8.2 
(Bagadi et al., 2012) 100 DNA sequencing KRAS exons 2 and 3 
NRAS exons 2 and 3 
BRAF exon 15 
India 23 2 17 Not 
done 
(Liao et al., 2012) 964 Pyro sequencing KRAS exons 2 and 3 
BRAF exon 15 
PIK3CA exons 9 and 20 
USA 35 Not 
done 
13.7 16.7 
(Bozzao et al., 2011) 209 HRM and Sanger sequencing KRAS exon 2 
BRAF exon 15 
PIK3CA exon 20 
Italy 43.5 Not 
done 
0 2.3 
(Palomba et al., 2012) 478 DNA sequencing KRAS exons 2 and 3 
BRAF exon 15 
Sardinia 30.3 Not 
done 
0.26 17.4 
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PIK3CA exon 9 and 20 
(Hsieh et al., 2012) 182 HRM KRAS exon 2 
BRAF exon 15 
PIK3CA exons 9 and 20 
Taiwan 33.5 Not 
done 
1.1 7.1 
(Ling et al., 2012) 331 DNA sequencing KRAS exon 2 
BRAF exon 11 and 15 
PIK3CA exons 9 and 20 
China 44.1 Not 
done 
5.8 2.6 
(Balschun et al., 2011) 21 Sanger sequencing and Pyro 
sequencing 
KRAS exons 2 and 3 
NRAS exons 2 and 3 
BRAF exon 15 
PIK3CA exon 20 
Germany 31.6 3.5 12.3 0 
(Wong et al., 2011) 29 Real Time PCR KRAS exon 2 
BRAF exon 15 
PIK3CA exon 9 and 20 
USA 34.9 Not 
done 
10.3 10.3 
(Saridaki et al., 2011) 112 KRAS and PIK3CA-DNA 
sequencing, BRAF - Real Time 
PCR 
KRAS exon 2 
BRAF exon 15 
PIK3CA exons 9 and 20 
Greece 33 Not 
done 
7.2 9.8 
(Janku et al., 2011) 504 DNA sequencing KRAS exons 2 and 3 
NRAS exons 2 and 3 
BRAF exon 15 
PIK3CA exons 9 and 20 
USA 19 8 9 11 
(Baba et al., 2011) 717 Pyro sequencing KRAS exon 2 
BRAF exon 15 
PIK3CA exons 9 and 20 
USA 37.7 Not 
done 
15.4 16.8 
(Kwon et al., 2011) 92 DNA sequencing KRAS exons 2 and 3 
BRAF exon 15 
PIK3CA exons 9 and 20 
Korea 20.7 Not 
done 
3.3 1.1 
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(Aoyagi et al., 2011) 134 DNA sequencing KRAS exon 2 
BRAF exon 15 
PIK3CA exons 9 and 20 
Japan 30.6 Not 
done 
0.75 13.4 
(De Roock et al., 2010) 1022 Mass spectrometry KRAS exons 2 and 3 
NRAS exons 2 and 3 
BRAF exon 15 
PIK3CA exons 9 and 20 
Belgium 40 2.6 4.7 14.5 
(Di Nicolantonio et al., 
2010) 
43 DNA sequencing KRAS exon 2 
BRAF exon 15 
PIK3CA exons 9 and 20 
Italy 43.5 Not 
done 
0 2.3 
(Lurkin et al., 2010) 294 Multiplex PCR and sequencing KRAS exons 2 and 3 
NRAS exons 2 and 3 
BRAF exon 15 
PIK3CA exons 9 and 20 
Germany 48.6 2 5.3 13.1 
(Perkins et al., 2010) 42 DNA sequencing KRAS exon 2 
BRAF exon 15 
PIK3CA exon 9  
France 45.2 Not 
done 
2.4 14.3 
(Baldus et al., 2010) 100 Pyro sequencing KRAS exon 2 
BRAF exon 15 
PIK3CA exons 9 and 20 
Germany 41 Not 
done 
7 21 
(Berg et al., 2010) 181 DNA sequencing KRAS exons 2 and 3 
BRAF exon 15 
PIK3CA exons 9 and 20 
Chinese 32 Not 
done 
16 3 
(Irahara et al., 2010) 225 Pyro sequencing KRAS exons 2 and 3 
NRAS exons 2 and 3 
BRAF exon 15 
PIK3CA exons 9 and 20 
USA 41 2.2 14 11 
(Roth et al., 2010) 1404 Real Time PCR KRAS exon 2 Swiss 37 Not 7.9 Not 
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BRAF exon 15 done done 
(Souglakos et al., 2009) 168 DNA sequencing KRAS exon 2 
BRAF exon 15 
PIK3CA exons 9 and 20 
UK 36.9 Not 
done 
7.7 15.5 
(Ogino et al., 2009) 450 Pyro sequencing KRAS exon 2 
BRAF exon 15 
PIK3CA exons 9 and 20 
USA 35.7 Not 
done 
15.8 18.2 
(Perrone et al., 2009) 32 DNA sequencing KRAS exon 2 
BRAF exon 11,15 
PIK3CA exons 9 and 20 
Italy 24.1 Not 
done 
9.7 12.9 
(D. Lambrechts, 2009) 153 Squenome MALDI TOF 
MassArray 
KRAS exons 2,3 and 4 
NRAS exons 2 and 3 
BRAF exon 15 
PIK3CA exons 9 and 20 
Belgium 42 5.4 9.8 12 
(Velho et al., 2008) 150 PCR and sequencing KRAS exon 2 
BRAF exon 15 
PIK3CA exon 20 
Portugal 31 Not 
done 
18 14 
(Simi et al., 2008) 116 HRM KRAS exon 2 
BRAF exon 15 
PIK3CA exons 9 and 20 
Italy 43 Not 
done 
9.5 17.2 
 (Freeman et al., 2008) 62 DNA sequencing KRAS exon 2 
BRAF exon 15 
PIK3CA exons 9 and 20 
USA 38.7 Not 
done 
5.6 3.2 
(Cappuzzo et al., 2008) 80 PCR and Suveyor digestion KRAS exon 2 
BRAF exon 11,15 
PIK3CA exons 9 and 20 
Italy 52.5 Not 
done 
5.06 17.7 
(Barault et al., 2008) 586 DNA sequencing KRAS exon 2 
BRAF exon 15 
France 33.8 Not 
done 
13.3 16.7 
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PIK3CA exons 1, 2,9 and 
20 
(Velho et al., 2005) 150 PCR-SSCP-Sequencing KRAS exon 2 
BRAF exon 15 
PIK3CA exons 9 and 20 
Portugal 20.7 Not 
done 
12 9.3 
(Fransen et al., 2004) 130 PCR-SSCP-Sequencing KRAS exons 2 and 3 
BRAF exon 11,15 
Sweden 40 Not 
done 
10 Not 
done 
(K Servomaa, 2000) 118 PCR-SSCP-Sequencing KRAS exons 2 and 3 Finland 14 Not 
done 
Not 
done 
Not 
done 
Current Study 203 DNA sequencing KRAS exons 2 and 3 
NRAS exons 2 and 3 
BRAF exon 15 
PIK3CA exons 9 and 20 
India 24 2 6 4 
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These variations in the mutation patterns could be due to racial differences, 
geographical differences, environmental factors, and lifestyle factors, which include 
obesity or physical inactivity, or other etiological factors. Nevertheless, future 
studies on large cohorts are required for in depth investigations on the genetic and 
epigenetic markers involved in colorectal cancer to aid in identification of new 
targets for personalised medicine. 
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Chapter 6      Survival Analysis 
 
6.1 Introduction 
Several studies have been performed to identify prognostic effects of various 
clinico-pathological factors in colorectal cancer (Desolneux et al., 2010, Gharbi et 
al., 2010, Laohavinij et al., 2010, Moghimi-Dehkordi et al., 2008, Rath and Gandhi, 
2014).  In Asia, the 5-year survival rate is around 42% as compared to the USA, 
where it is around 60% (Jemal et al., 2010b). Early stage detection of disease 
increases the patient survival rate to around 90%. However, in developing 
countries early detection is possible only in 35% of CRC patients due to lack of 
screening programs. Relative survival rates of CRC patients in Asian countries 
ranges from 28%-42%, with the highest being in China and lowest in India (Siegel 
et al., 2015). As reviewed in Chapter 2, the survival rates in Asian countries are 
lower as compared to European and Western developed countries. This has been 
attributed mainly to late diagnosis. Aggressive treatment besides early detection is 
another key strategy for improving overall survival. 
Further as summarized in Figure 2. 15, and reviewed in Treatment strategies 
section 2.6, 5-FU was the only drug used for decades for the treatment of CRC. 
With the use of combination of drugs in chemotherapy, the oncologists have 
achieved improvement in patient’s overall survival. Use of 5-FU plus Leucovorin 
(LV) either with irinotican (FOLFIRI) or oxaliplatin (FOLFOX) has led to 
improvement in survival. Further, the addition of monoclonal antibodies to standard 
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chemotherapy regime has improved the survival rates. The clinicians require 
accurate outcome prediction to adopt appropriate therapeutic regime.  
 
The aim of this phase of study was to examine the correlation between 
clinicopathological characteristics and survival outcome in the Indian CRC patient 
cohort (n=30). This may help in disease understanding and better patient 
management for the Indian patients. Hence, evaluation of progression free and 
overall survival of Indian CRC patients was carried out by exploring relevant 
clinicopathological factors affecting prognosis like age, sex, site, stage etc.  
 
6.2 Patients 
This study is a retrospective observational study comprising of a total of 30 Indian 
CRC patients studied between January 2013 till August 2016. All clinical and follow 
up data were collected from medical records. The data included age, sex, tumor 
differentiation, location of tumor, lymph node involvement, depth of invasion, date 
of onset, cause of recurrence if any, date of death and treatment given. The data 
was collected after every 3 months. Patients were treated with either FOLFOX 
(Folinic acid, 5-FU and Oxaliplatin) or CAPOX (Oxaliplatin and Capecitabine) or 
CAPIRI (Capecitabine and Irinotecan). Three patients were given bevacizumab 
(Avastin) and three were given cetuximab (Erbutix) in combination with 
chemotherapy. The study was conducted with approval from the scientific 
committee of Reliance Life Science Pvt Ltd. The study design was shared with the 
hospitals for obtaining clinical information of the patients who were referred to 
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Reliance Life Sciences Pvt. Ltd. for mutational analysis of the samples. Formalin 
fixed specimens was stained with haematoxylin – eosin (HE) and histological 
assessment was done. Direct sequencing was performed for KRAS, NRAS, BRAF 
and PIK3CA mutational analysis.  
6.3 Statistics 
Statistical analysis was done using GraphPad Prism 7 (GraphPad Software Inc, 
CA, USA) and MedCalc for Windows, version 16.0 (MedCalc Software, Ostend, 
Belgium). The Kaplan- Meier method was used for plotting survival curves.  
Progression free survival (PFS) is defined as the time from initial administration 
of treatment until the first objective evidence of disease progression or death from 
any cause. 
Overall survival (OS) is defined as the time from the initiation of the treatment 
until the death of the patient. Patients were censored at the time of last follow up or 
if they were alive after the end of the study, which was August 2016. 
To assess the differences in survival, log rank test was used. Univariate hazard 
ratios were identified along with multivariate using COX proportional hazard 
analysis. p value less than or equal () to 0.05 was considered as significant.  
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6.4 Results: 
Basic information data from the CRC patients is given in Table 6.1.  
Table 6.1a: Basic Data of CRC patients (n=30) 
 
Pt 
No. 
Age 
Date of 
diagnosis 
Date of 
death or lost 
follow up 
Alive (A) or 
dead (D) or 
left (L) 
No of  
years 
Round 
Down 
 
No. of 
years 
 
 
 
No. of 
days 
 
 
1 66 5/03/13 5/03/14 D 1 1 365 
2 74 18/06/12 1/07/13 D 1 1.04 378 
3 44 1/04/11 1/03/15 L 3 3.92 1430 
4 70 16/07/13 1/08/14 D 1 1.04 381 
5 69 24/08/13 15/07/15 L 1 1.89 690 
6 58 27/11/13 3/03/15 L 1 1.26 461 
7 45 6/09/13 6/07/15 D 1 1.83 668 
8 70 20/11/14 6/04/16 A 1 1.38 503 
9 56 2/01/14 1/08/15 D 1 1.58 576 
10 62 7/06/11 12/03/16 A 4 4.77 1740 
11 57 30/07/13 12/01/16 A 2 2.45 896 
12 59 6/07/15 12/05/16 A 0 0.85 311 
13 66 12/04/13 4/04/16 A 2 2.98 1088 
14 56 30/08/14 8/05/16 A 1 1.69 617 
15 52 6/08/13 10/06/15 D 1 1.84 673 
16 48 31/07/13 20/05/14 D 0 0.80 293 
17 63 1/03/14 11/05/15 L 1 1.19 436 
18 78 27/09/12 4/12/12 D 0 0.19 68 
19 60 28/02/13 1/02/15 L 1 1.93 703 
20 55 7/03/13 8/11/15 D 2 2.67 976 
21 45 17/12/14 29/04/16 A 1 1.37 499 
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22 51 26/01/13 25/02/16 A 3 3.08 1125 
23 62 8/05/13 18/06/15 D 2 2.11 771 
24 48 12/02/15 10/03/16 A 1 1.07 392 
25 50 6/06/13 21/07/15 D 2 2.12 775 
26 52 16/02/14 24/05/16 L 2 2.27 828 
27 65 26/03/13 19/07/16 A 3 3.32 1211 
28 67 27/05/13 13/08/16 A 3 3.22 1174 
29 71 14/07/14 6/08/16 D 2 2.07 754 
30 80 21/01/14 15/07/16 D 2 2.48 906 
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Table 6.1b: Clinicopathological Data of CRC patients (n=30) 
 
Pt No Age  
Date of 
diagnosis 
Date of death 
or lost follow 
up 
Alive or 
dead or 
left 
No.of 
yrs Gende
r Site 
Tumor 
differentiati
on 
Lymphnode 
mets Therapy Mutation P/M 
1 66 5/03/13 5/03/14 D 1 
M Colon PDA pT3N2 
CAPIRI+ERBUTI
X BRAF M 
2 74 18/06/12 1/07/13 D 1 F Rectum PDA ypT3N2b CAPOX ND P 
3 44 1/04/11 1/03/15 L 3 
M Rectum PDA ypT4N2b 
FOLFOX+CAPIR
I ND M 
4 70 16/07/13 1/08/14 D 1 M Colon MDA pT3pN0pM1 CAPIRI ND M 
5 69 24/08/13 15/07/15 L 1 F Rectum MDA pT4bN1aMx FOLFOX KRASCD12 M 
6 58 27/11/13 3/03/15 L 1 F Colon MDA T3N0 FOLFOX KRASCD12 P 
7 45 6/09/13 6/07/15 D 1 F Colon PDA T3N2MX FOLFOX ND P 
8 70 20/11/14 6/04/16 A 1 M Rectum MDA T3N1MX FOLFOX ND P 
9 56 2/01/14 1/08/15 D 1 
F Colon PDA T3N2 
FOLFOX+CAPIR
I ND M 
10 62 7/06/11 12/03/16 A 4 M Rectum MDA T3NOMX CAPOX ND P 
11 57 30/07/13 12/01/16 A 2 M Rectum MDA T3N1MX FOLFOX KRASCD12 P 
12 59 6/07/15 12/05/16 A 0 M Rectum MDA T3N0 CAPOX ND P 
13 66 12/04/13 4/04/16 A 2 M Rectum MDA T4N2M1 CAPOX+CAPIRI ND M 
14 56 30/08/14 8/05/16 A 1 
M Rectum MDA T3N2MX 
FOLFIRI+AVAS
TIN KRASCD12 M 
15 52 6/08/13 10/06/15 D 1 M Rectum MDA T3N0 FOLFOX ND M 
16 48 31/07/13 20/05/14 D 0 
F Colon PDA T4N2 
FOLFOX+AVAS
TIN ND P 
17 63 1/03/14 11/05/15 L 1 
F Colon MDA T4N2 
FOLFOX+ERBU
TIX ND P 
18 78 27/09/12 4/12/12 D 0 M Rectum MDA T3N2MX CAPOX ND P 
19 60 28/02/13 1/02/15 L 1 
F Colon MDA T3N1MX CAPOX ND P 
20 55 7/03/13 8/11/15 D 2 F Colon PDA T3N1 FOLFOX KRASCD12 P 
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21 45 17/12/14 29/04/16 A 1 F Colon MDA T3N1 FOLFOX ND M 
22 51 26/01/13 25/02/16 A 3 
M Colon MDA T3N0 
FOLFIRI+AVAS
TIN ND P 
23 62 8/05/13 18/06/15 D 2 F Rectum MDA T3N2MX FOLFOX KRASCD12 P 
24 48 12/02/15 10/03/16 A 1 M Rectum PDA T3N0 CAPOX ND P 
25 50 6/06/13 21/07/15 D 2 F Colon PDA T3N1 FOLFOX ND M 
26 52 16/02/14 24/05/16 L 2 
F Colon MDA T3N0 CAPOX ND P 
27 65 26/03/13 19/07/16 A 3 M Rectum MDA T3N1 FOLFOX ND P 
28 67 27/05/13 13/08/16 A 3 
F Rectum MDA T4N2 
FOLFOX+ERBU
TIX ND P 
29 71 14/07/14 6/08/16 D 2 
M Colon PDA T3N2MX FOLFOX ND M 
30 80 21/01/14 15/07/16 D 2 M Colon PDA T3N1MX FOLFOX KRAS CD12 M 
  
D-Dead, A-Alive, L-Lost follow up, P-Primary tumor, M-Metastatic tumor 
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6.4.1 Estimation of survival 
The first requirement for estimation of survival time is a well-defined starting point. 
In this study, the date of diagnosis was taken as the starting time. The outcome 
was defined as the death of the patient, so the death of patient was recorded. 
Survival time is the time between the starting point (occurrence of disease) and the 
outcome (death of the patient). The data of patients’ survival time in increasing 
duration is shown in Figure 6.1. The X axis shows the time in years and Y axis 
shows the patient. The bars in red denote the death of that particular patient.  
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Figure 6.1: The data of 30 patients aligned in order of their survival time. Red bars 
indicate the dead patients and yellow ones indicate the alive patients. 
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The data, in summary, is represented in the form of a tree diagram (Figure 6.2).  
Figure 6.2: Tree diagram for CRC patients (n=30). 
 
 
     
Figure Legend: The upper arm represents the dead patients and the lower arm 
represents the alive patients. Based on this data, the probability of dying can be calculated 
as 13/25=0.52=52%. 
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6.4.2 Censored observations 
A closed group consists of patients having all complete observations. However, in 
the clinical scenario of a retrospective study this is not possible as there would be 
some patients who would join the study at different time points and other patients 
that would have been lost to follow up due to migration. Such patients who have 
early termination of follow up are called as censored patients. 
In the present study, there were 6 patients who left during the study period. These 
patients were termed as censored. Hence, the results can be expressed as a tree 
diagram having three arms, one for patients who are alive, one for dead patients 
and another one for censored patients as shown in Figure 6.3. The probability of 
dying can then be calculated as D/N-(0.5XL) i.e.13/25-(0.5X6) =0.59=59%. 
Figure 6.3: Tree diagram showing 30 CRC cases of which 13 are dead, 6 have 
lost follow up and 11 are alive. 
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6.4.3 Actuarial Life Table 
The data of these 30 patients is also presented in the form of Actuarial life table in 
which cumulative survival is calculated along with probability of dying and 
probability of survival. Table 6.2 summarises actuarial life table for 30 patients and 
the survival curve is shown in Figure 6.4. 
 
Table 6.2: Actuarial Life Table for patients (n=30) 
 
No. 
of 
years 
No. of 
patients 
(N) 
No. of 
Dead 
(D) 
No. of 
Alive or 
Left A/L 
(N-0.5L) 
Prob. of 
Dying 
Prob. of 
Surviving 
Cumulative 
Survival 
0 30 2 1 29.5 0.07 0.932 0.93 
1 28 6 8 24 0.25 0.75 0.47 
2 14 5 3 12.5 0.40 0.600 0.2 
3 6 0 2 5 0.00 1.000 0.13 
4 4 0 1 3.5 0.00 1.000 0 
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Figure 6.4: Actuarial survival curve (n=30) 
 
 
Figure Legend: 
Probability of dying = D/N-(0.5L) 
Probability of survival = 1- Probability of death 
Cumulative survival = Multiplication of probability survivals of each year 
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6.4.4 Kaplan – Meier Survival Curve   
The method of estimation of survival probabilities when the exact time of death or 
censored data is known is called Kaplan-Meier survival curve analysis. It is a 
stepped line plot in which each step denotes the death of a patient. 
Figure 6.5: Kaplan-Meier survival curve for CRC patients (n=30). 
 
Figure Legend: The 3-year overall survival is 40% with median survival of 2.48 years i.e. 
29 months as shown in Figure 6.5 .The dots on the plot represent the censored patients 
and the drops are the patients, which died in the study. 
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6.4.4.1 Estimation of Progression free survival (PFS) and Overall Survival 
(OS) 
Patients were divided according to the different clinicopathological characteristics. 
PFS and OS were calculated using Kaplan-Meier curves with respect to different 
clinicopathological features. Figure 6.6 summarises the PFS and OS curves of 
Indian CRC patients.  
Figure 6.6: Kaplan Meier plots of PFS and OS for CRC patients (n=30). 
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 I 
 J 
Figure Legend:  
A and B: Age wise PFS and OS ; C and D : Tumor differentiation wise PFS and OS; E and 
F :Lymph node metastasis wise PFS and OS ; G and H : Primary or metastatic tumor wise 
PFS and OS ; I and J: Tumor site wise PFS and OS. MDA-Moderately differentiated 
adenocarcinoma ; PDA-Poorly differentiated adenocarcinoma  
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According to age factor, two groups were made, less than 60 years old and other 
more than 60 years. PFS and OS were compared in these two groups. The median 
PFS of patients below 60 years was 0.7 years (n=15, HR=0.834,95%CI=0.3543 to 
1.9636) and above 60 years was 0.6 years (n=15, HR=0.94,95%CI=0.3178 to 
2.8032) . The median OS of patients below 60 years was 2.7 years (n=15, 
HR=0.94,95%CI=0.3178 to 2.8032) and above 60 years was 2.5 years (n=15, 
HR=1.06,95%CI=0.3567 to 3.1462). There was no significant association between 
the two plots both by univariate and multivariate analysis (p>0.05) (Figure 6.6 A 
and B, Table 6.3).  
 
As per histological differentiation - moderately differentiated adenocarcinoma 
(MDA) and poorly differentiated adenocarcinoma (PDA), median PFS of PDA 
(n=11, 0.5 years, 95%CI= 0.40-0.70) was shorter than that of MDA (n=19, 0.8 
years, 95%CI= 0.50-0.90), as verified in both univariate (HR=0.503, 95%CI= 
0.2001 to 1.2643, p=0.08 ) and multi variate (HR= 0.331, 95%CI=0.1047 to 1.0468, 
p=0.058) analysis.  
The median OS of PDA was significantly shorter than that of MDA as verified both 
by univariate (HR=0.25, 95%CI= 0.07682 to 0.7499, p=0.009 ) and multivariate 
analysis (HR=0.1605, 95%CI= 0.0237 to 1.0895, p=0.05 ) (Figure 6.6 C and D, 
Table 6.3) 
In the case of location of tumor i.e colon or rectum, primary or metastatic tumor 
and lymph node metastasis no significant association was observed for PFS and 
OS both by univariate and multivariate analysis (p>0.05).  The PFS and OS was 
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shorter in case of tumors located in rectum, metastatic tumors and tumors with 
lymph node metastasis (Figure 6.6 E-J, Table 6.3) . 
Table 6.3: Univariate and Multivariate analysis of PFS and OS 
  Univariate 
   PFS OS 
Clinicopath
ological 
features 
Reference 
category 
OR 95% CI p OR 95% CI p 
                
Age >60/<60 yrs 0.834 0.3543 to 
1.9636 
0.65 0.94 0.3178 to 
2.8032 
0.72 
Site Colon/Rectum 0.96 0.4061 to 
2.2771 
0.9 2.63 0.8756 to 
7.911 
0.08 
Differentiati
on 
PDA/MDA 0.503 0.2001 to 
1.2643 
0.08 0.25 0.07682 
to 0.7499 
0.009* 
Lymph 
node 
involvement 
Yes/No 0.55 0.2164 to 
1.4007 
0.23 0.53 0.1517 to 
1.828 
0.39 
Metastatic 
or Primary 
Primary/Metastatic 0.79 0.3264 to 
1.9152 
0.56 0.56 0.1875 to 
1.727 
0.3 
Mutation 
status 
Wild Type/ Any 
mutant 
0.68 0.2566 to 
1.8262 
0.36 0.86 0.2548 to 
2.918 
0.81 
Therapy Chemo/Chemo+bi
ological agent 
0.91 0.2984 to 
2.8045 
0.86 0.83 0.2021 to 
3.4482 
0.8 
 
  Multivariate 
   PFS OS 
Clinicopath
ological 
features 
Reference 
category 
OR 95% CI p OR 95% CI p 
                
Age >60/<60 yrs 1.472
2 
0.5944 to 
3.6461 
0.403
3 
0.456 0.1233 to 
1.6866 
0.2393 
Site Colon/Rectum 0.648
8 
0.2294 to 
1.8349 
0.414
7 
1.707
4 
0.4122 to 
7.0717 
0.4606 
Differentiati
on 
PDA/MDA 0.331
1 
0.1047 to 
1.0468 
0.059
8 
0.160
5 
0.0237 to 
1.0895 
0.0542
* 
Lymph 
node 
involvement 
Yes/No 0.76 0.1136 to 
5.1044 
0.779 0.752
5 
0.1133 to 
4.9961 
0.7684 
Metastatic 
or Primary 
Primary/Metastatic 0.907
4 
0.3490 to 
2.3591 
0.842 0.833
6 
0.2093 to 
3.3207 
0.7963 
Mutation 
status 
Wild Type/ Any 
mutant 
1.503
1 
0.5732 to 
3.9417 
0.407
3 
0.674
9 
0.1709 to 
2.6663 
0.5749 
Therapy Chemo/Chemo+bi
ological agent 
0.597
3 
0.1827 to 
1.9529 
0.393
9 
0.77 0.1450 to 
4.0739 
0.76 
*Statistically significant 
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PFS-Progression free survival, OS-Overall survival, OR-Odds ratio, 95%CI-95%Confidence interval, PDA-
Poorly differentiated adenocarcinoma, MDA-Moderately differentiated adenocarcinoma 
 
Further in this study, twenty two patients had tumors with no mutations (all wild-
type tumors) and 8 had tumors with mutation in either KRAS codons 12 or 13 or 
BRAF (any of the mutations). Among the 8 patients with any of the mutations, 7 
had KRAS codon 12 or 13 mutations one had BRAF mutation (Table 6.4). 
Patients with tumor mutations were more likely to have worse PS in comparison 
with all wild-type tumors. No other significant difference was seen between the two 
groups (Table 6.4). 
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Table 6.4:  Patient, disease and treatment characteristics (n=30). 
Clinicopathological 
features 
  Wild type (n=22) Any mutant (n=8) p value 
          
Age         
  >60 11 (50.0) 4 (50.0) 0.99 
  <60 11 (50.0) 4 (50.0)   
          
Gender         
  Male 12 (54.5) 4 (50.0) 0.99 
  Female 10 (45.5) 4 (50.0)   
          
Dead/Alive         
  Dead 9 (40.9) 4 (50.0) 0.69 
  Alive 13 (59.1) 4 (50.0)   
          
Site         
  Colon 11 (50.0) 4 (50.0) 0.99 
  Rectum 11 (50.0) 4 (50.0)   
          
Tumor Diff         
  MDA 14 (63.6) 5 (62.5) 0.99 
  PDA 8 (36.4) 3 (37.5)   
          
Lymph node 
metastasis 
        
  YES 15 (68.1) 7 (87.5) 0.39 
  NO 7 (31.9) 1 (12.5)   
          
Therapy         
  Chemo 18 (81.8) 6 (75.0) 0.64 
  Chemo+ 
Biological agent 
4 (18.2) 2 (25.0)   
          
Primary/metastasis         
  Primary 14 (63.6) 4 (50.0) 0.67 
  Metastasis 8 (36.4) 4 (50.0)   
          
Mutation         
  KRAS 0 7   
  NRAS 0 0   
  BRAF 0 1   
  PIK3CA 0 0   
Chapter 6. Survival Analysis 
 248 
Figure 6.7: Kaplan Meier plots for comparison between patients with tumor 
mutation or wild type tumors. 
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Figure 6.8: Kaplan Meier plots for comparison between different therapy options. 
 A 
 B 
Figure Legend: A-PFS plot and B-OS plot. 
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Among the 8 patients with mutations, one was treated with second-line anti-EGFR-
containing regimen, one was treated with second line anti VEGF treatment i. e 
bevacizumab and six were treated with chemotherapy.  
The median PFS of patients with KRAS or BRAF mutations (n = 8; 6 months; 95% 
CI, 5-7 months) was shorter than that of patients with all wild-type tumors (n = 22; 7 
months; 95% CI, 4-9 months), as verified in both univariate (HR 1.46; 95% CI, 
0.5476 to 3.8978; P = 0.36) and multivariate analyses (HR 1.50; 95% CI, 0.5732 to 
3.9417; P = 0.407) (Figure 6.7 A, Table 6.3).  
The median OS of patients with KRAS or BRAF mutations (n = 8; 2.1 years; 95% 
CI, 1.800 to 2.1 years) was shorter than that of patients with all wild-type tumors (n 
= 22; 2.5 years; 95% CI, 2.100 to 2.700 years), as verified in both univariate (HR 
1.1; 95% CI, 0.3316 to 3.6657; P = 0.86) and multivariate analyses (HR 0.75; 95% 
CI, 0.2033 to 2.7878; P = 0.6) (Figure 6.7 B, Table 6.3).  
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6.5 Discussion  
In the past few years, there have been several studies done to determine the 
association of a range of variables with the survival of CRC patients (Laohavinij et 
al., 2010, Moghimi-Dehkordi et al., 2008, Ratto et al., 1998, Desolneux et al., 2010, 
Ghazali et al., 2010). The age, gender, site of CRC, tumor differentiation, invasion 
of tumor, lymph node metastases and other variables have been studied. However, 
determination of prognostic factor is still a challenge. The overall survival rate 
currently in Asian countries is approximately 60% as the majority of 
adenocarcinomas are still diagnosed at the later stages. If the disease is 
diagnosed at an early stage then the survival rate is observed as 90% (Moghimi-
Dehkordi and Safaee, 2012). In this study, the effect of different clinico-pathological 
features on the Indian patients survival rate was evaluated. 
It was observed that overall survival was 37% with median survival of 29 months 
which is similar to the survival rate observed in a study published by Yeole et al. in 
2001 on the Indian population (Yeole et al., 2001). The incidence rates of colon 
and rectal tumors are low in comparison to the population in Western developed 
countries. In India, rectal tumors are more common than colon (Mohandas and 
Desai, 1998). However, a significant increase has been noted in colon cancer 
cases over the past two decades. The present study data shows that the incidence 
of colon cancer in India was more in comparison to rectal cancer (colon -35% and 
rectum – 28%).  
Few other researchers from China have also reported the decline in rectal cancer 
cases (Xu et al., 2006, Wan et al., 2001).The reason for this change is unclear, it 
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could be due to improvisation in early diagnosis, changing dietary habits or 
etiological changes (McMichael and Potter, 1985, Mohandas and Desai, 1998). For 
example, alcohol consumption has been associated with rectal cancers while 
family history is strongly associated with colon cancers (Bongaerts et al., 2008, 
Andrieu et al., 2004). Literature indicates that patients having colon as the site of 
tumor have a better prognosis than those having rectum (Moghimi-Dehkordi et al., 
2008, Ratto et al., 1998, Wang et al., 2008). Further, it has been observed that 
poorer survival has been associated with proximal colon, rather than distal colon 
and as such there is not much difference in the survival rate of distal colon and 
rectal tumors (Hemminki et al., 2010, Meguid et al., 2008, Wray et al., 2009). 
These differences in survival according to tumor site could instead be due to 
differences in tumor aggressiveness or due to screening methodologies used. Few 
studies have shown that colonoscopy and sigmoidoscopy are associated with 
higher incidence and mortality with proximal colon cancers in comparison to distal 
colon cancers (Newcomb et al., 2003, Atkin et al., 2010, Brenner et al., 2009, 
Baxter et al., 2009). Proximal colon cancers exhibit rapid tumor progression, which 
could be due to their diagnosis as interval cancers. Also these tumors frequently 
show the presence of CIMP, MSS/MSI-L along with BRAF mutated status. These 
all factors are associated with poorer survival in proximal tumors (Baxter et al., 
2011, Shaukat et al., 2010, Phipps et al., 2013). Similarly it has been reported MSI-
H tumors are significantly present in proximal colons and MSI-H tumors have 
favourable survival outcome (Guastadisegni et al., 2010).  
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In the current study the median overall survival of patients with colon tumors was 
observed to be 21 months. There was however no significant association observed 
for PFS and OS with respect to site of tumor origin. 
The likelihood of being diagnosed with CRC increases after the age of 40 years 
and the occurrence of CRC cases is higher in patients after the age of 50 years 
(Fund and Research, 2007). Incidence rate is seen to higher in patients with age 
above 60 years, however, the incidence of CRC is seen to be increasing in the 
younger population of 40 years and below (O'Connell et al., 2004, You et al., 2012, 
Siegel et al., 2009). Some studies have shown that early onset of the disease is 
associated with poorer survival outcome (Fang et al., 2010, Gharbi et al., 2010, 
Moghimi-Dehkordi et al., 2008, Zhang et al., 2010).  
The increasing incidence of CRC in younger populations could be due to lack of 
screening at a younger age, behavioural factors such as alcohol consumption, 
smoking and lifestyle factor like obesity. The pesticide consumption in India has 
increased several hundred folds from 154 metric tons in 1954 to 41,822 metric tons 
in 2009-2010. In low income countries like India only 10% of the contaminated 
water is treated rest all is discharged into water bodies. This highly contaminated 
water can cause adverse health effects including cancer. In an epidemiological 
study from Egypt, researchers have shown prevalence of young onset CRC in 
people with exposure to pesticides (Lo et al., 2010). 
 
Some studies that have shown the better survival in younger patients which could 
be due to aggressive therapy regimes used for younger patients, low risk of 
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postoperative complications and higher treatment completion rates of surgery and 
adjuvant therapy. Also the younger patient group may include hereditary CRC like 
Lynch syndrome which is seen to have better survival rates (O'Connell et al., 
2004). 
To study the effect of age on survival the patients were divided in two categories 
above 60 years and below 60 years. No significant association was observed 
between the survivals of these two groups. However, the median overall survival 
for patients above the age of 60 was 28 months and below 60 years was 30 
months which concurs with few studies reporting poor survival rate in older patients 
when compared with that of younger ones (Rosenberg et al., 2008, Laohavinij et 
al., 2010). It has been observed that in the young patients CRC is more aggressive 
and has poor pathological features (Chou et al., 2011).  
 
In this study, significant association was observed between patients survival rates 
and poorly differentiated adenocarcinoma (PDA). PDA is associated with poor 
survival in comparison to moderately differentiated adenocarcinoma (p<0.05) 
(Figure 6.8) as seen in other studies (Laohavinij et al., 2010, Moghimi-Dehkordi et 
al., 2008). Histologically, PDA account for around 4.8% to 23% of all colorectal 
cancer cases (Benedix et al., 2010, YOSHIDA et al., 2011, Xiao et al., 2013). PDA 
is directly associated with a poor prognosis as reported in previous studies(Ishihara 
et al., 2012, Bjerkeset et al., 1987). PDA cases mostly occur in advanced stages or 
metastatic stages which could be the reason for poor survival. 
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Lymph node metastasis is a critical predictor of survival and recurrence in CRC. 
Several studies have found a significant association between numbers of lymph 
node resected and improved survival (Chang et al., 2007, Gunderson et al., 2010, 
Chen and Bilchik, 2006). As increased survival is noted in patients with lymph node 
involvement, better therapeutic advantage is suggested in higher lymph node 
retrieval. In the current study, the overall survival of patients with lymph node 
involvement was 25 months, which was seen to be better than patients with no 
lymph node involvement. However, the survival curves are non-significant. ASCO, 
NCCN and the American College of Surgeons Commission on Cancer (CoC) 
indicate that a minimum of 12 lymph node count is associated with improved 
outcome in the patients (Nelson et al., 2001).The actual mechanism between 
lymph node count and survival is unclear. However, there are various factors that 
affect the number of lymph node examined like patient age, extent of surgical 
resection and tumor location. It has been observed that right-sided tumors show 
the presence of higher number of lymph nodes (Chang et al., 2007). Numbers of 
lymph nodes involved reflect the patients improved immune response. More lymph 
node involvement indicates a greater immune response and hence improved 
survival (Pagès et al., 2005). 
 
CRC can be prevented if detected at an early phase and if adenomatous polyps 
are removed early. If the tumor is diagnosed when it is in localised stage then the 
survival outcome of the patient is better than in those cases where in the diagnosis 
occurs at the metastatic stage (Fatemi et al., 2010). In the current study, it was 
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observed that if the tumor is localised i.e. present at the primary stage then the 
median survival is 31 months in comparison to the metastatic tumors in which the 
median survival is 26 months. However, the survival curve was not statistically 
significant. In one study published on a Dutch population, it was observed that 
metastatic tumors have significantly improved survival. This change observed 
could be due to increased used and improvisation in chemotherapy, use of 
adjuvant and neoadjuvant therapies and better selection of patients eligibility for 
surgery (Meulenbeld et al., 2008).  
Together with the clinico-pathological features, mutation in the RAS –RAF pathway 
is observed in around 30-50% of colorectal cancer tumors implying that only the 
remaining 50% of patients would benefit from anti-EGFR therapy. Cetuximab plus 
FOLFOX helps in improving the survival rate and disease free progression 
(Bokemeyer et al., 2008). Cetuximab and FOLFIRI both improve the survival and 
response rate both in KRAS wild type tumors (Assenat et al., 2011). In current 
study, the overall survival rate in mutated tumors with mutation in KRAS or BRAF 
genes studied was 25 months and in wild type was 29 months although statistical 
significance was not observed.  
 
These experimental evidences of survival rates of CRC patients in relation to 
different clinico-pathological features in this retrospective analysis of the Indian 
population suggests that there are many factors which could influence the 
prognosis of colorectal cancer patients. However, the present study has limitations. 
Due to a smaller sample size, current study may not exactly reflect the prevalence 
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of colorectal cancer in the entire Indian population, however it reflects the nature of 
disease and the effect of different clinico-pathological features on survival for 
Indian CRC cases. This study indicates the differences in presentation of CRC in 
Indian population and also the effect of various factors on survival that may differ 
from the population in Western developed nations. One of the major limitation of 
the present study was that owing to the small number of patients, no data was 
available specifying BRAF, NRAS and PIK3CA mutation due to which impact of 
these mutations on the survival could not be studied. As seen in Chapter 5, the 
frequency of BRAF, NRAS and PIK3CA mutations in Indian population is 5.9%, 2% 
and 4% respectively. Further the survival analysis involved only seven patients for 
KRAS and single patient for BRAF out of a small sample size selected (n=30), from 
the total patients studied for mutation analysis (n=203). According to the published 
literature patients with BRAF mutations are often refractory to systemic 
chemotherapy and have poor prognosis hence screening for BRAF mutations has 
become important. However, the study findings are extrapolative and hypothesis 
generating which can be further analysed in larger cohort. 
This study supports the hypothesis that clinical and pathological characteristics are 
better determinants of prognosis in CRC patients. Amongst all the 
clinicopathological features studied through univariate and multivariate analyses, 
the feature that has the  significant impact on the survival outcome, is the tumor 
differentiation status. Thus, early detection and timely evaluation of tumor becomes 
extremely important in CRC, which can further lead to improved survival. 
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Chapter 7    Summary and Future Work 
 
Colorectal cancer is one of the leading causes of cancer worldwide. It is the most 
common of all gastrointestinal malignancies. The chapter 2 highlights that in 
existing literature wide geographical, racial and ethnic difference in incidence are 
observed for this cancer. The majority of studies showing genetic and epigenetic 
changes correlation with CRC have been carried out in the population of Western 
developed nations. Very little data is available on the Indian population. This study 
was hence undertaken with an aim  to evaluate the genetic alterations in KRAS, 
BRAF, NRAS and PIK3CA genes and the correlation of these molecular alterations 
with clinicopathological characteristics in 203 CRC patients. Further, the correlation 
between clinicopathological features and survival was studied in in a subset of 
Indian population sample size (n=30). The percentage of molecular alterations 
observed in this study corresponds with those reported in literature for CRC cases 
described in COSMIC database.  
All the molecular analysis performed in this study was according to current 
recommendations of CAP and NABL guidelines. Hence, the molecular data 
obtained from this study can be associated to the clinical data and errors possibly 
related to technical issues are unlikely. Also, the samples analyzed in the current 
study constituted a random fraction of Indian CRC patients and is hence a 
balanced representation of entire Indian population.  
  
Chapter 7. Summary and Future Work 
 259 
7.1 Mutation Studies in 203 CRC patients 
Analysis of mutation distribution in KRAS, BRAF, NRAS and PIK3CA genes was 
carried out using Sanger sequencing, which is the cost effective methodology and 
‘Gold Standard’ for mutation analysis. Sanger sequencing allowed evaluation of all 
the hotspot regions in all four genes. Various steps were undertaken in our 
laboratory to ensure optimal procedures for mutational testing through direct 
sequencing. As mentioned above, these included strict adherence to current 
recommendations by CAP and NABL guidelines and involvement of experienced 
pathologists in representative tissue sample section and for performing tumour 
macrodissection. Furthermore, mutational analyses were performed using widely 
accepted protocols. The laboratory is also registered in external quality control 
audits. The minimum allelic sensitivity of Sanger sequencing was established as 
20% using commercially available reference standards. Samples having tumor 
percentage of 20% were processed by macro dissection to enrich the tumor 
content. Samples below the tumor percentage of 20 were not included in the study.  
 
In a total of 36% of CRC cases at least one mutation in the analyzed hot spot 
region was observed. The prevalence of KRAS, BRAF, NRAS and PIK3CA 
mutations in the present study were 24%, 6%, 2% and 4%, respectively which 
concurs well with the COSMIC database reported frequencies. Hence, it can be 
seen that approximately 12% of CRC patients have mutations in NRAS, BRAF or 
PIK3CA in KRAS wild type population. However, it was observed that the mutation 
frequency of BRAF V600E was relatively lower in the Indian population as 
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compared to what is reported in the COSMIC database. The reason for this 
difference may be the structure of COSMIC database that screens for the 
information available in literature for the somatic mutations and displays its 
relationship to the particular human cancer. This amino acid substitution of V to E 
at codon position 600 in BRAF was observed in 6% of cases versus 10.1% in the 
COSMIC database. However, this observed frequency of 6% was in concordance 
with the study performed by Bagadi et. al. and Bisht et. al. on the Indian population 
(Bagadi et al., 2012, Bisht et al., 2014).BRAF mutations were found to mutually 
exclusive with KRAS mutations. Three cases showed coexistence of PIK3CA and 
KRAS mutations together, which confirms the reported observations that PIK3CA 
mutations can coexist with other molecular alterations (Thesis Chapters 4 and 5). 
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7.2 Correlation of mutations in KRAS, BRAF, NRAS and PIK3CA genes 
with clinico-pathological data for a 203 Indian CRC patient cohort 
The statistical analysis of clinicopathological characteristics and mutation analysis 
was performed using Chi-square tests. Significant positive association was 
observed for KRAS mutations with age and tumor differentiation (p<0.05). The 
mutation rate in patients above 50 years was higher than the rate in patients below 
50 years. Also, KRAS mutations were significantly associated positively with 
moderately and poorly differentiated adenocarcinoma, as compared to well-
differentiated adenocarcinoma. Other clinicopathological findings like gender, 
tumor location, stage and lymph-node metastasis, showed no significant 
association with KRAS mutations (p>0.05), which is in accordance with recent 
reports for the Indian population.  
In the case of BRAF, a statistically significant correlation was observed in 
moderately differentiating and poorly differentiating adenocarcinomas, but not in 
well-differentiated adenocarcinomas. This study supports previous reports that 
found that BRAF mutation status is correlated with specific clinicopathological 
features and hence identifies a distinctive subgroup of patients having specific 
clinico-pathological features (Li et al., 2011). 
No significant association was observed between any of the clinico-pathological 
features with NRAS or PIK3CA mutations. However, this study agrees well with 
other population based studies not only in terms of distribution of mutations and 
clinical and pathological features but also in terms of association between these 
mutations and the clinical data (Thesis Chapter 5).  
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7.3 Correlation of clinico-pathological data with survival in Indian patient 
cohort 
In the past few years, there have been many studies carried out to determine the 
association of numerous variables with the survival in case of CRC (Laohavinij et 
al., 2010, Moghimi-Dehkordi et al., 2008, Ratto et al., 1998, Desolneux et al., 2010, 
Ghazali et al., 2010). The age, gender, site of CRC, tumor differentiation, invasion 
of tumor, lymph node metastases and other variables have been studied. However, 
determination of prognostic factor is still a challenge. The overall survival rate 
currently in Asian countries is approximately 60% as the majority of 
adenocarcinomas are still diagnosed at the later stages while the highest survival 
rate is observed in the USA as 64% (Moghimi-Dehkordi and Safaee, 2012). 
Amongst the Asian countries, the highest survival rate is seen in China and the 
lowest in India (Shiono et al., 2005, Yeole et al., 2001). In this study, it was 
observed that overall survival was 37% with median survival of 25 months. In terms 
of anatomic location, the median survival for colon was seen to be 21 months. The 
differences in survival according to tumor site could be due to differences in tumor 
aggressiveness or due to screening methodologies used. Further, the median 
survival for patients above the age of 60 was 25 months and below 60 years was 
30 months which concurs with few studies reporting poor survival rate in older 
patients when compared with that of younger ones. However, recently it has been 
observed that the incidence of CRC is rising in the younger population in India. It 
has been observed that in the young patients CRC is more aggressive and has 
poor pathological features (Chou et al., 2011). With regard to differentiation of 
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tumor, the current study data reveals a significant association in the survival rate of 
patients with poorly differentiated adenocarcinoma (PDA). PDA is positively 
associated with poor survival (median survival of 21 months) in comparison to 
MDA (p0.05) as observed in previous studies. PDA cases mostly occur in 
advanced stages or metastatic stages which could be the reason for poor survival. 
The overall survival in the case of patients with lymph node involvement was found 
to be 25 months, which was higher than patients with no lymph node involvement. 
Numbers of lymph nodes involved reflect the patients’ improved immune response. 
The more the lymph node involvement, the greater the immune response and 
hence improved survival. 
If the tumor is diagnosed when it is in a localised stage then the survival outcome 
of the patient is better than those cases where in the diagnosis occurs at the 
metastatic stage. In the current  study, it was observed that if the tumor is 
localised, i.e. present at primary stage, then the median survival was 31 months in 
comparison to the metastatic tumors in which the median survival was 26 months. 
The survival rate in mutated tumors was 25 months and in wild type was 29 
months though statistical significance was not observed (Thesis Chapter 6). 
Patients’ selection has recently entered a new era of personalised therapy. The 
establishment of biomarkers and clinicopathological features prior to treatment can 
lead to improved survival. The impact of different genetic and epigenetic alterations 
such as mutations, SNP’s, methylation status and copy number, required for 
efficacy of treatment, requires further study to determine the mechanisms of action 
for the specific drug molecule used. This thesis investigated a variety of CRC 
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cases in the Indian population for studying the effect of different factors on survival.  
Taken together, the findings of current study shows for the first time that at the 
genetic level, mutations in one of the four genes (KRAS, BRAF, NRAF and 
PIK3CA) occur at a lower frequency than in the population in Western developed 
countries. Data supports the hypothesis that (i) rate of mutations in critical CRC 
genes involved in the tumor growth and survival i.e. KRAS, BRAF, NRAS and 
PIK3CA differ according to racial differences, and (ii) that different 
clinicopathological factors would have impact on clinical outcome of the patient in 
the context of Indian patient cohort. Results from therapeutic data analysis 
(Chapter 6) shows that the knowledge of tumor differentiation status can influence 
decision making for patient and hence improve response rate and outcome of CRC 
patient. This data  needs to be validated in larger cohort to potentially influence 
treatment decisions in Indian patients, and hence is a step forward towards 
personalised treatment. 
 
In brief, the following conclusions can be drawn from this study: 
1. The prevalence of KRAS, BRAF, NRAS and PIK3CA mutations in CRC 
patients in the present study was 24%, 6%, 2% and 4%, respectively, 
which is at a much lower frequency when compared to the data available 
for populations in Western developed nations.  
2. BRAF mutations were found to be mutually exclusive with KRAS 
mutations. However, coexistence of PIK3CA mutations with KRAS 
mutant patients was observed. These results concur with the published 
literature on populations in Western developed nations. 
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3. Significant statistical association (p<0.05) was observed between the 
following parameters: 
a. KRAS mutations with age and tumor differentiation. Mutation rate in 
patients above 50 years was higher than for patients below 50 years 
of age. KRAS mutations were significantly associated positively with 
moderately and poorly differentiated adenocarcinoma, as compared 
to well-differentiated adenocarcinoma. 
b. BRAF statistically significant positive correlation was observed in 
moderately differentiating and poorly differentiating adenocarcinomas 
than in well-differentiated adenocarcinomas. 
4. No significant association was observed between any of the 
clinicopathological features with NRAS or PIK3CA mutations in Indian cases. 
5. In terms of correlation between survival and clinicopathological features, the 
following observations were made: 
a. The 3- year overall survival in Indian patients was observed to be 37%, with 
median survival of 25 months, which is much lower in comparison to that in 
developed nations.  
b. Significant association was observed in the survival rate of patients with 
poorly differentiated adenocarcinoma (PDA). PDA is inversely associated with poor 
survival (median survival of 21 months) in comparison to moderately differentiated 
adenocarcinoma (MDA) (p0.05).  
c. It was observed that if the tumor is localised, that is, present at the primary 
stage, then the median survival is 31 months, in comparison to metastatic tumors 
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in which the median survival is 26 months. The survival rate in mutated tumors was 
25 months and in wild type was 29 months, although statistical significance was 
not observed. 
 
The current study data reflects the nature of disease and the effect of different 
clinicopathological features on survival in case of Indian CRC cases. These 
experimental evidences of survival rates of CRC patients in relation to different 
clinico-pathological features in the Indian population indicates that there are 
numerous factors that influence the prognosis of colorectal cancer patients. 
However, life expectancy has not increased much in these years. Though the data 
has inherent limitations due to small sample size analysis, this retrospective study 
supports the hypothesis (based on existed literature) that clinical and pathological 
characteristics, especially tumor differentiation are good determinants of prognosis 
in CRC patients. 
Recently mutations in KRAS exon4 and NRAS exon 4 have been shown to have 
an effect on therapeutic response. However, the reported percentage of these 
mutations is low, ranging from 0.5 to 2.2%. Further studies are required to 
establish the prevalence and effect of these mutations of exon 4 in the Indian 
population. 
In terms of a forward path, additional studies are required in the Indian CRC 
population to determine the effect of additional genetic and epigenetic markers, 
such as AKT, PTEN, MAPK, and other receptors molecules such as MET, MSI, 
CIMP, which could provide an alternative pathway to survival. Also, larger cohort 
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needs to be studied to evaluate the effect of different mutations in correlation with 
clinicopathological features on survival. Thus the future strategy to improve survival 
outcomes and clinical management of CRC, lies in personalized therapy which is 
still an evolving approach with a focus to identify highly specific and sensitive 
predictive biomarkers. Hence, there is a strong need to identify, develop and 
validate more biomarkers that will assist with clinical decision-making. As reviewed 
recently (Patil et al 2016), Next Gen Sequencing and multi-gene sequencing 
(parallel sequencing technology), data reveals that along with the mutations in 
genes of EGFR pathway, mutations SMAD-4 and FBXW7 are also responsible for 
resistance to therapy. Also, advances in imaging techniques such as FDG-PET, 
DWI, DCE-MRI could potentially serve as predictive imaging biomarkers to anti-
angiogenesis inhibitors(Atreya and Goetz, 2013). Considering the current progress 
and focus in personalized medicine, and with the recent genomic profiling of CRC 
patient tumors and the development of new proteomic and modeling studies, 
selecting and stratifying CRC patients based on their molecular profile will be 
improved in future. 
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     Appendix 
I. Haematoxylin and eosin (H&E) Analysis  
Preparation of reagents: 
1. Haematoxylin Solution (Harris):  
 Potassium or ammonium (alum): 100 g  
 Distilled water: 1000 ml  
Heat to dissolve. Add 50 ml of 10% alcoholic haematoxylin solution and heat to boil 
for 1 min. Remove from heat and slowly add 2.5 g of mercuric oxide (red). Heat to 
the solution and until it becomes dark purple color. Cool the solution in cold water 
bath and add 20 ml of glacial acetic acid (concentrated). Filter before use and store 
at room temperature. 
2. Eosin-Phloxine B Solution:    
Eosin Stock Solution:  
 Eosin Y: 1 g  
 Distilled water: 100 ml  
 Mix to dissolve. 
 Phloxine Stock Solution:  
 Phloxine B: 1 g  
 Distilled water: 100 ml  
Mix to dissolve.  
3. Eosin-Phloxine B Working Solution:  
 Eosin stock solution: 100 ml  
 Phloxine stock solution: 10 ml  
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 Ethanol (95%): 780 ml  
 Glacial acetic acid: 4 ml  
Mix well and store at room temperature. 
4. 1% Acid Alcohol Solution (for differentiation): 
 Hydrochloric acid: 3 ml  
 70% ethanol: 300 ml  
Mix well and store at room temperature. 
II. Reagents required for DNA extraction using Invitrogen Purelink Genomic DNA 
kit: 
Preparation of Reagents: 
1. Purelink Wash Buffer WB1: 
Buffer WB1 was diluted with 80 ml of 100% ethanol to make the volume to 200 ml. 
2. Purelink Wash Buffer WB2: 
Buffer WB2 was diluted with 80 ml of 100% ethanol to make the volume to 185 ml. 
III. Gel electrophoresis Reagent Preparation:  
1. 1XTBE Buffer 
 Tris-180 grams 
 EDTA-9.3 grams 
 Boric Acid-55 grams 
pH-7.5 
Volume adjusted to 1 liter with MilliQ water 
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List of Chemicals 
Sr 
No. Chemical Company Catalogue 
1 SeaKem LE Agarose Lonza  50004 
2 FG, BDT V3.1 RR1000 ABI 4337456 
3 Boric acid Merck  6505001730 
4 BSA Sigma A7030- 100 g 
5 DMSO Sigma D2650 
6 
DNA Extraction kit: 
Purelink Invitrogen  K1820-02 
7 EDTA Thomas Baker 74298 
8 Ethidium bromide Sigma 160539 
9 Ethanol Changshu Yangyuan XK-13-201-00185 
10 Generuler 100bp Ladder MBI Fermantas SM0241 
11 
GOTAQ(R)Flexi DNA 
Polymerase Promega M829B 
12 Hi Di Formamide ABI 4311320 
13 
N-RAS G12V Reference 
Standard Horizon Diagnostics HD203 
14 
N-RAS Q61K Reference 
Standard Horizon Diagnostics HD247 
15 PCR Nucleotide Mix Promega C114H 
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16 10 X EDTA Buffer Thermo Scientific  402824 
17 5X Seq Buffer Thermo Scientific  4339843 
18 HPLC grade water Merck O61765010001730 
19 
Montage PCR u96 
Cleanup Plates Millipore LSKMPCR50 
20 
Montage PCR u96 Seq. 
Rxn Cleanup Kit  Millipore LSKS09624 
21 POP6 Thermo Scientific  4316357 
22 Primers Sigma - 
23 1XPBS Gibco 20012-050 
24 5X Seq Buffer Thermo Scientific  4339843 
25 
Flat Deck Thermo-Fast 96 
detection plate            Thermo Scientific  AB-1400             
26 DPX Mountant Merck AF2 AF 52226 
27 Formaldehyde solution Qualigens 12755 
28 Formamide SRL 62758 
29 Hydrogen Peroxide Qulaigens 15465 
30 Tri Sodium citrate Qulaigens 14005 
31 Hydrogen Peroxidase Thomas Baker 90383 
32 Xylene Xlar  Qualigens 32295 
33  Reference Standards Horizon Diagnostics HD203 
34 Trizma base Sigma T1503 
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List of Instruments 
Sr 
No. Instrument Model Company 
1 Biosafety Cabinate 1590V Klenzaids 
2 Fume Hood AFA1000 Kewaunee 
3 
Gel Electrophoresis 
Appratus SubcellGT Biorad 
4 pH Meter PICO+ LabIndia 
5 Incubator 450X450 mm Trishul Equipment 
6 Hot Air Oven PEW180ASS Pathak Electric Work 
7 Floatation bath 3120058 
Thermo Electron 
Corporation 
8 Microtome Finesse ME 
Thermo Electron 
Corporation 
9 
Bright field Olympus 
Microscope BX51 BX51 Olympus 
10 
CCD camera for 
microphotography ProgRes C3 Olympus 
11 Genetic Analyser 3100 3100 Life Technologies 
12 Dry Bath DB-3D Techne 
13 PCR Thermal Cycler MyCycler Biorad 
14 Micro Centrifuge 5415D Eppendorf 
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15 Gel Documentation System 
Pharmacia Biotech 
011E991 GE Biosciences 
16 
Nano drop 
Spectrophotometer ND-1000 Nanodrop 
17 Laminar Hood 1560R Klenzaids 
18 Microwave CE118KF Samsung 
19 Analytical Balance BP121S Sartorius 
20 Semianalytical Balance BP1200 Sartorius 
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List of Software’s 
Sr. 
No. Software Company 
1 Sequencing Analysis Software Life Technologies 
2 Image Total Master GE Biosciences 
3 BioEdit www.mbio.ncsu.edu/bioedit/bioedit.html 
4 GraphPad QuickCals GraphPad Software, Inc 
5 GraphPad Prism GraphPad Software, Inc 
6 MedCalc MedCalc Software, Ostend, Belgium 
 
Accreditations and Approvals 
i. Accreditation with College of American Pathologist (CAP) - LAP No: 7194405,  
AU ID-1449073, CLIA No: 99D20118815, Issue date: 12 Sep 2013 
 
ii.  Accreditation with National Accreditation Board for testing and calibration  
Laboratory  (NABL) in accordance with ISO15189:2007 - NABL No. M-0090, 
Issue date:19 Dec 2015 
 
iii.  Registration with Maharashtra Industrial Development Corporation, 
Registration  No.11/24/MIDC/001.IEM No. 686,687,688/SIA/IMO/2008/ 
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